abstract_id,abstract_title,session_title,ground_truth,approach_2_success,approach_2_indication,approach_2_confidence,approach_2_word_count,approach_2_length,approach_2_clinical_terms,approach_2_complexity,approach_2_has_abbreviations,approach_2_has_parentheses,approach_2_error,inter_model_avg_similarity,inter_model_consensus,approach_2_indication_response
393216,"Surgical Quality For Patients (Pts) Treated With Neoadjuvant Chemotherapy Vs Chemoradiation For Locally Advanced Rectal Cancer (Larc): Prospect (Ncctg N1048, Alliance)",Colorectal Cancer,Locally Advanced Rectal Cancer,True,Locally Advanced Rectal Cancer,0.95,4,30,2,0.4,False,False,,,No comparison,Locally Advanced Rectal Cancer
393219,"Effectiveness And Safety Of Rectal Arterial Infusion Chemotherapy Combined With Anti-Pd1 Antibody For Microsatellite Stable Locally Advanced Rectal Cancer: Early Outcome Report Of A Two-Stage, Single Armed, Phase II Study (Raic)",Colorectal Cancer,Microsatellite Stable Locally Advanced Rectal Cancer,True,Microsatellite Stable Locally Advanced Rectal Cancer,0.95,6,52,2,0.5,False,False,,,No comparison,Microsatellite Stable Locally Advanced Rectal Cancer
147461,Depth Of Response And Mrd Status In Ultra High-Risk Myeloma And Plasma Cell Leukemia Treated With Dara-Cvrd And Augmented Autologous Transplant: Results Of The Risk-Stratified Uk Optimum/Muknine Trial,Myeloma And Other Monoclonal Gammopathies - Clinical,Ultra High-Risk Myeloma;;Plasma Cell Leukemia,True,Ultra High-Risk Myeloma;;Plasma Cell Leukemia,0.95,5,45,2,0.45,False,False,,,No comparison,Ultra High-Risk Myeloma;;Plasma Cell Leukemia
147482,Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis (Mf) Therapy And After Prior Ruxolitinib (Rux): Results From The Jakarta And Jakarta2 Trials,Myeloproliferative Neoplasms - Clinical,First-Line Myelofibrosis,True,First-Line Myelofibrosis;;Previously Treated Myelofibrosis,0.95,4,58,1,0.3,False,False,,,No comparison,First-Line Myelofibrosis;;Previously Treated Myelofibrosis
180260,Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis,"Clonal Hematopoiesis, Aging and Inflammation: Poster I",RUNX1-Familial Platelet Disorder;;Myeloid Malignancy,True,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy;;Clonal Hematopoiesis,0.95,5,74,1,0.35,False,False,,,No comparison,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy;;Clonal Hematopoiesis
147495,The Burden Of Sickle Cell Disease (Scd) On Patients In Ghana And Nigeria Compared With Other Low-/Middle-Income And High-Income Countries: Results From The Sickle Cell World Assessment Survey (Sway),Sickle Cell Disease,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
262190,"Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor Of Wild-Type And C481S Mutated Bruton Tyrosine Kinase For B-Cell Malignancies: Efficacy And Safety Of The Phase 2 Dose-Expansion Bellwave-001 Study",Chronic lymphocytic leukemia and related disorders - Clinical,B-Cell Malignancy,True,BTK Wild Type B-Cell Malignancy;;BTK C481S-Mutated B-Cell Malignancy,0.95,8,68,0,0.4,True,False,,,No comparison,BTK Wild Type B-Cell Malignancy;;BTK C481S-Mutated B-Cell Malignancy
327727,The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed Acute Myeloid Leukemia,0.95,5,38,3,0.55,False,False,,,No comparison,Newly Diagnosed Acute Myeloid Leukemia
327732,Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Adult Acute Myeloid Leukemia,True,Adult Acute Myeloid Leukemia;;Myelodysplasia,0.95,4,44,2,0.4,False,False,,,No comparison,Adult Acute Myeloid Leukemia;;Myelodysplasia
147508,Belumosudil For Chronic Graft-Versus Host Disease After 2 Or More Prior Lines Of Therapy: The Rockstar Study (Kd025-213),Stem Cell Transplantation - Clinical,Chronic Graft-Versus Host Disease,True,Chronic Graft-Versus Host Disease,0.95,4,33,2,0.4,False,False,,,No comparison,Chronic Graft-Versus Host Disease
147511,Narsoplimab (Oms721) Treatment Contributes To Improvements In Organ Function In Adult Patients With High-Risk Transplant-Associated Thrombotic Microangiopathy,Stem Cell Transplantation - Clinical,,True,Adult High-Risk Transplant-Associated Thrombotic Microangiopathy,0.95,5,64,0,0.25,False,False,,,No comparison,Adult High-Risk Transplant-Associated Thrombotic Microangiopathy
213047,Parkinson's Disease and the Impact on Urologic Health in Older Adults,Geriatric Urological Society (GUS),Elderly Parkinson's Disease,True,Elderly Parkinson's Disease,0.95,3,27,1,0.25,False,False,,,No comparison,Elderly Parkinson's Disease
327741,Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",NPM1-Mutant Acute Myeloid Leukemia,True,NPM1-Mutated Acute Myeloid Leukemia;;FLT3-ITD-High Acute Myeloid Leukemia;;FLT3-ITD-Low Acute Myeloid Leukemia;;Elderly Acute Myeloid Leukemia,0.95,13,142,2,0.85,True,False,,,No comparison,NPM1-Mutated Acute Myeloid Leukemia;;FLT3-ITD-High Acute Myeloid Leukemia;;FLT3-ITD-Low Acute Myeloid Leukemia;;Elderly Acute Myeloid Leukemia
180285,Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy,Bone Marrow Failure: Poster I,Severe Aplastic Anemia,True,Severe Aplastic Anemia,0.95,3,22,1,0.25,False,False,,,No comparison,Severe Aplastic Anemia
294973,Changing GEC Patient Care with IO plus Chemotherapy in First-Line,MSD - Navigating through the rapidly evolving treatment landscape for GI Cancers - A Clinical & Patient Centric Approach towards implementing Immunotherapy,First-Line Gastrointestinal Cancer,True,First-Line Gastroesophageal Cancer,0.95,3,34,1,0.25,False,False,,,No comparison,First-Line Gastroesophageal Cancer
262206,Bosutinib Dose Optimization In The Second-Line Treatment Of Elderly Cml Patients: Extended 3-Year Follow-Up And Final Results Of The Best Study,Chronic myeloid leukemia - Clinical,Second-Line Elderly Chronic Myeloid Leukemia,True,Elderly Second-Line Chronic Myeloid Leukemia,0.95,5,44,2,0.45,False,False,,,No comparison,Elderly Second-Line Chronic Myeloid Leukemia
147521,Thrombophilia As Risk Factor For Asparaginase Related Venous Thromboembolism In Pediatric And Young Adult Patients Affected By Acute Lymphoblastic Leukemia,Thrombosis And Vascular Biology - Biology & Translational Research,Pediatric Young Adult Venous Thromboembolism,True,Thrombophilia;;Asparaginase-Related Venous Thromboembolism;;Pediatric Acute Lymphoblastic Leukemia;;Young Adult Acute Lymphoblastic Leukemia,0.95,10,140,2,0.7,False,False,,,No comparison,Thrombophilia;;Asparaginase-Related Venous Thromboembolism;;Pediatric Acute Lymphoblastic Leukemia;;Young Adult Acute Lymphoblastic Leukemia
393283,"A Phase I Study Of Safety, Pharmacokinetics, And Pharmacodynamics Of Scr-6920, A Protein Arginine Methyltransferase 5(Prmt5) Inhibitor, In Patients With Advanced Malignant Tumors",Developmental Therapeutics,Advanced Malignant Tumor,True,Advanced Malignant Tumor,0.95,3,24,2,0.35,False,False,,,No comparison,Advanced Malignant Tumor
262209,Real-Life Outcomes Of Ponatinib Treatment In Patients With Chronic Myeloid Leukemia (Cml) Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All): 5-Year-Data From A Belgian Registry,Chronic myeloid leukemia - Clinical,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,7,77,4,0.75,False,False,,,No comparison,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia
180298,"Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria",Bone Marrow Failure: Poster I,Paroxysmal Nocturnal Hemoglobinuria,True,Paroxysmal Nocturnal Hemoglobinuria,0.95,3,35,0,0.15,False,False,,,No comparison,Paroxysmal Nocturnal Hemoglobinuria
393291,"Preclinical Evaluation Of Hlx42, A Novel Egfr-Targeting Adc, For Cetuximab Or Tki Resistant Cancer",Developmental Therapeutics,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
180300,Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry,Bone Marrow Failure: Poster I,Adult Late-Onset Telomere Biology Disorder,True,Adult Late Onset Telomere Biology Disorder;;Telomeropathy;;Bone Marrow Failure,0.95,8,78,1,0.5,False,False,,,No comparison,Adult Late Onset Telomere Biology Disorder;;Telomeropathy;;Bone Marrow Failure
327760,Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Newly Diagnosed IDH-Mutated TP53-Mutated Acute Myeloid Leukemia,True,Newly Diagnosed IDH/TP53-Mutated Acute Myeloid Leukemia,0.95,6,55,3,0.6,True,False,,,No comparison,Newly Diagnosed IDH/TP53-Mutated Acute Myeloid Leukemia
311376,Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity,"Abstracts: RA - Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease",Rheumatoid Arthritis,True,Anti-CCP-Positive Rheumatoid Arthritis,0.95,3,38,1,0.25,True,False,,,No comparison,Anti-CCP-Positive Rheumatoid Arthritis
229467,"The novel adjuvant, ADA-1, restores age-associated defects in the adaptive immune response to Clostridioides difficile infection and vaccination in an aging mouse model",Vaccines and Immunity against Bacteria and Parasites,Clostridioides Difficile Infection,True,Clostridioides Difficile Infection,0.95,3,34,0,0.15,False,False,,,No comparison,Clostridioides Difficile Infection
327778,The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Acute Myeloid Leukemia,True,Acute Myeloid Leukemia;;MRD-Positive Acute Myeloid Leukemia,0.95,6,59,3,0.6,True,False,,,No comparison,Acute Myeloid Leukemia;;MRD-Positive Acute Myeloid Leukemia
147554,Antibodies To Pegylated E. Coli Asparaginase Predict The Occurrence Of Hypersensitivity Reactions In High-Risk Patients Undergoing The Consolidation Phase Of The Aieop-Bfm All 2009 Protocol.,Acute Lymphoblastic Leukemia - Clinical,High-Risk Acute Lymphoblastic Leukemia,True,High-Risk Acute Lymphoblastic Leukemia;;Hypersensitivity Reaction,0.95,5,65,2,0.45,False,False,,,No comparison,High-Risk Acute Lymphoblastic Leukemia;;Hypersensitivity Reaction
327789,"Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity","Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Mixed Phenotypic Acute Leukemia,True,Mixed Phenotypic Acute Leukemia,0.95,4,31,2,0.4,False,False,,,No comparison,Mixed Phenotypic Acute Leukemia
213104,What Clinical Innovations and Other Interventions Are Needed?,Quality Improvement Summit: Laying the Foundation for Primary Palliative Care in Urology,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
393329,A Phase 1 Study Of Bal0891 As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Solid Tumors.,Developmental Therapeutics,Advanced Solid Tumor,True,Advanced Solid Tumor,0.95,3,20,2,0.35,False,False,,,No comparison,Advanced Solid Tumor
376946,Automated Metrics From The Electronic Health Record Enable Evaluation Of Palliative Care In Patients With Acute Myeloid Leukaemia: A Data Science Approach,Quality of life and palliative care,Acute Myeloid Leukemia,True,Acute Myeloid Leukaemia,0.95,3,23,1,0.25,False,False,,,No comparison,Acute Myeloid Leukaemia
262259,Multiplex Deletion Of Myeloid Antigens Cd33 And Cll-1 By Crispr/Cas9 In Human Hematopoietic Stem Cells Highlights The Potential Of Next-Generation Transplants For Aml Treatment.,"Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research",Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
229493,Pan-coronavirus neutralizing S2 human monoclonal antibodies and utility of direct respiratory administration as combination therapy with S1 antibodies against SARS-CoV-2,Vaccination and immunotherapy against COVID-19,SARS-CoV-2 Infection,True,COVID-19,0.95,1,8,0,0.05,True,False,,,No comparison,COVID-19
393337,Efficacy And Safety Of High-Dose Chemotherapy As Second Or Subsequent Salvage Therapy In Relapsed Or Refractory Germ Cell Cancer Patients: A Multicentric Analysis,Germ Cell (Testicular) Cancer And Penile Cancer,Relapsed or Refractory Germ Cell Cancer,True,Relapsed/Refractory Germ Cell Cancer,0.95,4,36,3,0.5,False,False,,,No comparison,Relapsed/Refractory Germ Cell Cancer
376961,Lifetime Clinical Outcomes Of Cpx-351 Versus 7+3 Modeled From The 5-Year Results Of A Randomized Phase 3 Trial For Older Adults With Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia,Acute myeloid leukemia - Clinical,Elderly Newly Diagnosed High-Risk Secondary Acute Myeloid Leukaemia,True,Elderly Newly Diagnosed High-Risk Acute Myeloid Leukaemia;;Elderly Newly Diagnosed Secondary Acute Myeloid Leukaemia,0.95,13,116,2,0.85,False,False,,,No comparison,Elderly Newly Diagnosed High-Risk Acute Myeloid Leukaemia;;Elderly Newly Diagnosed Secondary Acute Myeloid Leukaemia
295042,Invited Discussant 1312O and 1313O,Proffered Paper session: Policy and preventive strategies,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
229509,Osteoclast differentiation alters monocyte inflammatory responses to Staphylococcus aureus,Cells of the Innate Immune System,Staphylococcus Aureus Infection,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
180358,Targeting Metabolic Vulnerabilities in Primary Effusion Lymphoma Using the Novel Nucleoside Analog 6-Eti,Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I,Primary Effusion Lymphoma,True,Primary Effusion Lymphoma,0.95,3,25,1,0.25,False,False,,,No comparison,Primary Effusion Lymphoma
327817,Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Pediatric Acute Myeloid Leukemia,True,Pediatric Acute Myeloid Leukemia,0.95,4,32,2,0.4,False,False,,,No comparison,Pediatric Acute Myeloid Leukemia
311433,Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population,"Abstracts: SLE - Diagnosis, Manifestations, and Outcomes II: Complications",Systemic Lupus Erythematosus,True,Severe COVID-19;;Systemic Lupus Erythematosus,0.95,4,45,1,0.3,True,False,,,No comparison,Severe COVID-19;;Systemic Lupus Erythematosus
327823,Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",NPM1-Mutated Acute Myeloid Leukemia,True,NPM1-Mutated Acute Myeloid Leukemia,0.95,4,35,2,0.4,False,False,,,No comparison,NPM1-Mutated Acute Myeloid Leukemia
311447,CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus,Abstracts: SLE - Treatment,Refractory Systemic Lupus Erythematosus,True,Refractory Systemic Lupus Erythematosus,0.95,4,39,1,0.3,False,False,,,No comparison,Refractory Systemic Lupus Erythematosus
311449,Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares,Abstracts: SLE - Treatment,Systemic Lupus Erythematosus,True,Systemic Lupus Erythematosus Flare,0.95,4,34,0,0.2,False,False,,,No comparison,Systemic Lupus Erythematosus Flare
409754,Audience Q&A,Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases,,True,Complement-Mediated Kidney Disease,0.95,3,34,1,0.25,False,False,,,No comparison,Complement-Mediated Kidney Disease
393371,Ccne1 Amplification Defines A Good Prognostic Subgroup Among Brcawt/Hrdneg Advanced High-Grade Ovarian Cancer (Hgoc),Gynaecological Cancers,Advanced High-Grade Ovarian Cancer,True,Advanced High-Grade BRCA Wild Type/HRD-Negative Ovarian Cancer,0.95,7,62,4,0.75,True,False,,,No comparison,Advanced High-Grade BRCA Wild Type/HRD-Negative Ovarian Cancer
262300,Monoallelic And Biallelic Germline Mutations Affecting The Transcription Factor Helios Cause Pleiotropic Defects Of Immunity,"Hematopoiesis, stem cells and microenvironment",,True,Helios-Mutated Germline Pleiotropic Defect of Immunity,0.95,6,54,0,0.3,False,False,,,No comparison,Helios-Mutated Germline Pleiotropic Defect of Immunity
393379,Correlation Between Chemotherapy Response Score (Crs) And Germline Brca1/2 (Gbrca) Status In Women Diagnosed With Figo Stage Iiic/Iv High-Grade Serous Ovarian Cancer (Hgsoc),Gynaecological Cancers,Stage IIIc/IV High-Grade Serous Ovarian Cancer,True,Stage IIIC High Grade Serous Ovarian Cancer;;Stage IV High Grade Serous Ovarian Cancer,0.95,13,86,3,0.95,True,False,,,No comparison,Stage IIIC High Grade Serous Ovarian Cancer;;Stage IV High Grade Serous Ovarian Cancer
213157,Society for the Study of Male Reproduction (SSMR),Society for the Study of Male Reproduction (SSMR),,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
393382,The Predictive Role Of Circulating Exosomal Pd-L1 In Cervical Cancer Immunotherapy,Gynaecological Cancers,Cervical Cancer,True,Cervical Cancer,0.95,2,15,1,0.2,False,False,,,No comparison,Cervical Cancer
344232,Chair Introduction,Intercepting Molecular Residual Disease in the Clinic,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
180389,Safety and Efficacy of Isavuconazole in Patients Aged 65 Years or Older with Invasive Fungal Disease: A Post-Hoc Analysis from the VITAL and Secure Studies,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Elderly Invasive Fungal Disease,True,Elderly Invasive Fungal Disease,0.95,4,31,1,0.3,False,False,,,No comparison,Elderly Invasive Fungal Disease
180390,Clinical Characteristics Associated with Venous Thromboembolism in Patients with Non-APL Acute Myeloid Leukemia,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Venous Thromboembolism;;Acute Myeloid Leukemia,True,Venous Thromboembolism;;Non-APL Acute Myeloid Leukemia,0.95,5,54,2,0.45,True,False,,,No comparison,Venous Thromboembolism;;Non-APL Acute Myeloid Leukemia
262320,"Brentuximab Vedotin, Etoposide, Solumedrol, High Dose Ara-C & Platinum Followed By Hdt & Apbsct For Refractory/Relapsed Hodgkin Lymphoma Patients: Long-Term Results Of The Geltamo Group Breshap Study",Hodgkin lymphoma - Clinical,Refractory/Relapsed Hodgkin Lymphoma,True,Refractory/Relapsed Hodgkin Lymphoma,0.95,3,36,3,0.45,False,False,,,No comparison,Refractory/Relapsed Hodgkin Lymphoma
180403,Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Adult Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia,True,Adult Newly Diagnosed Ph Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,0.95,9,80,4,0.85,False,False,,,No comparison,Adult Newly Diagnosed Ph Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
327859,Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Acute Lymphoblastic Leukemia,True,High Hyperdiploid Acute Lymphoblastic Leukemia,0.95,5,46,2,0.45,False,False,,,No comparison,High Hyperdiploid Acute Lymphoblastic Leukemia
393400,Tumor-Informed Ctdna Detection As A Predictive Marker For Postoperative Residual Disease In Epithelial Ovarian Cancer: A Feasibility Study,Gynaecological Cancers,Epithelial Ovarian Cancer,True,Residual Epithelial Ovarian Cancer,0.95,4,34,1,0.3,False,False,,,No comparison,Residual Epithelial Ovarian Cancer
327865,Clinical Significance of IGH Clonality Analysis with RNA Sequencing in B-Cell Precursor Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",B-Cell Precursor Acute Lymphoblastic Leukemia,True,B-Cell Precursor Acute Lymphoblastic Leukemia,0.95,5,45,2,0.45,False,False,,,No comparison,B-Cell Precursor Acute Lymphoblastic Leukemia
327866,The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Relapsed KMT2A-Rearranged Infant Childhood Leukemia,True,KMT2A-Rearranged Infant Leukemia;;KMT2A-Rearranged Childhood Leukemia,0.95,5,69,1,0.35,False,False,,,No comparison,KMT2A-Rearranged Infant Leukemia;;KMT2A-Rearranged Childhood Leukemia
262328,"Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) Btk Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 Bruin Study",Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,Previously Treated Mantle Cell Lymphoma,True,Previously Treated Mantle Cell Lymphoma,0.95,5,39,2,0.45,False,False,,,No comparison,Previously Treated Mantle Cell Lymphoma
393407,Mental And Socioeconomic Burden In Co-Parents And Children Of Patients With Endometrial And Cervical Cancer: A Swedish Population-Based Study,Gynaecological Cancers,Childhood Endometrial Cancer;;Childhood Cervical Cancer,True,Endometrial Cancer;;Cervical Cancer,0.95,3,35,1,0.25,False,False,,,No comparison,Endometrial Cancer;;Cervical Cancer
147649,Phase 1 First-In-Human Study Of Irreversible Flt3 Inhibitor Ff-10101-01 In Relapsed Or Refractory Acute Myeloid Leukemia,Acute Myeloid Leukemia - Clinical,Relapsed/Refractory Acute Myeloid Leukemia,True,Relapsed/Refractory Acute Myeloid Leukemia,0.95,4,42,4,0.6,False,False,,,No comparison,Relapsed/Refractory Acute Myeloid Leukemia
327877,The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Pediatric T-Cell Acute Lymphoblastic Leukemia,True,Pediatric T-Cell Acute Lymphoblastic Leukemia,0.95,5,45,2,0.45,False,False,,,No comparison,Pediatric T-Cell Acute Lymphoblastic Leukemia
311500,"A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis",Abstracts: Vasculitis - ANCA-Associated,ANCA-Associated Vasculitis,True,ANCA-Associated Vasculitis,0.95,2,26,0,0.1,True,False,,,No comparison,ANCA-Associated Vasculitis
180429,Modified Intensive Induction Treatment for Elderly Acute Myeloid Leukemia Patients Based on Peripheral Blast Clearance Rate: A Phase II Single-Arm Study,"Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Elderly Acute Myeloid Leukemia,True,Elderly Acute Myeloid Leukemia,0.95,4,30,2,0.4,False,False,,,No comparison,Elderly Acute Myeloid Leukemia
311504,Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR <=20 in the Avacopan ADVOCATE Trial,Abstracts: Vasculitis - ANCA-Associated,ANCA-Associated Vasculitis,True,ANCA-Associated Vasculitis,0.95,2,26,0,0.1,True,False,,,No comparison,ANCA-Associated Vasculitis
229586,Microbiota drive concomitant expression of IL-17 and the inhibitory receptor PD-1 to regulate effector functions of gd17 cells in the intestine,Neonatal and Fetal Mucosal Immunity,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
180437,Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial,"Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Adult Newly Diagnosed Acute Myeloid Leukemia,True,Adult Newly Diagnosed Acute Myeloid Leukemia,0.95,6,44,3,0.6,False,False,,,No comparison,Adult Newly Diagnosed Acute Myeloid Leukemia
377049,"Therapeutic Potential And Strategies Of Pim447, A Pan-Pim Inhibitor, Targeting Refractory Myeloid Leukemia With Kit-Driven T(8/21)",Acute myeloid leukemia - Biology & Translational Research,Refractory Myeloid Leukemia,True,Kit-Driven Refractory Myeloid Leukemia;;Refractory Kit-Driven Myeloid Leukemia,0.95,7,78,2,0.55,False,False,,,No comparison,Kit-Driven Refractory Myeloid Leukemia;;Refractory Kit-Driven Myeloid Leukemia
180442,"Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study","Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Adult Newly Diagnosed Acute Myeloid Leukemia,True,Adult Newly Diagnosed Acute Myeloid Leukemia,0.95,6,44,3,0.6,False,False,,,No comparison,Adult Newly Diagnosed Acute Myeloid Leukemia
295132,"Neo-adjuvant therapy in luminal breast cancer: Who to treat, which regimen, and what duration?","The three ""Ws"" of early breast cancer management",Luminal Breast Cancer,True,Luminal Breast Cancer;;Early Stage Breast Cancer,0.95,6,48,3,0.6,False,False,,,No comparison,Luminal Breast Cancer;;Early Stage Breast Cancer
147677,Validation And Clinical Application Of An Unsupervised Analysis Approach To Measurable Residual Disease Testing In Acute Myeloid Leukemia,Acute Myeloid Leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
180445,Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",IDH1-Mutated IDH2-Mutated Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia;;Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia,0.95,11,104,3,0.85,False,False,,,No comparison,Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia;;Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia
327904,BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas,Lymphomas: Translational-Molecular and Genetic: Poster II,BCL6-Rearranged Indolent B-Cell Lymphoma;;Marginal Zone Lymphoma,True,BCL6-Rearranged Indolent B-Cell Lymphoma;;Marginal Zone Lymphoma,0.95,6,64,1,0.4,False,False,,,No comparison,BCL6-Rearranged Indolent B-Cell Lymphoma;;Marginal Zone Lymphoma
409825,Advocacy and Policy: What Can Nephrologists and National Organizations Do?,Winning Team: The Nephrology Workforce for the 21st Century,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
147689,Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd,Acute Myeloid Leukemia - Clinical,Acute Myeloid Leukemia,True,Persistent MRD Acute Myeloid Leukemia,0.95,5,37,2,0.45,True,False,,,No comparison,Persistent MRD Acute Myeloid Leukemia
180465,Integrated Transcriptomics and Proteomics Identifies Therapeutic Targets in Pediatric Acute Myeloid Leukemia,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Pediatric Acute Myeloid Leukemia,True,Pediatric Acute Myeloid Leukemia,0.95,4,32,2,0.4,False,False,,,No comparison,Pediatric Acute Myeloid Leukemia
409842,Do All Collagen Variants Cause Glomerular Disease?,Collagen IV Conundrums: Genetic Variants and Clinical Management,,True,Glomerular Disease,0.95,2,18,1,0.2,False,False,,,No comparison,Glomerular Disease
164086,Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments,LBA01: Late-breaking Abstract I - Benign,,True,Chronic Residual Fragment,0.85,3,25,1,0.25,False,False,,,No comparison,Chronic Residual Fragment
327929,Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas,Lymphomas: Translational-Molecular and Genetic: Poster III,B-Cell Lymphoma,True,B-Cell Lymphoma,0.95,2,15,1,0.2,False,False,,,No comparison,B-Cell Lymphoma
180473,Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
180478,Duplex-Sequencing Uncovers Low-Frequency Mutations in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,True,Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia,0.95,5,52,2,0.45,False,False,,,No comparison,Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
213248,"BPH Guidelines: Conflict and Contrast in the AUA, EAU, NICE BPH Guidelines",Society of Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
377088,Clinical Characteristics Of Patients With Prolonged Viral Shedding Of Omicron Variant In Haematological Disease,Infections in hematology (incl. supportive care/therapy),Haematological Disease,True,Haematological Disease,0.95,2,22,1,0.2,False,False,,,No comparison,Haematological Disease
295167,Circulating tumour DNA for monitoring of response to neoadjuvant chemotherapy in patients with high grade serous ovarian carcinoma,Thermo Fisher Scientific - Connecting patients everywhere to precision oncology,High Grade Serous Ovarian Carcinoma,True,High Grade Serous Ovarian Carcinoma,0.95,5,35,2,0.45,False,False,,,No comparison,High Grade Serous Ovarian Carcinoma
164102,MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results of a Phase IIb Multicenter Study,LBA02: Late-breaking Abstract II - Malignant,Intermediate-Risk Prostate Cancer,True,Intermediate-Risk Prostate Cancer,0.95,3,33,1,0.25,False,False,,,No comparison,Intermediate-Risk Prostate Cancer
213255,Microbiome and BPH,Society of Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
311555,Itchy Rash and Starry Eyed,Adult Thieves Market Poster,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
213252,Rapid Fire,Society of Benign Prostate Disease,Benign Prostate Disease,True,Benign Prostate Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Benign Prostate Disease
377096,"Azacitidine, Venetoclax And Gilteritinib For Patients With Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia: A Subgroup Analysis From A Phase Ii Study",Acute myeloid leukemia - Clinical,Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia,True,Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia,0.95,6,51,3,0.6,False,False,,,No comparison,Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
344332,Chair Introduction,"Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials",,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
393489,Efficacy Of Notch Inhibitors (Ni) Relative To Prior Systemic Therapy Or Observation In Patients (Pts) With Recurrent/Metastatic (R/M) Adenoid Cystic Carcinoma (Acc),"Head and neck cancers, excl. thyroid",Recurrent/Metastatic Adenoid Cystic Carcinoma,True,Recurrent/Metastatic Adenoid Cystic Carcinoma,0.95,4,45,1,0.3,False,False,,,No comparison,Recurrent/Metastatic Adenoid Cystic Carcinoma
180497,A Prospective Study of Clonal Evolution in Follicular Lymphoma: Circulating Tumor DNA Correlates with Overall Tumor Burden and Fluctuates over Time without Therapy,Lymphomas: Translational-Molecular and Genetic: Poster I,Follicular Lymphoma,True,Follicular Lymphoma,0.95,2,19,1,0.2,False,False,,,No comparison,Follicular Lymphoma
180501,Differential Gene Expression in Circulating T-Cells in Long-Term Adolescent/Young Adult Hodgkin Lymphoma (AYAHL) Survivors and Their Unaffected Twins,Lymphomas: Translational-Non-Genetic: Poster I,Adolescent/Young Adult Hodgkin Lymphoma,True,Adolescent and Young Adult Hodgkin Lymphoma,0.95,6,43,1,0.4,False,False,,,No comparison,Adolescent and Young Adult Hodgkin Lymphoma
262425,Familial Erythrocytoses In The Czech Republic - Genetic Characterization And Hepcidin Regulation,"Iron metabolism, deficiency and overload",Familial Erythrocytosis,True,Familial Erythrocytosis,0.95,2,23,0,0.1,False,False,,,No comparison,Familial Erythrocytosis
213274,"The ""Butterfly"" transurethral retraction device for BPH - over 1 year follow up",MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
311577,Q&A,Adult Thieves Market: Show Me Your Best Cases,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
377120,Axicabtagene Ciloleucel Versus Tisagenlecleucel Car-T Cells In Relapsed Or Refractory Diffuse Large B Cell Lymphoma,"Gene therapy, cellular immunotherapy and vaccination - Clinical",Relapsed/Refractory Diffuse Large B Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.95,5,49,3,0.55,False,False,,,No comparison,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
377121,Single Nucleotide Polymorphisms In Patients With Endothelial Damage After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation,Stem cell transplantation - Clinical,,True,Pediatric Endothelial Damage,0.95,3,28,0,0.15,False,False,,,No comparison,Pediatric Endothelial Damage
229667,The biological mechanisms of metformin effects on aging-associated inflammation in obesity,Immuneregulation-Innate Immune Responses,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
213291,Minimally Invasive and Endoscopic Therapies for Benign Prostatic Hyperplasia: Head-to-Head Comparison of Short-Term Outcomes by Network Meta-Analysis,MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
327983,Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study,Lymphomas: Translational-Non-Genetic: Poster II,Relapsed/Refractory Non-Hodgkin Lymphoma,True,Relapsed/Refractory Non-Hodgkin Lymphoma,0.95,3,40,3,0.45,False,False,,,No comparison,Relapsed/Refractory Non-Hodgkin Lymphoma
180529,Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated with Third-Line Therapy in the United States: A Real-World EHR Study,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I",Third-Line Follicular Lymphoma,True,Third-Line Follicular Lymphoma,0.95,3,30,1,0.25,False,False,,,No comparison,Third-Line Follicular Lymphoma
311607,"UTI Biofilms, Amyloid, and Lupus Flares",Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes,,True,Urinary Tract Infection;;Amyloidosis;;Lupus Flare,0.95,4,49,0,0.2,False,False,,,No comparison,Urinary Tract Infection;;Amyloidosis;;Lupus Flare
377144,A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab For Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup Analysis From A Phase Ii Study,Clinical updates in ALL,Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia,True,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,7,67,4,0.75,False,False,,,No comparison,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia
327998,"Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma",Lymphomas: Translational-Non-Genetic: Poster III,Second-Line Relapsed or Refractory Classical Hodgkin Lymphoma,True,Second-Line Relapsed/Refractory Classical Hodgkin Lymphoma,0.95,5,58,3,0.55,False,False,,,No comparison,Second-Line Relapsed/Refractory Classical Hodgkin Lymphoma
409919,Audience Q&A,What's Complement Got to Do with It? ANCA Vasculitis and the Complement System,ANCA Vasculitis,True,ANCA Vasculitis,0.95,2,15,0,0.1,True,False,,,No comparison,ANCA Vasculitis
147776,"Discovery Of Hbw-3-20, The First Reversible Inhibitor Of Bruton'S Tyrosine Kinase (Btk) With High Brain Exposure",Aggressive Non-Hodgkin Lymphoma - Clinical,Aggressive Non-Hodgkin Lymphoma,True,Aggressive Non-Hodgkin Lymphoma,0.95,3,31,1,0.25,False,False,,,No comparison,Aggressive Non-Hodgkin Lymphoma
328003,Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion,Lymphomas: Translational-Non-Genetic: Poster III,High Grade B Cell Lymphoma,True,High Grade B Cell Lymphoma,0.95,5,26,2,0.45,False,False,,,No comparison,High Grade B Cell Lymphoma
262464,Potentiating Anti-Cd20 Monoclonal Antibody Therapy By Targeting Complement C3 Activation Fragments Covalently Deposited On Lymphoma Cells,Lymphoma Biology & Translational Research,Lymphoma ,True,Lymphoma,0.95,1,8,1,0.15,False,False,,,No comparison,Lymphoma
213317,How does the type of urinary diversion affect health related quality of life (HRQOL) in the course of four years after radical cystectomy? - A propensity score-matched analysis,MP03: Bladder Cancer: Invasive I,Invasive Bladder Cancer,True,Invasive Bladder Cancer,0.95,3,23,1,0.25,False,False,,,No comparison,Invasive Bladder Cancer
147782,Investigation Of Preterm Intraventricular Hemorrhage-Induced Inflammatory Response And Microrna Levels In Human Choroid Plexus Epithelial Cells,Bleeding Disorders (Congenital And Acquired),Congenital Bleeding Disorder;;Acquired Bleeding Disorder,True,Intraventricular Hemorrhage;;Bleeding Disorder;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder,0.95,7,104,1,0.45,False,False,,,No comparison,Intraventricular Hemorrhage;;Bleeding Disorder;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder
147785,"Haemophilia B Leyden, An Age-Related Mechanism For An Increase Of Factor Ix: Case Report And Literature Review",Bleeding Disorders (Congenital And Acquired),Haemophilia B Leyden,True,Haemophilia B Leyden;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder,0.95,7,78,1,0.45,False,False,,,No comparison,Haemophilia B Leyden;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder
328014,Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader,Lymphomas: Translational-Non-Genetic: Poster I,Lymphoma,True,Cutaneous T-Cell Lymphoma,0.95,3,25,1,0.25,False,False,,,No comparison,Cutaneous T-Cell Lymphoma
328016,A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders,Lymphomas: Translational-Non-Genetic: Poster I,Lymphoproliferative Disorder,True,Lymphoproliferative Disorder,0.95,2,28,1,0.2,False,False,,,No comparison,Lymphoproliferative Disorder
213341,Trends in holmium laser enucleation of the prostate for treatment of benign prostatic hyperplasia,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
213344,En-Bloc enucleation technique with early apical release and urinary sphincter preservation using Pulse modulation (Virtual Basket) vs En-Bloc HoLEP,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
295266,How to incorporate digital medicine in survivorship care after breast cancer,How to incorporate digital medicine in survivorship care after breast cancer,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
213348,Thulium YAG vs Thulium Fiber Laser Enucleation of the Prostate (ThuLEP vs TFLEP): a Multi-institution Trial to Compare Intra and Early Postoperative Outcomes.,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
377189,Changings In Genetic Definition And Management Of Acquired Aplastic Anemia: A Single Center Experience,Bone marrow failure syndromes incl. PNH - Clinical,Acquired Aplastic Anemia,True,Acquired Aplastic Anemia,0.95,3,24,0,0.15,False,False,,,No comparison,Acquired Aplastic Anemia
311657,Challenges in Psoriatic Disease: When Skin and Joint Symptoms Are Divergent,Challenges in Psoriatic Disease: Divergent Skin and Joints,Psoriatic Disease,True,Psoriatic Disease,0.95,2,17,1,0.2,False,False,,,No comparison,Psoriatic Disease
377194,Arginine Deprivation Induces Acquisition Of A Senescent Phenotype And Favors Genomic Instability In Multiple Myeloma Plasma Cells,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
409966,Controversies in the Management of Dyslipidemia in Children with CKD,Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?,Childhood Dyslipidemia,True,Dyslipidemia;;Childhood Chronic Kidney Disease,0.95,4,46,2,0.4,False,False,,,No comparison,Dyslipidemia;;Childhood Chronic Kidney Disease
393583,"Comparative Efficacy Of Systemic Sequential Regorafenib After Sorafenib Or Lenvatinib Treatment Failure For Advanced Hepatocellular Carcinoma: A Retrospective, Multi-Center, Real-World Study",Hepatocellular Carcinoma (Hcc),Advanced Hepatocellular Carcinoma,True,Advanced Hepatocellular Carcinoma,0.95,3,33,2,0.35,False,False,,,No comparison,Advanced Hepatocellular Carcinoma
262514,Clinical Significance Of Routine High-Resolution Strucural Variant Profiling In Myelodysplastic Syndromes,Myelodysplastic syndromes - Clinical,Myelodysplastic Syndrome,True,Myelodysplastic Syndrome,0.95,2,24,1,0.2,False,False,,,No comparison,Myelodysplastic Syndrome
262522,Runx1 Variants With High Variant Allele Frequency In Myeloid Neoplasms. Germline Or Not?,Myelodysplastic syndromes - Clinical,Myeloid Neoplasm,True,RUNX1-Altered Myeloid Neoplasm,0.95,3,30,0,0.15,False,False,,,No comparison,RUNX1-Altered Myeloid Neoplasm
164220,Panel Discussion,Society for Pediatric Urology (SPU),,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
409981,Power of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repositories,Power of Large Biorepositories in Diabetic Kidney Disease,Diabetic Kidney Disease,True,Diabetic Kidney Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Diabetic Kidney Disease
147837,Influence Of Inflammatory Cytokines On S100A Proteins Expression In Cll Patients,Chronic Lymphocytic Leukemia And Related Disorders - Biology & Translational Research,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Chronic Lymphocytic Leukemia
262527,Characterization Of Multiple Myeloma Cell Lines With Acquired-Resistance To Proteasome Inhibitors Highlights A Link Between Resistance And Metabolic Deregulation,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
409986,Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1,A Rocky Course: Bones and Stones Through the Life Span,Cystinuria;;Primary Hyperoxaluria Type 1;;Genetic Stone Disease,True,Genetic Stone Disease;;Cystinuria;;PH1,0.95,3,38,1,0.25,False,False,,,No comparison,Genetic Stone Disease;;Cystinuria;;PH1
311696,Proposed ACR/EULAR Classification Criteria for CNO,Development of Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO),Pediatric Chronic Nonbacterial Osteomyelitis,True,Pediatric Chronic Nonbacterial Osteomyelitis;;Pediatric Chronic Recurrent Multifocal Osteomyelitis,0.95,8,98,1,0.5,False,False,,,No comparison,Pediatric Chronic Nonbacterial Osteomyelitis;;Pediatric Chronic Recurrent Multifocal Osteomyelitis
344465,Chairperson,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
344467,Reprogramming the tumor-immune microenvironment by targeting galectin-glycan interactions,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
295316,Gender differences in colorectal cancer screening,Sex and gender differences in oncology: From prevention to care,Colorectal Cancer,True,Colorectal Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Colorectal Cancer
147864,Effectiveness And Safety Of Ibrutinib In Chronic Lymphocytic Leukemia (Cll) And Mantle Cell Lymphoma (Mcl) In Belgian Routine Clinical Practice With A 3-Year Follow-Up,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,True,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,0.95,5,50,3,0.55,False,False,,,No comparison,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma
393627,Tertiary Lymphoid Structures Localization And Maturation Heterogeneities Correlate With Divergent Clinical Outcomes And Immune Responses Of Clear Cell Renal Cell Carcinoma,Investigational Immunotherapy,Clear Cell Renal Cell Carcinoma,True,Clear Cell Renal Cell Carcinoma,0.95,5,31,1,0.35,False,False,,,No comparison,Clear Cell Renal Cell Carcinoma
213405,Medications mostly associated with haematuria: assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries,"MP07: Bladder & Urethra: Anatomy, Physiology & Pharmacology",Haematuria,True,Haematuria,0.95,1,10,0,0.05,False,False,,,No comparison,Haematuria
164257,Controversies in the Management of High-Risk Prostate Cancer,Society of Urologic Oncology (SUO),High-Risk Prostate Cancer,True,High-Risk Prostate Cancer,0.95,3,25,1,0.25,False,False,,,No comparison,High-Risk Prostate Cancer
393639,Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database,Investigational Immunotherapy,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
262567,Efficacy And Safety Of Daratumumab Monotherapy In Newly Diagnosed Patients With Stage 3B Light Chain Amyloidosis: A Phase 2 Study By The European Myeloma Network,Myeloma and other monoclonal gammopathies - Clinical,Newly Diagnosed Stage 3B Light Chain Amyloidosis,True,Newly Diagnosed Stage IIIB Light Chain Amyloidosis,0.95,7,50,2,0.55,True,False,,,No comparison,Newly Diagnosed Stage IIIB Light Chain Amyloidosis
262569,High Responses Rates With Single Agent Belantamab Mafodotin In Relapsed Systemic Al Amyloidosis,Myeloma and other monoclonal gammopathies - Clinical,Relapsed Systemic Al Amyloidosis,True,Relapsed Systemic AL Amyloidosis,0.95,4,32,1,0.3,True,False,,,No comparison,Relapsed Systemic AL Amyloidosis
164266,Welcome and Introductory Remarks,Society for Basic Urologic Research (SBUR),,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
328106,Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I",Relapsed/Refractory Mantle Cell Lymphoma,True,Relapsed/Refractory Mantle Cell Lymphoma,0.95,4,40,3,0.5,False,False,,,No comparison,Relapsed/Refractory Mantle Cell Lymphoma
377263,Role Of Interleukin 6 And Angiopoietins 1 And 2 In The Evolution Of Patients Diagnosed With Multiple Myeloma,Myeloma and other monoclonal gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
213425,Long Term Fertility Implications Following Adolescent Testicular Torsion: A Retrospective Analysis of a New York State All-Payer Database,MP08: Pediatric Urology: Penis & Scrotum,,True,Adolescent Testicular Torsion,0.95,3,29,0,0.15,False,False,,,No comparison,Adolescent Testicular Torsion
295345,Presentation by Expert,Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?,Chronic Lymphocytic Leukemia,True,First-Line Chronic Lymphocytic Leukemia,0.95,4,39,2,0.4,False,False,,,No comparison,First-Line Chronic Lymphocytic Leukemia
393651,Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy After Relapse On A Prior Adjuvant Checkpoint Inhibitor And Subsequent Surgical Resection In Patients With Braf V600-Mutated Stage Iii/Iv Melanoma,Melanoma And Other Skin Tumours,Braf V600-Mutated Stage III/IV Melanoma,True,Relapsed Resected BRAF V600-Mutated Stage III/IV Melanoma,0.95,7,57,2,0.55,True,False,,,No comparison,Relapsed Resected BRAF V600-Mutated Stage III/IV Melanoma
393652,Adjuvant Treatment With Anti-Pd-1 In Acral Melanoma Patients: A Nationwide Study,Melanoma And Other Skin Tumours,Acral Melanoma,True,Acral Melanoma,0.95,2,14,0,0.1,False,False,,,No comparison,Acral Melanoma
262579,Survival Outcomes Of Patients With Multiple Myeloma In France: A Cohort Study Using The French National Healthcare Database (Snds),Myeloma and other monoclonal gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
262577,Incidence And Clinical Outcome Of Sars-Cov-2 Infection After Vaccination In Patients With Monoclonal Gammopathy Of Undetermined Significance (Mgus),Myeloma and other monoclonal gammopathies - Clinical,Sars-Cov-2 Infection;;Monoclonal Gammopathy,True,Monoclonal Gammopathy of Undetermined Significance,0.95,5,50,0,0.25,False,False,,,No comparison,Monoclonal Gammopathy of Undetermined Significance
295352,How to write and respond to a critical peer review,Young Oncologist Brunch 2: How to write and respond to a critical peer review,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
377273,Preliminary Exploration On Lag-3 Expression Of Bone Marrow-Derived Macrophages In Severe Aplastic Anemia,Bone marrow failure syndromes incl. PNH - Biology & Translational Research,Severe Aplastic Anemia,True,Severe Aplastic Anemia,0.95,3,22,1,0.25,False,False,,,No comparison,Severe Aplastic Anemia
410042,Common Variants in Mendelian Disease Genes as Risk Factors for CKD,"APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases",Chronic Kidney Disease,True,Nephrotic Syndrome;;Chronic Kidney Disease,0.95,4,42,3,0.5,False,False,,,No comparison,Nephrotic Syndrome;;Chronic Kidney Disease
344512,Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss,"New Insights into Cancer Initiation, Evolution, Therapy and Survivorship through Big Data Analysis",Cancer ,True,TP53-Aberrated Cancer,0.95,2,21,1,0.2,False,False,,,No comparison,TP53-Aberrated Cancer
295362,State of the art first-line management of patients with advanced RCC,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,Advanced Renal Cell Carcinoma,True,First-Line Advanced Renal Cell Carcinoma,0.95,5,40,2,0.45,False,False,,,No comparison,First-Line Advanced Renal Cell Carcinoma
311747,Q&A,"Experts Roundtable: Current and Future Payment Models, MIPS, and Other Hot Topics in Practice Management",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
393665,First-Line Nivolumab Plus Ipilimumab In Advanced Melanoma Patients Previously Treated With Adjuvant Systemic Therapy.,Melanoma And Other Skin Tumours,Advanced Melanoma,True,First-Line Previously Treated Advanced Melanoma,0.95,5,47,2,0.45,False,False,,,No comparison,First-Line Previously Treated Advanced Melanoma
295365,Q&A and discussion,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,Advanced Renal Cancer,True,Advanced Renal Cancer,0.95,3,21,2,0.35,False,False,,,No comparison,Advanced Renal Cancer
344518,BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules,Late-Breaking Research: Chemistry,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
377287,"A Novel Approach Of Dual Metagenomics Next-Generation Sequencing For Early Diagnosis Of Blood Stream Infection In Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study",Infections and SCT complications,Febrile Neutropenia,True,Blood Stream Infection;;Febrile Neutropenia,0.95,4,43,0,0.2,False,False,,,No comparison,Blood Stream Infection;;Febrile Neutropenia
410057,Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm,Maternal and Environmental Factors: Effect on Kidney Formation and Function,Kidney Injury,True,Kidney Injury,0.95,2,13,0,0.1,False,False,,,No comparison,Kidney Injury
213447,Quality of Information in Spanish on BRCA and Genetic Testing in Prostate Cancer on YouTube,MP09: Prostate Cancer: Detection & Screening I,Prostate Cancer,True,Prostate Cancer,0.95,2,15,1,0.2,False,False,,,No comparison,Prostate Cancer
295375,TNBC today: How can we increase survival for a very heterogenous and aggressive disease?,"Gilead and Kite Oncology - Redefining the Lines of TNBC, Real-world management: improving survival for patients with metastatic TNBC",Triple-Negative Breast Cancer,True,Metastatic Triple-Negative Breast Cancer;;Aggressive Triple-Negative Breast Cancer,0.95,7,82,2,0.55,False,False,,,No comparison,Metastatic Triple-Negative Breast Cancer;;Aggressive Triple-Negative Breast Cancer
328146,"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)",Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III,Early Stage Classic Hodgkin Lymphoma,True,Early Stage Classic Hodgkin Lymphoma,0.95,5,36,3,0.55,False,False,,,No comparison,Early Stage Classic Hodgkin Lymphoma
328150,Late Effects Comparison between Two Chemotherapy Regimens for Hodgkin Lymphoma,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III,Hodgkin Lymphoma,True,Hodgkin Lymphoma;;T/NK Cell Lymphoma,0.95,4,36,1,0.3,True,False,,,No comparison,Hodgkin Lymphoma;;T/NK Cell Lymphoma
147934,"Selection, Expansion, And New Pretreatment Of Human Natural Killer Cells With Anti-Cd38 Monoclonal Antibody For Efficient Treatment Of Multiple Myeloma.","Gene Therapy, Cellular Immunotherapy And Vaccination - Biology & Translational Research",Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
180704,Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx),Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I,Relapsed/Refractory Chronic Lymphocytic Leukemia,True,Relapsed/Refractory Chronic Lymphocytic Leukemia,0.95,4,48,4,0.6,False,False,,,No comparison,Relapsed/Refractory Chronic Lymphocytic Leukemia
213477,Endoscopic Injection Of The Bladder Neck Using Dextranomer Hyaluronate (Dx/Ha) In The Pediatric Patient: Results Of A Single Center Analysis With Long Term Follow Up,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Pediatric Neurogenic Bladder,True,Pediatric Neurogenic Bladder,0.95,3,28,0,0.15,False,False,,,No comparison,Pediatric Neurogenic Bladder
213478,A Technique to Prevent Stomal Stenosis in Reconstructive Urology,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",,True,Pediatric Stomal Stenosis,0.95,3,25,0,0.15,False,False,,,No comparison,Pediatric Stomal Stenosis
295399,"Triple, double and monotherapy: what is the sequence for best outcomes?",Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer,True,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer,0.95,6,48,2,0.5,False,False,,,No comparison,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer
262634,T Cell Response And Omicron Variant Neutralisation Following Vaccination Against Sars-Cov-2 In Patients With Chronic Myeloid Disorders,Myeloproliferative neoplasms - Biology & Translational Research,Chronic Myeloid Disorder,True,Chronic Myeloid Disorder,0.95,3,24,2,0.35,False,False,,,No comparison,Chronic Myeloid Disorder
213480,Survival analysis among Utah residents with spina bifida born between 1950 and 2015,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Spina Bifida,True,Spina Bifida,0.95,2,12,0,0.1,False,False,,,No comparison,Spina Bifida
295405,Therapeutic approaches in unresectable / advanced HCC,AstraZeneca - Immunotherapy: the evolving treatment landscape in hepatobiliary cancers,Unresectable/Advanced Hepatocellular Carcinoma,True,Unresectable/Advanced Hepatocellular Carcinoma,0.95,3,46,2,0.35,False,False,,,No comparison,Unresectable/Advanced Hepatocellular Carcinoma
393710,Transforming Growth Factor-Beta-1 And Soluble Co-Inhibitory Immune Checkpoints As Putative Drivers Of Immune Suppression In Advanced Basal Cell Carcinoma,Melanoma And Other Skin Tumours,Advanced Basal Cell Carcinoma,True,Advanced Basal Cell Carcinoma,0.95,4,29,2,0.4,False,False,,,No comparison,Advanced Basal Cell Carcinoma
410094,Value of Urine Microscopy in Clinical Practice: Illustration by Cases,"Liquid ""Gold,"" Urinary Sediment Microscopy: Current Utility of an Old Tool",,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
262640,Peripheral Blood Cytotoxic T Cells Show Early Exhausted Features In Myelofibrosis Patients,Myeloproliferative neoplasms - Biology & Translational Research,Myelofibrosis ,True,Myelofibrosis,0.95,1,13,0,0.05,False,False,,,No comparison,Myelofibrosis
328177,Primary Cutaneous Gamma-Delta T-Cell Lymphoma (PCGDTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,True,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,0.95,5,45,1,0.35,False,False,,,No comparison,Primary Cutaneous Gamma-Delta T-Cell Lymphoma
311793,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) IV,Fellows-In-Training: Roundtables,Adult Pediatric Rheumatic Disease,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
213484,Short and Long Term Renal Outcomes in Clinically Matched Cohorts of Newborns with PUV Managed by Primary Vesicostomy Versus Primary Valve Ablation,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Neonatal Posterior Urethral Valve,True,Pediatric Neurogenic Bladder;;Neonatal Posterior Urethral Valves,0.95,6,64,0,0.3,False,False,,,No comparison,Pediatric Neurogenic Bladder;;Neonatal Posterior Urethral Valves
311791,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) III,Fellows-In-Training: Roundtables,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
311808,Roundtable 08 - How to Establish a Career Niche IV,Fellows-In-Training: Roundtables,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
295427,Metastatic non-small-cell lung cancer: Discussion / Q&A,ESMO Clinical Practice Guidelines session 2,Metastatic Non-Small-Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
393731,Evaluation Of The Transcriptomic Presence Of Tumor Associated Antigens (Taas) From Antibody Drug Conjugates (Adcs) And Pd-L1 In Melanoma: Options For New Clinical Opportunities,Melanoma And Other Skin Tumours,Melanoma,True,Melanoma;;Skin Tumor,0.95,2,20,1,0.2,False,False,,,No comparison,Melanoma;;Skin Tumor
311815,Roundtable 10 - Early Career Niche in Pediatric Rheumatology: Amplified Pain Syndrome III,Fellows-In-Training: Roundtables,Pediatric Amplified Pain Syndrome III,True,Pediatric Amplified Pain Syndrome III,0.95,5,37,1,0.35,True,False,,,No comparison,Pediatric Amplified Pain Syndrome III
262670,Higher Estimated Plasma Volume Status Is Associated With Increased Thrombotic Risk And Impaired Survival In Patients With Primary Myelofibrosis,Myeloproliferative neoplasms - Clinical,Primary Myelofibrosis,True,Primary Myelofibrosis,0.95,2,21,0,0.1,False,False,,,No comparison,Primary Myelofibrosis
295442,Invited Discussant LBA54 and 972O,"Proffered Paper session: NSCLC, metastatic",Metastatic Non-Small Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
393754,"A Phase II Single-Arm Interventional Trial Evaluating The Activity And Safety Of Cabozantinib (Cbz) Plus Temozolomide (Tmz) In Lung And Gastroenteropancreatic Neuroendocrine Neoplasms (Gep-Nens) Progressed After Ssa Therapy, Everolimus, Sunitinib Or Prrt: Cabotem Trial",Neuroendocrine Tumours,Lung Neuroendocrine Neoplasm;;Gastroenteropancreatic Neuroendocrine Neoplasm ,True,Progressive Lung Neuroendocrine Neoplasm;;Progressive Gastroenteropancreatic Neuroendocrine Neoplasm,0.95,7,100,0,0.35,False,False,,,No comparison,Progressive Lung Neuroendocrine Neoplasm;;Progressive Gastroenteropancreatic Neuroendocrine Neoplasm
377370,Subclonal And Clonal Variants In Tp53 And Kras Combined With Poor Treatment Response Identify A Subgroup Of Ultra-High-Risk Patients Of Pediatric T-Lymphoblastic Leukemia (T-All),Acute lymphoblastic leukemia - Biology & Translational Research,TP53-Mutated KRAS-Mutated Ultra High-Risk Pediatric T-Lymphoblastic Leukemia,True,Pediatric Ultra High-Risk T-Lymphoblastic Leukemia,0.95,5,50,1,0.35,False,False,,,No comparison,Pediatric Ultra High-Risk T-Lymphoblastic Leukemia
262689,Responses To Avapritinib In Patients With Advanced Systemic Mastocytosis: Histopathologic Analyses From Explorer And Pathfinder Clinical Studies,Myeloproliferative neoplasms - Clinical,Advanced Systemic Mastocytosis,True,Advanced Systemic Mastocytosis,0.95,3,30,1,0.25,False,False,,,No comparison,Advanced Systemic Mastocytosis
328231,"The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial",Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,True,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,0.95,4,47,3,0.5,False,False,,,No comparison,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
148009,Real-World Treatment Patterns And Outcomes Of 3455 Previously Untreated Mantle Cell Lymphoma Patients In Us Routine Clinical Practice,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Previously Untreated Mantle Cell Lymphoma,True,Previously Untreated Mantle Cell Lymphoma,0.95,5,41,2,0.45,False,False,,,No comparison,Previously Untreated Mantle Cell Lymphoma
377385,Impacts On Outcomes And A Predictive Model Of Severe Thrombocytopenia In Patients With Chronic Phase Chronic Myeloid Leukemia Receiving Initial Nilotinib-Therapy,Chronic myeloid leukemia - Clinical,Severe Thrombocytopenia;;Chronic Phase Chronic Myeloid Leukemia,True,Severe Thrombocytopenia;;Chronic-Phase Chronic Myeloid Leukemia,0.95,5,63,3,0.55,False,False,,,No comparison,Severe Thrombocytopenia;;Chronic-Phase Chronic Myeloid Leukemia
148013,Prevalence Of Second Cancer During Long Term Follow-Up In Hairy Cell Leukemia Patients Treated With Cladribine: A Thirty-Year Experience,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Hairy Cell Leukemia,True,Second Cancer;;Hairy Cell Leukemia,0.95,4,34,2,0.4,False,False,,,No comparison,Second Cancer;;Hairy Cell Leukemia
262704,Low Serum Bdnf Levels Are Associated With Lower Platelets' Cd62P Reactivity And Increased Bleeding Tendency In Patients With Gaucher Disease,Platelet disorders,Gaucher Disease,True,Gaucher Disease,0.95,2,15,1,0.2,False,False,,,No comparison,Gaucher Disease
180787,Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I,Multiple Myeloma,True,Multiple Myeloma;;Plasma Cell Dyscrasia,0.95,4,39,1,0.3,False,False,,,No comparison,Multiple Myeloma;;Plasma Cell Dyscrasia
295477,5-hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions,Mini Oral session: Basic science & translational research,,True,Cancer;;Tumor,0.85,1,13,2,0.25,False,False,,,No comparison,Cancer;;Tumor
328247,Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >=65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >=1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,Elderly Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.95,5,49,3,0.55,False,False,,,No comparison,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
229946,Low birth weight is associated with sperm DNA fragmentation and assisted reproductive technology outcomes in primary infertile men - results of a cross-sectional study,PD09: Infertility: Epidemiology & Evaluation I,,True,Primary Infertility,0.95,2,19,0,0.1,False,False,,,No comparison,Primary Infertility
328253,"Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma",Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.95,5,49,3,0.55,False,False,,,No comparison,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
262717,Metabolic Abnormality And Glucocorticoid Receptor Modulation Of Myeloid-Derived Suppressor Cells In Immune Thrombocytopenia Patients And An Active Murine Model,Platelet disorders,Immune Thrombocytopenia,True,Immune Thrombocytopenia,0.95,2,23,0,0.1,False,False,,,No comparison,Immune Thrombocytopenia
410176,Earlier Intervention in Diabetic Kidney Disease Management Using the In Vitro Diagnostic Test PromarkerD Shows Economic Health Benefits over Current Standard of Care,Improving Clinical Outcomes in Diabetic Kidney Disease,Diabetic Kidney Disease,True,Diabetic Kidney Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Diabetic Kidney Disease
180799,"Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma",Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,0.95,4,32,2,0.4,False,False,,,No comparison,Newly Diagnosed Multiple Myeloma
262725,Economic Burden Of Transfusion-Dependent Beta-Thalassemia In The United States,"Quality of life, palliative care, ethics and health economics",Beta-Thalassemia,True,Transfusion-Dependent-Beta-Thalassemia,0.95,1,38,0,0.05,False,False,,,No comparison,Transfusion-Dependent-Beta-Thalassemia
311878,Roundtable 24 - Salivary Lip Biopsies in Practice IV,Fellows-In-Training: Roundtables,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
262728,Factors Associated With A Lymphoma Diagnosis Prior To Biopsy,"Quality of life, palliative care, ethics and health economics",Lymphoma,True,Lymphoma,0.95,1,8,1,0.15,False,False,,,No comparison,Lymphoma
377420,Expression Of The Long Non-Coding Rna Malat1 In Chronic Lymphocytic Leukemia,Chronic lymphocytic leukemia and related disorders - Biology & Translational Research,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Chronic Lymphocytic Leukemia
344653,Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma,Diagnostic and Prognostic Biomarkers 1,Malignant Uterine Leiomyosarcoma,True,Malignant Uterine Leiomyosarcoma;;Benign Leiomyoma,0.95,4,50,0,0.2,False,False,,,No comparison,Malignant Uterine Leiomyosarcoma;;Benign Leiomyoma
180817,"Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone",Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,0.95,4,32,2,0.4,False,False,,,No comparison,Newly Diagnosed Multiple Myeloma
328274,Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium,Aggressive Lymphomas: Clinical and Epidemiological: Poster II,Adolescent Adult Burkitt Lymphoma;;Adolescent Adult Leukemia,True,Adolescent Aggressive Burkitt Lymphoma;;Adult Aggressive Burkitt Lymphoma;;Adolescent Leukemia;;Adult Leukemia,0.95,9,110,2,0.65,False,False,,,No comparison,Adolescent Aggressive Burkitt Lymphoma;;Adult Aggressive Burkitt Lymphoma;;Adolescent Leukemia;;Adult Leukemia
393814,Personalized Tumor-Informed Circulating Tumor Dna (Ctdna) Analysis For Molecular Residual Disease (Mrd) Detection In Resected Non-Small Cell Lung Cancer (Nsclc) With Common Driver Genes,"Nsclc, Early Stage",Resected Non-Small Cell Lung Cancer,True,Resected Early Stage Non-Small Cell Lung Cancer,0.95,7,47,3,0.65,False,False,,,No comparison,Resected Early Stage Non-Small Cell Lung Cancer
213592,Are pre-operative urine cultures and cystoscopies before ureteral reimplantation clinically useful or cost effective?,MP17: Pediatric Urology: Upper & Lower Urinary Tract,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
344667,Detecting and intervening on rare pre-existing resistant subclones to BRAF/MEK inhibitors in metastatic melanoma,Diagnostic and Prognostic Biomarkers 1,Metastatic Melanoma,True,Metastatic Melanoma,0.95,2,19,0,0.1,False,False,,,No comparison,Metastatic Melanoma
180828,Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study,Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,Relapsed and/or Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
377438,Pharmacodynamic Activity Of Gen3014 (Hexabody-Cd38) In Patients With Multiple Myeloma Supports Enhanced Complement Dependent Cytotoxicity Of Gen3014 Compared To Daratumumab,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
311906,Q&A,Genetic Predisposition and the Balance Between Infection and Autoimmunity,,True,Infection;;Autoimmunity,0.95,1,23,0,0.05,False,False,,,No comparison,Infection;;Autoimmunity
393826,Concordance Of Pd-L1 Expression Between Biopsy And Matched Surgical Specimen In Early-Stage Non-Small Cell Lung Cancer: Lc-Scrum-Advantage/Mrd,"Nsclc, Early Stage",Early-Stage Non-Small Cell Lung Cancer,True,Early Stage Non-Small Cell Lung Cancer,0.95,6,38,3,0.6,False,False,,,No comparison,Early Stage Non-Small Cell Lung Cancer
393827,Predicting Pd-L1 Expression Using [18F]Fdg Pet/Ct In Early Stage Non-Small Cell Lung Cancer (Nsclc).,"Nsclc, Early Stage",Early Stage Non-Small Cell Lung Cancer,True,Early Stage PD-L1-Expressing Non-Small Cell Lung Cancer,0.95,7,55,3,0.65,True,False,,,No comparison,Early Stage PD-L1-Expressing Non-Small Cell Lung Cancer
213605,Is Excretory Phase Computerized Tomography Important for Evaluation of High Grade Renal Trauma?: Results from the Traumatic Renal Injury Collaboration for Kids (TRICK),MP17: Pediatric Urology: Upper & Lower Urinary Tract,Traumatic Renal Injury,True,Pediatric High Grade Renal Trauma,0.95,5,33,1,0.35,False,False,,,No comparison,Pediatric High Grade Renal Trauma
393830,Real-World Outcomes In Stage I-Iii Resectable Non-Small Cell Lung Cancer (Nsclc): Thassos-Intl Study,"Nsclc, Early Stage",Stage I-III Resectable Non-Small Cell Lung Cancer,True,Stage 1-3 Resectable Non-Small Cell Lung Cancer,0.95,7,47,2,0.55,False,False,,,No comparison,Stage 1-3 Resectable Non-Small Cell Lung Cancer
393832,Neoadjuvant Therapy With Anti-Pd-1/Pd-L1 Plus Platinum-Base Chemotherapy For Resectable Stage Ii-Iii Non-Small Cell Lung Cancer: A Systematic Review And Meta-Analysis Of Randomized Clinical Trials,"Nsclc, Early Stage",Resectable Stage II-III Non-Small Cell Lung Cancer,True,Resectable Stage 2-3 Non-Small Cell Lung Cancer,0.95,7,47,2,0.55,False,False,,,No comparison,Resectable Stage 2-3 Non-Small Cell Lung Cancer
164457,"Welcome and Why SOBPD Should Exist, Who We Are and Our Mission. Society Benefits, Annual meetings",Society for Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostate Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Benign Prostate Disease
180842,The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation,Experimental Transplantation: Basic and Translational: Poster I,Graft-Versus-Host Disease,True,Gut Graft-Versus-Host Disease,0.95,3,29,1,0.25,False,False,,,No comparison,Gut Graft-Versus-Host Disease
262759,Health-Related Quality Of Life In Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated With Iberdomide Plus Dexamethasone In A Phase 1B/2A Open-Label Dose Escalation Study,"Quality of life, palliative care, ethics and health economics",Relapsed/Refractory Multiple Myeloma ,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
164460,The Advent of Directed Medical BPH Care-How Alpha Blockers were Developed,Society for Benign Prostate Disease,Benign Prostatic Hyperplasia,True,Benign Prostate Disease;;Benign Prostatic Hyperplasia,0.95,5,53,1,0.35,False,False,,,No comparison,Benign Prostate Disease;;Benign Prostatic Hyperplasia
295539,Patient and Public Involvement in Cancer Research: The Needs and Perceptions of Older Adults Living with and After Cancer,Supportive care and symptom management,Older Adult Cancer,True,Older Adult Cancer,0.95,3,18,1,0.25,False,False,,,No comparison,Older Adult Cancer
164469,Photoselective Vaporization of the Prostate,Society for Benign Prostate Disease,Benign Prostate Disease,True,Benign Prostate Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Benign Prostate Disease
311932,How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?,How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?,Psoriatic Arthritis,True,Psoriatic Arthritis,0.95,2,19,0,0.1,False,False,,,No comparison,Psoriatic Arthritis
344700,OvaPrint - a novel cfDNA methylation liquid biopsy for cancer risk assessment in high grade serous ovarian carcinoma,Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,High Grade Serous Ovarian Carcinoma,True,High Grade Serous Ovarian Carcinoma,0.95,5,35,2,0.45,False,False,,,No comparison,High Grade Serous Ovarian Carcinoma
393855,First-Line Osimertinib In Patients With Egfr Mutated Lung Cancer With Uncommon Mutations (Ocelot Study - Interim Analysis),"Nsclc, Metastatic",EGFR-Mutated Lung Cancer,True,EGFR-Mutated Metastatic Non-Small Cell Lung Cancer,0.95,6,50,1,0.4,True,False,,,No comparison,EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
344703,Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED),Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
230018,Breast cancer: Online education's effect on clinician ability to assess risk of recurrence and understanding the latest data.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
148103,Cohesin Mutations Are Associated With A Poor Prognosis Phenotype And A Worse Clinical Outcome In Low-Risk Myelodysplastic Syndromes Patients,Myelodysplastic Syndromes - Biology & Translational Research,Low-Risk Myelodysplastic Syndrome,True,Low-Risk Myelodysplastic Syndrome,0.95,3,33,1,0.25,False,False,,,No comparison,Low-Risk Myelodysplastic Syndrome
262793,Long-Term Follow-Up Of Dutch Patients With Sickle Cell Disease Diagnosed By Neonatal Screening - Effect On The Morbidity And Mortality In The Netherlands.,Sickle cell disease,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
328332,Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group,Aggressive Lymphomas: Clinical and Epidemiological: Poster I,Sars-Cov-2 Infection;;Primary CNS Lymphoma,True,Primary CNS Lymphoma,0.95,3,20,1,0.25,True,False,,,No comparison,Primary CNS Lymphoma
262802,Allogeneic Hematopoietic Stem Transplantation (Hsct) In Patients Over 60 Years. Retrospective Experience Of Two Spanish Centers Between 2015-2020,Stem cell transplantation - Clinical,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
148116,Mesenchymal Stromal Cells As A Potential Therapeutic Tool In Enhancing Residual Healthy Haematopoiesis In Low-Risk Mds Patients,Myelodysplastic Syndromes - Biology & Translational Research,Low-Risk Myelodysplastic Syndrome,True,Low-Risk Myelodysplastic Syndrome,0.95,3,33,1,0.25,False,False,,,No comparison,Low-Risk Myelodysplastic Syndrome
377489,Prophylactic And Preemptive Use Of Dli Compare Favourably To Their Therapeutic Use In Adult Acute Lymphoblastic Leukemia (All) - Results Of A Multicentre Retrospective Study,Acute lymphoblastic leukemia - Clinical,Adult Acute Lymphoblastic Leukemia,True,Adult Acute Lymphoblastic Leukemia,0.95,4,34,2,0.4,False,False,,,No comparison,Adult Acute Lymphoblastic Leukemia
311960,"Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity",Ignite Session 1C,,True,Systemic Autoimmunity,0.95,2,21,0,0.1,False,False,,,No comparison,Systemic Autoimmunity
230042,Predictive value of circulating tumor cells FTH1 gene on the efficacy of neoadjuvant chemotherapy in non-metastatic breast cancer.,Breast Cancer-Local/Regional/Adjuvant,Non-Metastatic Breast Cancer,True,Non-Metastatic Breast Cancer,0.95,3,28,1,0.25,False,False,,,No comparison,Non-Metastatic Breast Cancer
213661,A Pilot Study of Outcomes after Robot-Assisted Sigmoid Vaginoplasty for Gender Dysphoria,MP20: Trauma/Reconstruction/Diversion: External Genitalia Reconstruction and Urotrauma (including transgender surgery) I,Gender Dysphoria,True,Gender Dysphoria,0.95,2,16,0,0.1,False,False,,,No comparison,Gender Dysphoria
410269,Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD,Interventions to Reduce CKD Progression,Primary Kidney Disease;;Chronic Kidney Disease,True,Primary Kidney Disease;;Chronic Kidney Disease,0.95,5,46,2,0.45,False,False,,,No comparison,Primary Kidney Disease;;Chronic Kidney Disease
393888,Updated Patient-Reported Outcomes From The Crown Study: Analyses In First-Line Alk+ Patients With (W) And Without (W/O) Baseline Brain Metastases (Bms) And W Or W/O Central Nervous System Adverse Events (Cns Aes),"Nsclc, Metastatic",First-Line ALK-Postive Metastatic Non-Small Cell Lung Cancer,True,First-Line ALK-Positive Metastatic Non-Small Cell Lung Cancer,0.95,7,61,2,0.55,True,False,,,No comparison,First-Line ALK-Positive Metastatic Non-Small Cell Lung Cancer
148133,Venetoclax Combined With Azacitidine In The Treatment Of Relapsed/Refractory High-Risk Myelodysplastic Syndromes And Acute Myeloid Leukemia: A Retrospective Single-Center Study,Myelodysplastic Syndromes - Clinical,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory High-Risk Acute Myeloid Leukemia,True,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory Acute Myeloid Leukemia,0.95,7,98,5,0.85,False,False,,,No comparison,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory Acute Myeloid Leukemia
230055,Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Node-Positive Breast Cancer,0.95,3,27,2,0.35,False,False,,,No comparison,Node-Positive Breast Cancer
230053,Neutrophil-lymphocyte ratio and prediction of pathological complete response to neoadjuvant treatment in breast cancer.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
410286,Differential cfDNA Methylation in Kidney Allograft Rejection,"Kidney Transplantation: Biomarkers, New and Old",,True,Kidney Allograft Rejection,0.95,3,26,0,0.15,False,False,,,No comparison,Kidney Allograft Rejection
410288,Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection,"Kidney Transplantation: Biomarkers, New and Old",,True,Kidney Transplant T Cell-Mediated Rejection,0.95,5,43,0,0.25,False,False,,,No comparison,Kidney Transplant T Cell-Mediated Rejection
410290,Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study,"Kidney Transplantation: Biomarkers, New and Old",Hypertension ,True,Hypertension;;Graft Failure,0.95,2,27,0,0.1,False,False,,,No comparison,Hypertension;;Graft Failure
230073,Impacts of subtypes on clinical feature and outcome of male breast cancer.,Breast Cancer-Local/Regional/Adjuvant,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
393915,Efficacy Of First-Line Treatment Options In Advanced Her2-Altered Non-Small Cell Lung Cancer: A Multi-Center Retrospective Study,"Nsclc, Metastatic",First-Line Advanced HER2-Altered Non-Small Cell Lung Cancer,True,First-Line Advanced HER2-Altered Non-Small Cell Lung Cancer,0.95,7,59,2,0.55,False,False,,,No comparison,First-Line Advanced HER2-Altered Non-Small Cell Lung Cancer
148158,Tumor Associated Macrophages Inhibit Cd8+T Cells Immune Responses Via Pd-1/Pd-L1 Pathway In Multiple Myeloma,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
262851,Efficacy And Safety Comparison Of Calcineurin Inhibitors Used For Gvhd Prophylaxis In Hematopoietic Stem Cell Transplantation In Children With Thalassemia,Stem cell transplantation - Clinical,Thalassemia,True,Childhood Thalassemia,0.95,2,21,0,0.1,False,False,,,No comparison,Childhood Thalassemia
213700,How is health-related quality of life affected by salvage cystectomy and urinary diversion as a last-line option for benign disease,"MP22: Trauma/Reconstruction/Diversion: Urethral Reconstruction (including Stricture, Diverticulum) I",,True,Stricture;;Diverticulum,0.95,1,23,0,0.05,False,False,,,No comparison,Stricture;;Diverticulum
180933,Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
180932,The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",Early Cytomegalovirus Infection,True,Adult Early Cytomegalovirus Infection,0.95,4,37,1,0.3,False,False,,,No comparison,Adult Early Cytomegalovirus Infection
393929,Real-World Routine Kras Testing Practices In France For Patients (Pts) With Advanced Or Metastatic (Am) Non-Small Cell Lung Cancer (Nsclc): Data From The Esme Cohort,"Nsclc, Metastatic",Advanced Or Metastatic Non-Small Cell Lung Cancer,True,Advanced/Metastatic Non-Small Cell Lung Cancer,0.95,5,46,2,0.45,False,False,,,No comparison,Advanced/Metastatic Non-Small Cell Lung Cancer
393942,Recurrence Of Infusion-Related Reaction (Irrs) Associated To Avimantamab,"Nsclc, Metastatic",Metastatic Non-Small Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
213726,Circulating tumor DNA is a strong predictor in patients treated with systemic therapy for urothelial carcinoma,MP23: Bladder Cancer: Invasive III,Urothelial Carcinoma,True,Invasive Urothelial Carcinoma,0.95,3,29,1,0.25,False,False,,,No comparison,Invasive Urothelial Carcinoma
230112,Survival trends of patients with Paget disease of the breast: A National Cancer Database (NCDB) study.,Breast Cancer-Local/Regional/Adjuvant,Paget Disease of the Breast,True,Paget Disease of the Breast,0.95,5,27,1,0.35,False,False,,,No comparison,Paget Disease of the Breast
410337,A Novel Glomerular Endothelium-Targeting Adeno-Associated Virus (AAV) Delivers Bacterial Proteinase to Treat Glomerulonephritis,"Bioengineering, Augmented Intelligence, Digital Health, and Data Science",Glomerulonephritis,True,Glomerulonephritis,0.95,1,18,0,0.05,False,False,,,No comparison,Glomerulonephritis
295653,Discussion,"Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management",,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
328423,"ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase",Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II,Newly Diagnosed Ph-Positive Chronic Myelogenous Leukemia in Chronic Phase,True,Newly Diagnosed Ph Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia,0.95,8,81,4,0.8,False,False,,,No comparison,Newly Diagnosed Ph Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia
410348,Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider,COVID-19: A New Understanding and Lessons Learned,COVID-19 Infection,True,COVID-19;;End Stage Renal Disease,0.95,4,33,2,0.4,True,False,,,No comparison,COVID-19;;End Stage Renal Disease
328431,Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Chronic Myeloid Leukaemia,True,Chronic Myeloid Leukemia,0.95,3,24,2,0.35,False,False,,,No comparison,Chronic Myeloid Leukemia
328438,Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia,0.95,3,24,2,0.35,False,False,,,No comparison,Chronic Myeloid Leukemia
328439,Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,BCR-ABL-Fusion Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia,0.95,3,24,2,0.35,False,False,,,No comparison,Chronic Myeloid Leukemia
180989,Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population,Autologous Transplantation: Clinical and Epidemiological: Poster I,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
328455,Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I,Intermediate-Risk High-Risk Chronic Myeloid Leukemia,True,Intermediate-Risk Chronic Myeloid Leukemia;;High-Risk Chronic Myeloid Leukemia,0.95,7,78,2,0.55,False,False,,,No comparison,Intermediate-Risk Chronic Myeloid Leukemia;;High-Risk Chronic Myeloid Leukemia
148233,"Survival Among Older Patients With Previously Treated Multiple Myeloma Treated With Selinexor, Bortezomib, And Dexamethasone (Xvd) In The Boston Study",Myeloma And Other Monoclonal Gammopathies - Clinical,Elderly Previously Treated Multiple Myeloma,True,Elderly Previously Treated Multiple Myeloma,0.95,5,43,2,0.45,False,False,,,No comparison,Elderly Previously Treated Multiple Myeloma
262924,A Phase 1/2 Study To Evaluate Ponatinib With Chemotherapy In Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Or With T315I Mutation,Acute lymphoblastic leukemia - Clinical,Relapsed/Intolerant Ph-Positive T315I Mutated Acute Lymphoblastic Leukemia,True,Pediatric Relapsed/Refractory Ph Chromosome-Positive Acute Lymphoblastic Leukemia;;Pediatric T315I-Mutated Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,13,158,5,1.0,False,False,,,No comparison,Pediatric Relapsed/Refractory Ph Chromosome-Positive Acute Lymphoblastic Leukemia;;Pediatric T315I-Mutated Ph Chromosome-Positive Acute Lymphoblastic Leukemia
410383,Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database,Kidney Transplantation: New Translational Insights,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
377619,Discontinuation Of Treatment With Thrombopoietin Receptor Agonists In Patients With Immune Thrombocytopenia: A Single-Center Clinical Experience,Bleeding disorders (congenital and acquired),Immune Thrombocytopenia,True,Immune Thrombocytopenia;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder,0.95,6,81,1,0.4,False,False,,,No comparison,Immune Thrombocytopenia;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder
213784,Rural Hospital Location is Associated with Higher Reported Prices for Ureteroscopy with Laser Lithotripsy Among Commercially Insured Patients,MP26: Stone Disease: Epidemiology & Evaluation I,Stone Disease,True,Stone Disease,0.95,2,13,1,0.2,False,False,,,No comparison,Stone Disease
394009,Challenge Of Systemic First-Line Treatment Of Elderly Lung Cancer Patients,"Nsclc, Metastatic",First-Line Elderly Lung Cancer,True,Elderly First-Line Metastatic Non-Small Cell Lung Cancer,0.95,7,56,1,0.45,False,False,,,No comparison,Elderly First-Line Metastatic Non-Small Cell Lung Cancer
344862,"Mini-tumors: Pre-clinical HCI assays to screen anti-cancer drugs in the context of organoids, cancer-associated fibroblasts and immune cells",Targeting the Tumor Microenvironment,Cancer,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
148257,Overall And Complete Response Rates As Potential Surrogates For Overall Survival In Relapsed Refractory Multiple Myeloma,Myeloma And Other Monoclonal Gammopathies - Clinical,Relapsed Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
295712,The impact of an Education WhatsApp Group to support nurses working in an acute oncology/haematology setting during the Covid-19 pandemic,"Empowering young cancer nurses academically, clinically and in career progression",Covid-19 Infection,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
230183,Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.,Breast Cancer-Metastatic,Hyperglycemia ,True,Metastatic Breast Cancer,0.95,3,24,1,0.25,False,False,,,No comparison,Metastatic Breast Cancer
394023,Gut Microbiome Is Associated With The Clinical Response To Anti-Pd-1 Based Immunotherapy In Untreated Advanced Non-Small-Cell Lung Cancer,"Nsclc, Metastatic",Untreated Advanced Non-Small-Cell Lung Cancer,True,Untreated Advanced Non-Small-Cell Lung Cancer,0.95,5,45,2,0.45,False,False,,,No comparison,Untreated Advanced Non-Small-Cell Lung Cancer
410410,IFNg-Induced APOL1 Expression and Pyroptotic Angiopathy in Human Kidney Organoids Mirrors a Nephrotic Gene Signature in Patient Biopsies,Glomerular Diseases: From Multiomics to Mechanisms,Glomerular Disease,True,Glomerular Disease;;Pyroptotic Angiopathy,0.95,3,41,1,0.25,False,False,,,No comparison,Glomerular Disease;;Pyroptotic Angiopathy
230186,Characteristics and outcomes of COVID-19 in adult cancer patients: Tertiary cancer center experience.,Care Delivery and Regulatory Policy,COVID-19 Infection;;Adult Cancer,True,COVID-19;;Adult Cancer,0.95,2,22,1,0.2,True,False,,,No comparison,COVID-19;;Adult Cancer
344870,"A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models",Targeting the Tumor Microenvironment,Tumor ,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
394030,"Harmoni: Randomized, Double-Blind, Multi-Center, Phase III Clinical Study Of Ivonescimab Or Placebo Combined With Pemetrexed And Carboplatin In Patients With Egfr-Mutant Locally Advanced Or Metastatic Non-Squamous Nsclc Who Have Progression Following Egfr-Tki Treatment","Nsclc, Metastatic",EGFR-Mutant Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer,True,EGFR-Mutated Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer,0.95,8,80,2,0.6,True,False,,,No comparison,EGFR-Mutated Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
394031,Tropion-Lung07: A Phase III Trial Of Datopotamab Deruxtecan (Dato-Dxd) Plus Pembrolizumab (Pembro) With Or Without Platinum Chemotherapy (Pt-Ct) As First-Line (1L) Therapy In Advanced/Metastatic (Adv/Met) Non-Small Cell Lung Cancer (Nsclc) With Pd-L1 Expression,"Nsclc, Metastatic",First-Line Advanced/Metastatic Non-Small Cell Lung Cancer,True,First-Line Advanced/Metastatic PD-L1-Expressing Non-Small Cell Lung Cancer,0.95,7,74,2,0.55,True,False,,,No comparison,First-Line Advanced/Metastatic PD-L1-Expressing Non-Small Cell Lung Cancer
148272,Survival And Outcomes Of Newly-Diagnosed Multiple Myeloma Patients Stratified By Transplant Status Diagnosed Between 2007-2018: Real-World Analysis From The Canadian Myeloma Research Group Database,Myeloma And Other Monoclonal Gammopathies - Clinical,Newly-Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,0.95,4,32,2,0.4,False,False,,,No comparison,Newly Diagnosed Multiple Myeloma
262962,Acute Promyelocytic Leukemia And Thrombosis: How To Identify The High-Risk Patients?,Acute myeloid leukemia - Clinical,Acute Promyelocytic Leukemia;;Thrombosis,True,Acute Promyelocytic Leukemia;;Thrombosis,0.95,3,40,2,0.35,False,False,,,No comparison,Acute Promyelocytic Leukemia;;Thrombosis
181042,Improving Completion Rates of Transcranial Doppler Ultrasounds in Children with Sickle Cell Disease Using Quality Improvement Efforts: In-Clinic Vs. Population-Based Assessments,Health Services Research-Non-Malignant Conditions: Poster I,Childhood Sickle Cell Disease ,True,Childhood Sickle Cell Disease,0.95,4,29,1,0.3,False,False,,,No comparison,Childhood Sickle Cell Disease
181043,Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need,Health Services Research-Non-Malignant Conditions: Poster I,,True,Non-Malignant Hematologic Disorder,0.95,3,34,1,0.25,False,False,,,No comparison,Non-Malignant Hematologic Disorder
181049,The Telemedicine Experience for Individuals with Sickle Cell Disease,Health Services Research-Non-Malignant Conditions: Poster I,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
377658,Early Severe Adverse Events Of Acute Myeloid Leukemia Therapy Depending On The Induction Therapy Regimen,Acute myeloid leukemia - Clinical,Acute Myeloid Leukemia ,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
394045,"Camrelizumab Plus Chemotherapy Versus Concurrent Chemoradiotherapy As Neoadjuvant Therapy For Resectable Thoracic Oesophageal Squamous Cell Cancer (Revo): A Multicenter, Randomized, Open-Label, Phase II Trial",Oesophagogastric Cancer,Resectable Thoracic Oesophageal Squamous Cell Cancer ,True,Resectable Thoracic Oesophageal Squamous Cell Cancer,0.95,6,52,1,0.4,False,False,,,No comparison,Resectable Thoracic Oesophageal Squamous Cell Cancer
213817,"Burden of depression and anxiety in men with high-risk, intermediate-risk or low-risk prostate cancer","MP28: Health Services Research: Practice Patterns, Quality of Life and Shared Decision Making III",High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,True,Depression;;Anxiety;;High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,0.95,7,107,1,0.45,False,False,,,No comparison,Depression;;Anxiety;;High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer
312127,Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis,Ignite Session 8A,Rheumatoid Arthritis,True,Rheumatoid Arthritis,0.95,2,20,0,0.1,False,False,,,No comparison,Rheumatoid Arthritis
262973,Efficacy Of Azacitidine And Venetoclax In Aml Patients May Be Limited By Interactionwith Posaconazole And Lack Of Standardised Treatment Protocol. Real World Data From 3 Major Centres In Singapore.,Acute myeloid leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
410433,Ethical Analysis on Mandating COVID-19 Vaccination Prior to Kidney Transplantation in Brazil,Coronavirus (COVID-19),COVID-19 Infection,True,COVID-19;;Kidney Transplantation,0.95,2,32,0,0.1,True,False,,,No comparison,COVID-19;;Kidney Transplantation
181055,Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation,Health Services Research-Non-Malignant Conditions: Poster I,Clostridium Difficile Infection,True,Clostridium Difficile Infection,0.95,3,31,0,0.15,False,False,,,No comparison,Clostridium Difficile Infection
262979,Characteristics And Outcome Of Patients With Acute Promyelocytic Leukemia In Southern Tunisia,Acute myeloid leukemia - Clinical,Acute Promyelocytic Leukemia,True,Acute Promyelocytic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Acute Promyelocytic Leukemia
410436,Comparison of 4 Predictive Scoring Methods as Assessment Tools for Cardiac Surgery Associated-Acute Kidney Injury in Post Coronary Artery Bypass Surgery Patients: A Single-Center Retrospective Study,Acute Kidney Injury,Acute Kidney Injury,True,Acute Kidney Injury,0.95,3,19,1,0.25,False,False,,,No comparison,Acute Kidney Injury
312133,Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation,Ignite Session 8A,Rheumatoid Arthritis,True,Rheumatoid Arthritis;;Acute Inflammation,0.95,3,40,1,0.25,False,False,,,No comparison,Rheumatoid Arthritis;;Acute Inflammation
328516,INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study,Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III,Relapsed/Refractory Myelofibrosis,True,Relapsed/Refractory Myelofibrosis,0.95,2,33,2,0.3,False,False,,,No comparison,Relapsed/Refractory Myelofibrosis
295751,Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study,"Proffered Paper session 2: GI, lower digestive",BRAF V600E-Mutated Metastatic Colorectal Cancer,True,BRAF V600E-Mutated Metastatic Colorectal Cancer,0.95,5,47,1,0.35,True,False,,,No comparison,BRAF V600E-Mutated Metastatic Colorectal Cancer
344908,"PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma",Drug Resistance in Molecular Targeted Therapies 2,Melanoma,True,Melanoma,0.95,1,8,0,0.05,False,False,,,No comparison,Melanoma
213839,Aquablation in very large prostates (>150mL): technique and multicenter case series,MP29: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology III,Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
148309,Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis,Myeloproliferative Neoplasms - Clinical,Primary Myelofibrosis,True,Primary Myelofibrosis,0.95,2,21,0,0.1,False,False,,,No comparison,Primary Myelofibrosis
344918,b-Escin eradicates cancer stem-like population in HER2-positive breast cancer with trastuzumab resistance,Drug Resistance in Molecular Targeted Therapies 2,HER2-Positive Breast Cancer,True,HER2-Positive Breast Cancer,0.95,3,27,2,0.35,False,False,,,No comparison,HER2-Positive Breast Cancer
295765,Can the molecular classification guide adjuvant medical treatment?,What is the optimal therapeutic approach in high-risk endometrial cancer?,High-Risk Endometrial Cancer,True,High-Risk Endometrial Cancer,0.95,3,28,1,0.25,False,False,,,No comparison,High-Risk Endometrial Cancer
181083,"Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)",Health Services Research-Lymphoid Malignancies: Poster I,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Chronic Lymphocytic Leukemia
263003,Utility Of Flt3 Inhibitors In Patients With Acute Myeloid Leukemia (Aml) And T(6;9)(P22;Q34),Acute myeloid leukemia - Clinical,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
295775,Management of treatment-related neurological complications,"Management of brain metastases: Systemic treatment, radiosurgery or both?",Brain Metastasis,True,Neurological Complication,0.95,2,25,0,0.1,False,False,,,No comparison,Neurological Complication
410465,A Rare Case of ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,Acute Kidney Injury,ANCA-Mediated Acute Interstitial Nephritis,True,Rare ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis;;ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,0.95,12,145,1,0.7,True,False,,,No comparison,Rare ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis;;ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis
295778,Discussion led by Chair,Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
410466,AKI and Spontaneous Rupture of the Urinary Collecting System,Acute Kidney Injury,Acute Kidney Injury,True,Acute Kidney Injury;;Spontaneous Rupture of the Urinary Collecting System,0.95,9,73,1,0.55,False,False,,,No comparison,Acute Kidney Injury;;Spontaneous Rupture of the Urinary Collecting System
394087,Gut Microbiome And Metabolome Are Associated With The Response To Chemoradiotherapy In Patients With Esophageal Cancer,Oesophagogastric Cancer,Esophageal Cancer,True,Esophageal Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Esophageal Cancer
394098,Factors Associated With Uptake Of Adjuvant Nivolumab In A Nationwide Esophageal Cancer Patient Cohort,Oesophagogastric Cancer,Esophageal Cancer,True,Esophageal Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Esophageal Cancer
181105,Vaso-Occlusive Events in Pediatric Sickle Cell Disease: Quantifying Social Disadvantage and Its Impact on Hospitalizations,Outcomes Research-Non-Malignant Conditions: Poster I,Pediatric Sickle Cell Disease,True,Pediatric Sickle Cell Disease;;Vaso-Occlusive Event,0.95,5,51,1,0.35,False,False,,,No comparison,Pediatric Sickle Cell Disease;;Vaso-Occlusive Event
181110,Sleep Characterization of Adolescent and Young Adult Patients with Sickle Cell Disease Using the Pittsburgh Sleep Quality Index,Outcomes Research-Non-Malignant Conditions: Poster I,Adolescent Young Adult Sickle Cell Disease,True,Adolescent and Young Adult Sickle Cell Disease,0.95,7,46,1,0.45,False,False,,,No comparison,Adolescent and Young Adult Sickle Cell Disease
181112,Comparison of Clinical and Thrombotic Outcomes in Sars-Cov-2- Pneumonia Versus Other Viral Pneumonia in an Urban Academic Medical Center,Outcomes Research-Non-Malignant Conditions: Poster I,Sars-Cov-2- Pneumonia,True,SARS-CoV-2 Pneumonia;;Viral Pneumonia,0.95,3,37,0,0.15,True,False,,,No comparison,SARS-CoV-2 Pneumonia;;Viral Pneumonia
181114,Venous Thromboembolism Post-COVID-19 Among Individuals with Sickle Cell Disease,Outcomes Research-Non-Malignant Conditions: Poster I,Sickle Cell Disease;;Venous Thromboembolism,True,Venous Thromboembolism;;COVID-19;;Sickle Cell Disease,0.95,4,53,1,0.3,True,False,,,No comparison,Venous Thromboembolism;;COVID-19;;Sickle Cell Disease
164735,Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19,The Interplay Between COVID and other Infections,,True,COVID-19,0.95,1,8,0,0.05,True,False,,,No comparison,COVID-19
263044,No Impact Of Statin Use On Response And Survival Rates In Newly Diagnosed Dlbcl Patients Treated With R-Da-Epoch,Aggressive Non-Hodgkin lymphoma - Clinical,Newly Diagnosed Diffuse Large B-Cell Lymphoma,True,Newly Diagnosed Diffuse Large B-Cell Lymphoma,0.95,6,45,2,0.5,False,False,,,No comparison,Newly Diagnosed Diffuse Large B-Cell Lymphoma
344966,Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer,New Drug Targets,High Grade Serous Ovarian Cancer,True,High Grade Serous Ovarian Cancer,0.95,5,32,2,0.45,False,False,,,No comparison,High Grade Serous Ovarian Cancer
295814,Stepping into the emerging needs in metastatic breast cancer,Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer,Metastatic Breast Cancer,True,Triple-Negative Metastatic Breast Cancer;;HR-Positive/HER2-Negative Metastatic Breast Cancer,0.95,7,92,3,0.65,True,False,,,No comparison,Triple-Negative Metastatic Breast Cancer;;HR-Positive/HER2-Negative Metastatic Breast Cancer
377741,Unmanipulated Peripheral Haploidentical Haematopoietic Stem Cell Transplant Is An Effective Consolidative Strategy For High-Risk Acute Myeloid Leukaemia And Myelodysplastic Syndrome,Stem cell transplantation - Clinical,High-Risk Acute Myeloid Leukaemia;;High-Risk Myelodysplastic Syndrome,True,High-Risk Acute Myeloid Leukaemia;;Myelodysplastic Syndrome,0.95,5,59,2,0.45,False,False,,,No comparison,High-Risk Acute Myeloid Leukaemia;;Myelodysplastic Syndrome
377743,Inotuzumab Ozogamicin Treatment In Adult Patients With Relapsed Or Refractory Philadelphia Chromosome-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life French Study,Acute lymphoblastic leukemia - Clinical,Adult Relapsed Or Refractory Ph-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,True,Adult Relapsed/Refractory Ph Chromosome-Negative CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,0.95,10,108,6,1.0,False,False,,,No comparison,Adult Relapsed/Refractory Ph Chromosome-Negative CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
164756,High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis,Updates in Mycobacteria,Tuberculous Meningitis,True,TB Meningitis,0.95,2,13,0,0.1,True,False,,,No comparison,TB Meningitis
263060,Burkitt Lymphoma International Prognostic Index (Bl-Ipi): Is It Efficient Enough In Adult Burkitt Lymphoma Patients?,Aggressive Non-Hodgkin lymphoma - Clinical,Adult Burkitt Lymphoma,True,Adult Burkitt Lymphoma,0.95,3,22,1,0.25,False,False,,,No comparison,Adult Burkitt Lymphoma
394135,Integrated Palliative Care For Patients Referred For Chimeric Antigen Receptor T-Cell (Car-T) Therapy: A Service Evaluation,Palliative Care,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
312224,Alarcon's NETting Neutrophils,Knowledge Bowl Preliminary Round,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
344993,Sex differences in the innate immune response to lung cancer,Innate Immunity to Tumors,Lung Cancer,True,Lung Cancer,0.95,2,11,1,0.2,False,False,,,No comparison,Lung Cancer
263082,Zanubrutinib In Combination With Lenalidomide And Rituximab Versus R-Minichop In Unfit Or Frail Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Aged Over Or Equal To 70 Years,Aggressive Non-Hodgkin lymphoma - Clinical,Elderly Newly Diagnosed Diffuse Large B-Cell Lymphoma,True,Elderly Newly Diagnosed Diffuse Large B-Cell Lymphoma,0.95,7,53,2,0.55,False,False,,,No comparison,Elderly Newly Diagnosed Diffuse Large B-Cell Lymphoma
345008,POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy,Targeting Replication Stress and the Immune Microenvironment,,True,POLE-Mutated Cancer,0.95,2,19,1,0.2,True,False,,,No comparison,POLE-Mutated Cancer
148407,Gbt021601 Improves The Pathophysiology Of Sickle Cell Disease In A Murine Model,Sickle Cell Disease,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
181176,Identification of Small Molecules That Induce Therapeutic Levels of Fetal Hemoglobin for Treatment of Sickle Cell Disease By Pairing Machine Learning with High-Resolution Single Cell RNA Sequencing Maps of Adult and Fetal Human Erythropoiesis,"Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II",Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
295865,Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer,"Mini Oral session: GI, lower digestive",Resected Stage I-III Colorectal Cancer,True,Resected Stage 1-3 Colorectal Cancer,0.95,5,36,2,0.45,False,False,,,No comparison,Resected Stage 1-3 Colorectal Cancer
328644,Validation of a Novel Algorithm with a High Specificity in Ruling out MDS,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster III,Myelodysplastic Syndrome,True,Myelodysplastic Syndrome,0.95,2,24,1,0.2,False,False,,,No comparison,Myelodysplastic Syndrome
312263,Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field,Moving on Up: Changing How We Define Early Knee OA and Get People Moving,Osteoarthritis ,True,Osteoarthritis;;Early Knee Osteoarthritis,0.95,3,41,1,0.25,False,False,,,No comparison,Osteoarthritis;;Early Knee Osteoarthritis
394187,Clinical And Molecular Features Of Young Onset Pancreatic Adenocarcinoma,Pancreatic Cancer,Young Onset Pancreatic Adenocarcinoma,True,Young Onset Pancreatic Adenocarcinoma,0.95,4,37,1,0.3,False,False,,,No comparison,Young Onset Pancreatic Adenocarcinoma
230348,"Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma.",Central Nervous System Tumors,Grade 2 Grade 3 Central Nervous System Tumor,True,Grade II Glioma;;Grade III Glioma,0.95,5,33,1,0.35,True,False,,,No comparison,Grade II Glioma;;Grade III Glioma
213966,Characteristics of Systemic Testosterone Therapy for Female Hypoactive Sexual Desire Disorder - A Claims Database Analysis,"MP35: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I",Hypoactive Sexual Desire Disorder,True,Female Hypoactive Sexual Desire Disorder,0.95,5,40,1,0.35,False,False,,,No comparison,Female Hypoactive Sexual Desire Disorder
148434,Minimal Residual Disease Monitoring And Preemptive Immunotherapies For Frequent 11Q23 Rearranged Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation,Stem Cell Transplantation - Clinical,11Q23 Rearranged Acute Leukemia,True,11Q23 Rearranged Acute Leukemia,0.95,4,31,2,0.4,False,False,,,No comparison,11Q23 Rearranged Acute Leukemia
394195,Diagnostic Performance Of Blood-Based Dna Methylation Assay Using Epigenetic-Specific Peptide Nucleic Acid In Pancreatic Adenocarcinoma,Pancreatic Cancer,Pancreatic Adenocarcinoma,True,Pancreatic Adenocarcinoma,0.95,2,25,1,0.2,False,False,,,No comparison,Pancreatic Adenocarcinoma
345045,Targeting CD73-adenosine axis for the treatment of multiple myeloma,Novel Antitumor Agents 1,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
230358,Assessment of neurocognitive functions using ACE-III scale in patients with high-grade glioma receiving adjuvant chemoradiation.,Central Nervous System Tumors,High-Grade Glioma,True,High Grade Glioma,0.95,3,17,1,0.25,False,False,,,No comparison,High Grade Glioma
230361,The effects of vascular endothelial cells on regulating post-irradiation microglia phenotype in irradiation-induced brain injury.,Central Nervous System Tumors,Brain Injury,True,Radiation-Induced Brain Injury,0.95,3,30,0,0.15,False,False,,,No comparison,Radiation-Induced Brain Injury
345049,Serological responses to tumor-associated adducts in pancreatic cancer,Adaptive Immunity to Tumors,Pancreatic Cancer,True,Pancreatic Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Pancreatic Cancer
377819,Characterisation Of Quality Of Life-Linked Patient-Reported Outcomes Through A Digital And Continuous Remote Monitoring Ecosystem In Sickle Cell Disease.,Sickle cell disease,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
181215,Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure,"Granulocytes, Monocytes, and Macrophages: Poster II",Pediatric Primary Hemophagocytic Lymphohistiocytosis,True,Pediatric Primary Hemophagocytic Lymphohistiocytosis,0.95,4,52,0,0.2,False,False,,,No comparison,Pediatric Primary Hemophagocytic Lymphohistiocytosis
213985,Robotic Bilateral Nephrectomy for Large Kidneys with Adult Polycystic Kidney Disease with Da Vinci Xi and Da Vinci SP,MP36: Renal Transplantation & Vascular Surgery,Adult Polycystic Kidney Disease,True,Adult Polycystic Kidney Disease,0.95,4,31,1,0.3,False,False,,,No comparison,Adult Polycystic Kidney Disease
181218,Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,B-Cell Lymphoma,True,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder;;B-Cell Lymphoma,0.95,6,89,2,0.5,False,False,,,No comparison,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder;;B-Cell Lymphoma
181219,Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder,True,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder,0.95,5,72,1,0.35,False,False,,,No comparison,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder
328676,The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster I,Myelodysplastic Syndrome,True,Cerebrovascular Accident;;Myelodysplastic Syndrome,0.95,3,50,1,0.25,False,False,,,No comparison,Cerebrovascular Accident;;Myelodysplastic Syndrome
213989,Pilot Trial for PIVoT: Prevention of recurrent urinary tract Infection using Vaginal Testosterone,MP37: Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia,Recurrent Urinary Tract Infection,True,Recurrent Urinary Tract Infection,0.95,4,33,0,0.2,False,False,,,No comparison,Recurrent Urinary Tract Infection
295910,Discussion led by Chair,How can we use ctDNA for early detection of cancer?,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
213982,The effect of renal transplantation on erectile functions in patients with end-stage renal disease.,MP36: Renal Transplantation & Vascular Surgery,End-Stage Renal Disease,True,End Stage Renal Disease,0.95,4,23,2,0.4,False,False,,,No comparison,End Stage Renal Disease
295920,Systemic therapeutic options,Oligometastatic disease and oligoprogression in breast cancer,Oligometastatic Disease;;Breast Cancer,True,Oligometastatic Breast Cancer;;Oligoprogressive Breast Cancer,0.95,5,61,1,0.35,False,False,,,No comparison,Oligometastatic Breast Cancer;;Oligoprogressive Breast Cancer
263162,The Value Of Anemia For Organ Damage Evaluation In Systemic Sclerosis Patients:A Multi-Center Retrospective Study,"Enzymopathies, membranopathies and other anemias",Systemic Sclerosis,True,Anemia;;Systemic Sclerosis,0.95,2,26,0,0.1,False,False,,,No comparison,Anemia;;Systemic Sclerosis
410619,A Rare Case of Zonisamide-Induced Distal Renal Tubular Acidosis (RTA),"Fluid, Electrolytes, and Acid-Base Disorders",Distal Renal Tubular Acidosis,True,Rare Zonisamide-Induced Distal Renal Tubular Acidosis;;Zonisamide-Induced Distal Renal Tubular Acidosis,0.95,10,103,0,0.5,False,False,,,No comparison,Rare Zonisamide-Induced Distal Renal Tubular Acidosis;;Zonisamide-Induced Distal Renal Tubular Acidosis
410621,Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia,"Fluid, Electrolytes, and Acid-Base Disorders",Severe Hyponatremia,True,Severe Hyponatremia,0.95,2,19,1,0.2,False,False,,,No comparison,Severe Hyponatremia
263163,Clinical Characteristics And Risk Factors Of Anemia In Patients With Systemic Sclerosis From The Pkuph-Ssc Cohort,"Enzymopathies, membranopathies and other anemias",Systemic Sclerosis,True,Enzymopathy;;Membranopathy;;Anemia;;Systemic Sclerosis,0.95,2,54,0,0.1,False,False,,,No comparison,Enzymopathy;;Membranopathy;;Anemia;;Systemic Sclerosis
214013,"Vascular, Neurologic and Hormonal Abnormalities in Men with Persistent Sexual Dysfunction after Discontinuation of Finasteride",MP38: Sexual Function/Dysfunction: Basic Research & Pathophysiology,Sexual Dysfunction,True,Persistent Sexual Dysfunction,0.95,3,29,0,0.15,False,False,,,No comparison,Persistent Sexual Dysfunction
394242,Young Adult Lung Cancer Demands More Attention In A Low-Resource Area: Bangladesh Perspective,Policy And Preventive Strategies,Young Adult Lung Cancer,True,Young Adult Lung Cancer,0.95,4,23,1,0.3,False,False,,,No comparison,Young Adult Lung Cancer
328700,Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eu-TCL1 Murine Model,Chronic Lymphocytic Leukemias: Basic and Translational: Poster II,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Chronic Lymphocytic Leukemia
312328,A Perplexing Situation,Pediatric Thieves Market Poster,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
328712,High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemias: Basic and Translational: Poster III,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Chronic Lymphocytic Leukemia
181258,"Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)",Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II,Severe Von Willebrand Disease,True,Severe Von Willebrand Disease,0.95,4,29,2,0.4,False,False,,,No comparison,Severe Von Willebrand Disease
345103,Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions,Cancer-associated Inflammation and Microbiome,Renal Cell Carcinoma,True,Primary Renal Cell Carcinoma;;Bone Metastasis,0.95,5,45,1,0.35,False,False,,,No comparison,Primary Renal Cell Carcinoma;;Bone Metastasis
377875,Alloantibodies In Von Willebrand Disease: About 6 Cases In Southern Tunisia,Bleeding disorders (congenital and acquired),Von Willebrand Disease,True,Von Willebrand Disease;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder,0.95,7,80,2,0.55,False,False,,,No comparison,Von Willebrand Disease;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder
312341,"Red but White, Itchy but Painful, Controlled yet Uncontrolled",Pediatric Thieves Market Poster,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
148508,Possible Correlation Of Mixed Chimerism With Post-Transplant Outcome In Patients With B Thalassemia:Risk Of Graft Failure,Thalassemias,B Thalassemia,True,B Thalassemia,0.95,2,13,0,0.1,False,False,,,No comparison,B Thalassemia
328738,The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II,Chronic Lymphocytic Leukemia,True,Covid-19;;Chronic Lymphocytic Leukemia,0.95,3,38,2,0.35,False,False,,,No comparison,Covid-19;;Chronic Lymphocytic Leukemia
410659,External Validation of a Risk Prediction Tool in Determining Early Death Among Elderly Patients Initiated on Dialysis,Geriatric Nephrology,,True,Elderly Kidney Disease,0.95,3,22,1,0.25,False,False,,,No comparison,Elderly Kidney Disease
263205,First-Line Treatment In Advanced Stage Folicular Lymphoma: A Single-Center Experience With R-Chop Vs Bendamustine-Rituximab.,Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,First-Line Advanced Stage Folicular Lymphoma,True,First-Line Advanced Follicular Lymphoma,0.95,4,39,2,0.4,False,False,,,No comparison,First-Line Advanced Follicular Lymphoma
312364,Balancing Risks and Benefits of Adding Immunosuppression to Steroids in PMR,Polymyalgia Rheumatica: New Tricks for an Old Disease,Polymyalgia Rheumatica,True,Polymyalgia Rheumatica,0.95,2,22,0,0.1,False,False,,,No comparison,Polymyalgia Rheumatica
295985,Welcome and Introduction,Novartis - Evidence-Based Practice in HR+/HER2 Advanced Breast Cancer: Illuminating the Treatment Path for Patients,HR-Positive HER2 Advanced Breast Cancer,True,Advanced HR-Positive/HER2-Negative Breast Cancer,0.95,4,48,4,0.6,True,False,,,No comparison,Advanced HR-Positive/HER2-Negative Breast Cancer
394296,Impact Of Intensified Androgen Deprivation Therapy (Adti) In The Metastatic Castration-Sensitive Prostate Cancer (Mcspc) Setting On Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Disease Characteristics And Survival Outcomes,Prostate Cancer,Metastatic Castration-Sensitive Prostate Cancer,True,Metastatic Castration-Sensitive Prostate Cancer;;Metastatic Castration-Resistant Prostate Cancer,0.95,7,96,2,0.55,False,False,,,No comparison,Metastatic Castration-Sensitive Prostate Cancer;;Metastatic Castration-Resistant Prostate Cancer
345147,Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing,Innovative Approaches for Tumor Profiling and Data Analysis 1,Ovarian Cancer,True,BRCA-Mutated Ovarian Cancer,0.95,3,27,1,0.25,True,False,,,No comparison,BRCA-Mutated Ovarian Cancer
377920,Atypical Chronic Myeloid Leukemia (Acml) And Autoimmune Disease: Report Of Two Cases.,Myeloproliferative neoplasms - Clinical,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,True,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,0.95,5,53,3,0.55,False,False,,,No comparison,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease
148549,Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain,Transfusion Medicine,,True,Red Blood Cell Autoantibody,0.95,4,27,0,0.2,False,False,,,No comparison,Red Blood Cell Autoantibody
263238,Protection Of Patients With Hematologic Malignancy From Severe Infection During Pandemia: Estonian Two Centres Experience,Infections in hematology (incl. supportive care/therapy),Hematologic Malignancy,True,Hematologic Malignancy;;Severe Infection,0.95,3,40,1,0.25,False,False,,,No comparison,Hematologic Malignancy;;Severe Infection
410696,Late-Onset Lupus Nephritis Presenting as Acute Decompensated Heart Failure,Glomerular Diseases,Late-Onset Lupus Nephritis,True,Late Onset Lupus Nephritis;;Acute Decompensated Heart Failure,0.95,7,61,1,0.45,False,False,,,No comparison,Late Onset Lupus Nephritis;;Acute Decompensated Heart Failure
164938,Infectious Complications of CD19-targeted Chimeric Antigen Receptor-modified T (CAR-T)-cell Immunotherapy,ID Complications associated with Novel Cellular & Immunotherapies in Cancer,Cancer,True,Infectious Complication,0.95,2,23,0,0.1,False,False,,,No comparison,Infectious Complication
345167,Integrin-mediated lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia,Cancer Cachexia,Cancer-Associated Cachexia,True,Pancreatic Cancer;;Cancer-Associated Cachexia,0.95,3,45,1,0.25,False,False,,,No comparison,Pancreatic Cancer;;Cancer-Associated Cachexia
263249,Tp53 Gene Mutation Diversity In Russian Patients With B-Cell Lymphomas,Lymphoma Biology & Translational Research,B-Cell Lymphoma,True,TP53-Mutated B-Cell Lymphoma,0.95,3,28,1,0.25,False,False,,,No comparison,TP53-Mutated B-Cell Lymphoma
263250,"Surgical Specimens Of Indolent And Aggressive B-Nhls Show Differences In Their Flow-Cytometry Profile Of Ploidy, Proliferating Fraction And Proportion Of Tumor-Associated Myeloid And T-Cell Subsets",Lymphoma Biology & Translational Research,Indolent Aggressive B-cell non-Hodgkin lymphoma,True,Indolent B-Cell Non-Hodgkin Lymphoma;;Aggressive B-Cell Non-Hodgkin Lymphoma,0.95,7,76,1,0.45,False,False,,,No comparison,Indolent B-Cell Non-Hodgkin Lymphoma;;Aggressive B-Cell Non-Hodgkin Lymphoma
410708,Porphyria Cutanea Tarda and Systemic Lupus Erythematosus: An Unusual Association in a Patient with Nephritic Syndrome,Glomerular Diseases,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome,True,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome,0.95,6,73,1,0.4,False,False,,,No comparison,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome
279637,Managing relapsed/refractory mantle cell lymphoma: a case study,Gilead and Kite Oncology: Chimeric antigen receptor T cells case studies: navigating patient management,Relapsed/Refractory Mantle Cell Lymphoma,True,Relapsed/Refractory Mantle Cell Lymphoma,0.95,4,40,3,0.5,False,False,,,No comparison,Relapsed/Refractory Mantle Cell Lymphoma
181344,Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia,Bone Marrow Failure: Poster II,Adult Severe Aplastic Anemia,True,Adult Severe Aplastic Anemia,0.95,4,28,1,0.3,False,False,,,No comparison,Adult Severe Aplastic Anemia
148578,L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemia - Clinical,Childhood Acute Pancreatitis;;Acute Lymphoblastic Leukemia,True,Childhood Acute Pancreatitis;;Childhood Acute Lymphoblastic Leukemia,0.95,6,68,2,0.5,False,False,,,No comparison,Childhood Acute Pancreatitis;;Childhood Acute Lymphoblastic Leukemia
410725,Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis,"Health Maintenance, Nutrition, and Metabolism",,True,End Stage Renal Disease;;Complex Congenital Heart Disease,0.95,7,57,2,0.55,False,False,,,No comparison,End Stage Renal Disease;;Complex Congenital Heart Disease
328806,Inhibition of Oxidative Phosphorylation and Glycolysis Reduces Viability in Multiple Myeloma By Affecting mTOR-Mediated Protein Synthesis,Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II,Multiple Myeloma,True,Multiple Myeloma;;Plasma Cell Dyscrasia,0.95,4,39,1,0.3,False,False,,,No comparison,Multiple Myeloma;;Plasma Cell Dyscrasia
312429,Wrap-Up,Review Course,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
214129,MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis,MP45: Prostate Cancer: Markers,Prostate Cancer,True,High-Risk Prostate Cancer;;Low-Risk Prostate Cancer,0.95,5,51,1,0.35,False,False,,,No comparison,High-Risk Prostate Cancer;;Low-Risk Prostate Cancer
296059,"Cosmesis (CA), late effects (LE) and Patient reported outcome measures (PROM) in high risk breast cancer (BC) treated with hypo-fractionated radiotherapy (RT): real world outcome from a developing country.","Breast cancer, early stage",High Risk Breast Cancer ,True,High-Risk Early Stage Breast Cancer,0.95,5,35,3,0.55,False,False,,,No comparison,High-Risk Early Stage Breast Cancer
296071,Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: a phase II clinical trial (NeoBCC),Melanoma and other skin tumours,Primary Basal Cell Carcinoma,True,Primary Basal Cell Carcinoma,0.95,4,28,1,0.3,False,False,,,No comparison,Primary Basal Cell Carcinoma
394376,Adjuvant Everolimus (Eve) In Patients (Pts) With Completely Resected Very High-Risk Renal Cell Cancer (Rcc) And Clear Cell Histology: Results From The Phase Iii Swog S0931 (Everest) Trial,Renal Cancer,Resected Very High-Risk Renal Cell Cancer,True,Resected Very High-Risk Clear Cell Renal Cell Cancer,0.95,8,52,1,0.5,False,False,,,No comparison,Resected Very High-Risk Clear Cell Renal Cell Cancer
230538,Comparative oncology analysis using genomic profiling of canine cancers by tissue and liquid biopsy testing reveals actionable somatic alterations with orthologs in human cancers.,Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology,Cancer,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
345226,Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
165004,The Impact of Molecular Diagnostics on the Management of Viral Infections in Pediatric Transplant Recipients,Controversies and Challenges in Pediatric Transplant ID,Pediatric Viral Infection,True,Viral Infection in Pediatric Transplant Recipients,0.95,6,50,0,0.3,False,False,,,No comparison,Viral Infection in Pediatric Transplant Recipients
345225,Sensitizing breast cancers to immune checkpoint inhibitors through CD27 agonism and vaccination against tumor-associated antigen,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
263309,Crispr-Cas9 Knockout Screen Identifies Rna Modification Enzymes Essential For Cell Survival In Multiple Myeloma,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
263312,"Trial-In-Progress: Phase Ii Study Of Phe885, A B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, In Adults With Relapsed And/Or Refractory Multiple Myeloma",Myeloma and other monoclonal gammopathies - Clinical,Adult Relapsed/Refractory Multiple Myeloma,True,Adult Relapsed/Refractory Multiple Myeloma,0.95,4,42,3,0.5,False,False,,,No comparison,Adult Relapsed/Refractory Multiple Myeloma
296081,Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal Cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER,Colorectal cancer,HER2-Positive Metastatic Colorectal Cancer,True,HER2-Positive Metastatic Colorectal Cancer,0.95,4,42,2,0.4,False,False,,,No comparison,HER2-Positive Metastatic Colorectal Cancer
197778,Mitochondrial Interventions: Small Molecule and Gene Therapy,Mitochondrial Interventions: Small Molecule and Gene Therapy (Mitochondrial Interventions: Small Molecule and Gene Therapy),,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
296082,A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration,"NSCLC, metastatic",Lung Disease,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
296084,"The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer - the randomized NORDIC9-study",Colorectal cancer,Elderly Metastatic Colorectal Cancer,True,Elderly Metastatic Colorectal Cancer,0.95,4,36,1,0.3,False,False,,,No comparison,Elderly Metastatic Colorectal Cancer
263316,Chemo Or Chemo-Free Regimens In Heavily Pretreated Multiple Myeloma? Role Of Bendamustine-Bortezomib-Dexamethasone (Bvd) In Novel Agents' Era,Myeloma and other monoclonal gammopathies - Clinical,Heavily Pretreated Multiple Myeloma,True,Heavily Pretreated Multiple Myeloma,0.95,4,35,1,0.3,False,False,,,No comparison,Heavily Pretreated Multiple Myeloma
148631,Relationship Between Genetic Aberrations In The 17P13/Tp53 Locus And Immunohistochemical Protein P53 Expression In Tumor Cells Of Diffuse Large B-Cell Lymphoma,Aggressive Non-Hodgkin Lymphoma - Clinical,Diffuse Large B-Cell Lymphoma,True,Diffuse Large B-Cell Lymphoma,0.95,4,29,1,0.3,False,False,,,No comparison,Diffuse Large B-Cell Lymphoma
312472,A New Classification of Ear Chondritis Revealed by Genetic Studies,The Ears Have It: Autoimmune Hearing Loss and Relapsing Polychondritis,Ear Chondritis,True,Autoimmune Hearing Loss;;Relapsing Polychondritis;;Ear Chondritis,0.95,5,65,0,0.25,False,False,,,No comparison,Autoimmune Hearing Loss;;Relapsing Polychondritis;;Ear Chondritis
410777,Ravulizumab De Novo in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS): First Worldwide Cases,Pediatric Nephrology,De Novo Pediatric Atypical Hemolytic Uremic Syndrome,True,Pediatric De Novo Atypical Hemolytic Uremic Syndrome,0.95,7,52,1,0.45,False,False,,,No comparison,Pediatric De Novo Atypical Hemolytic Uremic Syndrome
345240,"CRB-601, an avb8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment","Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",,True,Tumor,0.95,1,5,1,0.15,False,False,,,No comparison,Tumor
148636,Health-Related Quality Of Life Effect Of Mogamulizumab By Patient Blood Involvement,Aggressive Non-Hodgkin Lymphoma - Clinical,Aggressive Non-Hodgkin Lymphoma,True,Aggressive Non-Hodgkin Lymphoma,0.95,3,31,1,0.25,False,False,,,No comparison,Aggressive Non-Hodgkin Lymphoma
263328,Opportunities Of Therapy In Patients With Newly Diagnosed Multiple Myeloma With Dialysis-Dependent Renal Impairment,Myeloma and other monoclonal gammopathies - Clinical,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma;;Dialysis-Dependent Renal Impairment,0.95,6,69,2,0.5,False,False,,,No comparison,Newly Diagnosed Multiple Myeloma;;Dialysis-Dependent Renal Impairment
296096,"DeLLphi-303: phase 1b first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)",SCLC,Extensive Stage Small Cell Lung Cancer ,True,First-Line Extensive Stage Small Cell Lung Cancer,0.95,7,49,2,0.55,False,False,,,No comparison,First-Line Extensive Stage Small Cell Lung Cancer
165030,To See or Not To See: COVID-19 Visitor Restrictions in Pediatric Healthcare Settings,The Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology - Controversies in Pediatric Infection Prevention,COVID-19 Infection,True,Pediatric COVID-19,0.95,2,18,0,0.1,True,False,,,No comparison,Pediatric COVID-19
328871,Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo,Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
148649,Dose-Adjusted Edoch-Rituximab In Elderly Patients With High Grade Diffuse Large B-Cell Lymphoma,Aggressive Non-Hodgkin Lymphoma - Clinical,Elderly High Grade Diffuse Large B-Cell Lymphoma,True,Elderly High Grade Diffuse Large B-Cell Lymphoma,0.95,7,48,2,0.55,False,False,,,No comparison,Elderly High Grade Diffuse Large B-Cell Lymphoma
148651,"Front-Mind: A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy And Safety Of R-Chop + Tafasitamab + Lenalidomide Vs R-Chop Alone For Newly-Diagnosed High-Risk Dlbcl",Aggressive Non-Hodgkin Lymphoma - Clinical,Newly-Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,True,Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,0.95,7,55,2,0.55,False,False,,,No comparison,Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
230572,A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients.,Gastrointestinal Cancer-Colorectal and Anal,Metastatic Colorectal Cancer,True,Metastatic Colorectal Cancer,0.95,3,28,1,0.25,False,False,,,No comparison,Metastatic Colorectal Cancer
181422,The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models,Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II,B-Cell Lymphoma,True,B-Cell Lymphoma,0.95,2,15,1,0.2,False,False,,,No comparison,B-Cell Lymphoma
296109,Early mortality in patients with cancer treated with immunotherapy in routine practice,Investigational immunotherapy,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
148656,Inhibitors In Mild Haemophilia A: Experience Of A Single Spanish Center,Bleeding Disorders (Congenital And Acquired),Mild Haemophilia A,True,Mild Haemophilia A;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder,0.95,7,76,2,0.55,False,False,,,No comparison,Mild Haemophilia A;;Congenital Bleeding Disorder;;Acquired Bleeding Disorder
279728,Deciphering the role of the bone marrow microenvironment in hematological malignancies using 3D Human Organotypic Marrow Environment (3D-HOMEs),YoungEHA Research Meeting - Session 5: Microenvironment in benign and malignant hematology & Closing,Hematological Malignancy ,True,Hematological Malignancy,0.95,2,24,0,0.1,False,False,,,No comparison,Hematological Malignancy
214197,When Node-Positive Prostate Cancer Should Be Considered A Systemic Disease? Assessing The Prognostic Role Of Preoperative 68Ga-PSMA PET/CT Results In Patients With Lymph Node Invasion At Final Pathology,MP48: Prostate Cancer: Advanced (including Drug Therapy) III,Node-Positive Prostate Cancer,True,Node-Positive Prostate Cancer,0.95,3,29,2,0.35,False,False,,,No comparison,Node-Positive Prostate Cancer
230598,Clinical and prognostic features of BRAF V600E-mutant resectable colorectal cancer: A single-center retrospective analysis of Chinese patients.,Gastrointestinal Cancer-Colorectal and Anal,BRAF V600E-mutated Resectable Colorectal Cancer,True,BRAF V600E-Mutated Resectable Colorectal Cancer,0.95,5,47,1,0.35,True,False,,,No comparison,BRAF V600E-Mutated Resectable Colorectal Cancer
378058,Tailoring treatment in CLL: Selecting the right treatment and duration for the right patient in relapse setting,You have a new match! Pairing treatments and patients together for optimal treatment in chronic lymphocytic leukaemia (CLL),Chronic Lymphocytic Leukemia,True,Relapsed Chronic Lymphocytic Leukaemia,0.95,4,38,2,0.4,False,False,,,No comparison,Relapsed Chronic Lymphocytic Leukaemia
279755,How should Measurable Residual Disease (MRD) assessment inform treatment decisions?,Jazz Pharmaceuticals: Should we expect long term survival in high-risk Acute Myeloid Leukaemia (AML)?,High-Risk Acute Myeloid Leukemia,True,High-Risk Acute Myeloid Leukaemia,0.95,4,33,1,0.3,False,False,,,No comparison,High-Risk Acute Myeloid Leukaemia
181452,Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",Ph-Positive Acute Lymphoblastic Leukemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,5,51,3,0.55,False,False,,,No comparison,Ph Chromosome-Positive Acute Lymphoblastic Leukemia
181453,A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",MRD-Positive B-Cell Acute Lymphoblastic Leukemia,True,MRD-Positive B-Cell Acute Lymphoblastic Leukemia,0.95,5,48,3,0.55,True,False,,,No comparison,MRD-Positive B-Cell Acute Lymphoblastic Leukemia
263373,"Primary Myelofibrosis In Young Patients <=50 Years: Clinicopathological Characteristics, Genetic Landscape And Disease Outcome. A Single Center Experience",Myeloproliferative neoplasms - Clinical,Adult Primary Myelofibrosis,True,Primary Myelofibrosis,0.95,2,21,0,0.1,False,False,,,No comparison,Primary Myelofibrosis
148685,Clinical Features Of Large Granular Lymphocytic Leukemia-Associated Pure Red Cell Aplasia: Results From A Single Center In China,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia,True,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia,0.95,7,58,1,0.45,False,False,,,No comparison,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia
279766,Current challenges for patient management,Takeda: Long term proteasome inhibition for multiple myeloma in the era of COVID, COVID;;Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
214230,Implications of Positive Surgical Margins following Robotic Partial Nephrectomy,MP50: Kidney Cancer: Localized: Surgical Therapy III,Kidney Cancer,True,Localized Kidney Cancer,0.95,3,23,1,0.25,False,False,,,No comparison,Localized Kidney Cancer
230619,Modifiable and non-modifiable risk factors associated with early-onset colorectal cancer: Analysis of the National Health Interview Survey.,Gastrointestinal Cancer-Colorectal and Anal,Early-Onset Colorectal Cancer,True,Early Onset Colorectal Cancer,0.95,4,29,2,0.4,False,False,,,No comparison,Early Onset Colorectal Cancer
197852,Accelerated Brain Aging is Independently Associated with Increased Likelihood of All-Cause Mortality: Findings from the Second Wave of Dallas Heart Study (DHS-2),Accelerated Brain Aging in Neuropsychiatric Disorders: Methodological Challenges and and Potential Applications to Prognosticate Clinical Outcomes,Neuropsychiatric Disorder,True,Neuropsychiatric Disorder,0.95,2,25,1,0.2,False,False,,,No comparison,Neuropsychiatric Disorder
328928,Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
296164,Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial,Colorectal cancer,Microsatellite Stable pMMR Colorectal cancer,True,Microsatellite Stable Colorectal Cancer,0.95,4,39,1,0.3,False,False,,,No comparison,Microsatellite Stable Colorectal Cancer
197861,Prenatal Cannabis Exposure and Outcomes during Middle Childhood,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",Prenatal Cannabis Exposure,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
197863,Differential Effects of Adolescent versus Early Adult Cannabis Initiation on Longitudinal Brain Development: Evidence for Adolescence as a Period of Vulnerability,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
148704,Subcutaneous Immunoglobulins Use In Immunodeficiency Secondary To Chronic Lymphocytic Leukaemia: Monocentric Experience In Covid-19 Era,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Chronic Lymphocytic Leukaemia,True,Immunodeficiency;;Chronic Lymphocytic Leukaemia,0.95,3,47,1,0.25,False,False,,,No comparison,Immunodeficiency;;Chronic Lymphocytic Leukaemia
148706,Pattern Of Minimal Residual Disease In Tunisian Chronic Myeloid Leukemia Patients,Chronic Myeloid Leukemia - Biology & Translational Research,Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia,0.95,3,24,2,0.35,False,False,,,No comparison,Chronic Myeloid Leukemia
296166,Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group,"Breast cancer, early stage",Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
296175,Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST),Colorectal cancer,First-Line Metastatic Colorectal Cancer,True,First-Line Metastatic Colorectal Cancer,0.95,4,39,1,0.3,False,False,,,No comparison,First-Line Metastatic Colorectal Cancer
197874,Neuron Subtype Specific Molecular Mechanisms in Fentanyl Abstinence,Cell-Type Specific Molecular Biology of Addiction,,True,Addiction,0.95,1,9,0,0.05,False,False,,,No comparison,Addiction
197882,Altered Adult Neurogenesis and Cognition in Mesial Temporal Lobe Epilepsy Patients,Evidence of adult neurogenesis in human brain and its changes with aging and disease,Mesial Temporal Lobe Epilepsy,True,Adult Mesial Temporal Lobe Epilepsy,0.95,5,35,0,0.25,False,False,,,No comparison,Adult Mesial Temporal Lobe Epilepsy
148732,Diagnostic Importance Of Bone Marrow Aspiration In Children With Anemia Of Unknown Etiology,"Enzymopathies, Membranopathies And Other Anemias",Childhood Anemia,True,Childhood Anemia of Unknown Etiology,0.95,5,36,0,0.25,False,False,,,No comparison,Childhood Anemia of Unknown Etiology
394495,Novel Nomogram Based On The Expression Of Dll3 And Pd-L1 For Predicting The Prognosis Of Small Cell Lung Cancer Patients,Sclc,Small Cell Lung Cancer,True,DLL3-Expressing Small Cell Lung Cancer;;PD-L1-Expressing Small Cell Lung Cancer,0.95,9,79,1,0.55,True,False,,,No comparison,DLL3-Expressing Small Cell Lung Cancer;;PD-L1-Expressing Small Cell Lung Cancer
181510,ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Childhood Acute Myeloid Leukemia,True,Childhood Acute Myeloid Leukemia,0.95,4,32,2,0.4,False,False,,,No comparison,Childhood Acute Myeloid Leukemia
181511,Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Acute Myeloid Leukemia,True,ALK Fusion Monosomy7 Acute Myeloid Leukemia,0.95,6,43,2,0.5,True,False,,,No comparison,ALK Fusion Monosomy7 Acute Myeloid Leukemia
328968,"Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study",Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
165128,Modeled Impact of the COVID-19 Pandemic and Associated Reduced Adult Vaccinations on Herpes Zoster in the United States,Adult Vaccines,Herpes Zoster Infection,True,Adult Herpes Zoster,0.95,3,19,0,0.15,False,False,,,No comparison,Adult Herpes Zoster
296202,Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA),Basic Science,Extensive Stage Small-Cell Lung Cancer,True,Extensive Stage Small Cell Lung Cancer,0.95,6,38,2,0.5,False,False,,,No comparison,Extensive Stage Small Cell Lung Cancer
148747,Prognostic Factors Of Worse Survival In Newly Diagnosed Advanced-Stage Hodgkin Lymphoma In Taiwan: A Nationwide Retrospective Study,Hodgkin Lymphoma - Clinical,Newly Diagnosed Advanced-Stage Hodgkin Lymphoma,True,Newly Diagnosed Advanced Hodgkin Lymphoma,0.95,5,41,3,0.55,False,False,,,No comparison,Newly Diagnosed Advanced Hodgkin Lymphoma
312583,Improving The Performance Of Early Breast Cancer Diagnosis By A Model Combining Breast Ultrasound With Methylation Markers In Non-Invasive Circulating Tumor Dna,Detection/Diagnosis: Detection/Diagnosis - Other,Early Breast Cancer,True,Early Breast Cancer,0.95,3,19,2,0.35,False,False,,,No comparison,Early Breast Cancer
378125,The US experience in ALL,Adult acute lymphoblastic leukemia (EWALL),Acute Lymphoblastic Leukemia,True,Adult Acute Lymphoblastic Leukemia,0.95,4,34,2,0.4,False,False,,,No comparison,Adult Acute Lymphoblastic Leukemia
312590,Orphan Non-Coding Rnas For Early Detection Of Breast Cancer With Liquid Biopsy,Detection/Diagnosis: Detection/Diagnosis - Other,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
263441,Variant Haemoglobin Assessment And Correlation With Phenotypic Presentation At Diagnosis In Sickle Cell Disease : A Single Centre Retrospective Analysis Of Central Gujarat Cohort,Sickle cell disease,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
296214,Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma,Melanoma and other skin tumours,Metastatic Uveal Melanoma,True,Metastatic Uveal Melanoma,0.95,3,25,0,0.15,False,False,,,No comparison,Metastatic Uveal Melanoma
165143,Immunologic Hyporesponsiveness with Subsequent Dosing of Meningococcal Vaccines: Re-Evaluating the Current Paradigm,Adult Vaccines,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
378137,Regulation of GvHD in the hematopoietic niche,Mesenchymal stromal cells: Progress in biology and engineering of mesenchymal stromal cells,Graft-Versus-Host Disease,True,Graft-versus-Host Disease,0.95,2,25,1,0.2,False,False,,,No comparison,Graft-versus-Host Disease
296217,Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial,Melanoma and other skin tumours,High-Risk Stage III Melanoma,True,Resected High-Risk Stage III Melanoma,0.95,5,37,1,0.35,True,False,,,No comparison,Resected High-Risk Stage III Melanoma
279835,RWD of CAR T-cell therapy in older adults: The UK experience,Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
378147,AI approach for advanced analysis of flow-cytometryc data,Diagnosis in hematological diseases: Morphology and flow cytometry: 2.0 diagnostics in hematology: The role of artificial intelligence,,True,Hematological Disease,0.95,2,21,1,0.2,False,False,,,No comparison,Hematological Disease
410917,Integrating Electronic Health Data Records to Develop and Validate a Predictive Model of Hospital-Acquired AKI in Non-Critically Ill Patients,"AI, Digital Health, Data Science - I",Acute Kidney Injury,True,Hospital-Acquired Acute Kidney Injury,0.95,4,37,1,0.3,False,False,,,No comparison,Hospital-Acquired Acute Kidney Injury
230700,Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1b and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Metastatic Pancreatic Cancer,True,Metastatic Pancreatic Cancer,0.95,3,28,1,0.25,False,False,,,No comparison,Metastatic Pancreatic Cancer
197935,No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,Poster Session I (In-Person),,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
230706,"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).","Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Second-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma,True,Second-Line Advanced/Metastatic Esophageal Squamous Cell Carcinoma,0.95,6,66,2,0.5,False,False,,,No comparison,Second-Line Advanced/Metastatic Esophageal Squamous Cell Carcinoma
214324,Using Magnetic Resonance Imaging to Define Focal Therapy Templates in Patients with Intermediate-Risk Prostate Cancer,MP55: Prostate Cancer: Localized: Ablative Therapy,Intermediate-Risk Prostate Cancer,True,Intermediate-Risk Localized Prostate Cancer,0.95,4,43,1,0.3,False,False,,,No comparison,Intermediate-Risk Localized Prostate Cancer
329014,Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,Monoclonal Gammopathy,True,Hypercalcemia;;Monoclonal Gammopathy of Undetermined Significance,0.95,5,65,0,0.25,False,False,,,No comparison,Hypercalcemia;;Monoclonal Gammopathy of Undetermined Significance
181569,Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma,Lymphomas: Translational-Non-Genetic: Poster II,Diffuse Large B Cell Lymphoma,True,Diffuse Large B Cell Lymphoma,0.95,5,29,1,0.35,False,False,,,No comparison,Diffuse Large B Cell Lymphoma
197955,Mutations in Kalrn Disrupt Gamma-Band Oscillations in the Auditory Cortex of Adult Mice,Poster Session I (In-Person),,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
148806,Suppression Of Akr1B1 Reduces Cell Proliferation And Enhances Sensitivity To Hypomethylating Agents By Inhibiting Mtorc1 Signaling Pathway In High-Risk Myelodysplastic Syndrome,Myelodysplastic Syndromes - Biology & Translational Research,High-Risk Myelodysplastic Syndrome,True,High-Risk Myelodysplastic Syndrome,0.95,3,34,1,0.25,False,False,,,No comparison,High-Risk Myelodysplastic Syndrome
148807,"Polymorphism Of Gstm1, Gstt1 And Cytokine Genes In Patients With Myelodysplastic Syndrome",Myelodysplastic Syndromes - Biology & Translational Research,Myelodysplastic Syndrome,True,Myelodysplastic Syndrome,0.95,2,24,1,0.2,False,False,,,No comparison,Myelodysplastic Syndrome
214345,The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy,MP56: Bladder Cancer: Invasive V,Bladder Cancer,True,Invasive Bladder Cancer,0.95,3,23,1,0.25,False,False,,,No comparison,Invasive Bladder Cancer
312650,Role Of Postmastectomy Radiation Therapy In Breast Cancer Patients According To Pathologic Nodal Status After Neoadjuvant Chemotherapy,Treatment - Surgery And Radiotherapy: Radiotherapy,Breast Cancer,True,Node-Negative Breast Cancer;;Node-Positive Breast Cancer,0.95,5,56,3,0.55,False,False,,,No comparison,Node-Negative Breast Cancer;;Node-Positive Breast Cancer
181581,"Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma","Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II",High-Risk Elderly Mantle Cell Lymphoma,True,Elderly High-Risk Mantle Cell Lymphoma,0.95,5,38,1,0.35,False,False,,,No comparison,Elderly High-Risk Mantle Cell Lymphoma
148814,A Phase 3 Study Of The Efficacy And Safety Of Luspatercept Versus Epoetin Alfa For The Treatment Of Anemia Due To Lower-Risk Mds In Esa-Naive Patients Requiring Rbc Transfusions (The Commands Trial),Myelodysplastic Syndromes - Clinical,Low-Risk Myelodysplastic Syndrome,True,Low-Risk Myelodysplastic Syndrome;;Anemia,0.95,3,41,1,0.25,False,False,,,No comparison,Low-Risk Myelodysplastic Syndrome;;Anemia
394576,Prevention Of Taxane Chemotherapy Induced Nail Changes And Peripheral Neuropathy By Application Of Extremity Cooling: A Prospective Single Center Study With Intrapatient Comparison,Supportive Care,Peripheral Neuropathy,True,Nail Change;;Peripheral Neuropathy,0.95,3,34,0,0.15,False,False,,,No comparison,Nail Change;;Peripheral Neuropathy
263509,Genetic And Epigenetic Factors Driving Primary Mediastinal B-Cell Lymphoma Pathogenesis And Outcome,Presidential Symposium,Primary Mediastinal B-Cell Lymphoma,True,Primary Mediastinal B-Cell Lymphoma,0.95,4,35,1,0.3,False,False,,,No comparison,Primary Mediastinal B-Cell Lymphoma
394584,Initial Geriatric Assessment And Chemotherapy Tolerability Treatment In Brazilian Patients With Malignant Neoplasm Of The Digestive System.,Supportive Care,Malignant Neoplasm,True,Geriatric Malignant Neoplasm of the Digestive System,0.95,7,52,0,0.35,False,False,,,No comparison,Geriatric Malignant Neoplasm of the Digestive System
263513,Ubtf-Atxn7L3 Gene Fusion Due To 17Q21.31 Deletion Defines Novel High-Risk All Subtype Amenable To Mrd-Based Treatment Intensification,From biology to preclinical models in ALL,High-Risk Acute Lymphoblastic Leukemia,True,UBTF-ATXN7L3 Fusion High-Risk Acute Lymphoblastic Leukemia,0.95,6,58,2,0.5,True,False,,,No comparison,UBTF-ATXN7L3 Fusion High-Risk Acute Lymphoblastic Leukemia
345435,Cellos: High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology,Tumor Organoids for Therapeutic Testing,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
230744,Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Cancer-Associated Thrombosis;;Biliary Tract Cancer,True,Biliary Tract Cancer;;Cancer-Related Thrombosis,0.95,4,47,1,0.3,False,False,,,No comparison,Biliary Tract Cancer;;Cancer-Related Thrombosis
197976,Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma,Poster Session I (In-Person),Trauma,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
296288,Real World Evidence of First-line Cetuximab (CX) plus Paclitaxel (PX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),"Head and neck cancer, excluding thyroid",Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,True,Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,0.95,9,65,1,0.55,False,False,,,No comparison,Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
148828,Validation Of Algorithms To Identify First-Line Therapy (Induction And Maintenance) For Multiple Myeloma For Use In Electronic Healthcare Databases,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,First-Line Multiple Myeloma,True,First-Line Multiple Myeloma,0.95,3,27,1,0.25,False,False,,,No comparison,First-Line Multiple Myeloma
230749,Clinical utility of immunotherapy hyperprogressive genes in hepatocellular carcinoma patients.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Hepatocellular Carcinoma,True,Hyperprogressive Hepatocellular Carcinoma,0.95,3,41,1,0.25,False,False,,,No comparison,Hyperprogressive Hepatocellular Carcinoma
148829,A Clinical-Decision Tool To Improve The Strategy Of Multiple Myeloma Treatment,Myeloma And Other Monoclonal Gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
296292,Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma,Hepatocellular carcinoma (HCC),hepatocellular carcinoma,True,Hepatocellular Carcinoma,0.95,2,24,1,0.2,False,False,,,No comparison,Hepatocellular Carcinoma
279909,Classification of immunodeficiency-related lymphoproliferative disorders,Pediatric hematology: Immunodeficiency-related lymphoproliferative disorders,Immunodeficiency-Related Lymphoproliferative Disorder,True,Pediatric Immunodeficiency-Related Lymphoproliferative Disorder,0.95,4,63,1,0.3,False,False,,,No comparison,Pediatric Immunodeficiency-Related Lymphoproliferative Disorder
378207,Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL,Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden,Chronic Lymphocytic Leukemia,True,Chronic Lymphocytic Leukemia;;Infection,0.95,3,39,2,0.35,False,False,,,No comparison,Chronic Lymphocytic Leukemia;;Infection
394614,"Mortality Within 30 Days After Last Dose Of Intravenous Systemic Anti-Cancer Therapy: Single-Center, One-Year, Retrospective Analysis",Supportive Care,,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
345465,A non-surgical approach to develop an orthotopic colorectal cancer mouse model,Mouse Models of Human Cancer,Colorectal Cancer,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
214394,ATM mutations are associated with high-risk architectural features in men with familial prostate cancer,MP58: Prostate Cancer: Detection & Screening VII,Familial Prostate Cancer ,True,High-Risk ATM-Mutated Familial Prostate Cancer,0.95,5,46,1,0.35,True,False,,,No comparison,High-Risk ATM-Mutated Familial Prostate Cancer
394619,Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors,Supportive Care,Advanced High Grade Ovarian Carcinoma,True,Venous Thromboembolism;;Advanced High Grade Ovarian Carcinoma,0.95,6,61,3,0.6,False,False,,,No comparison,Venous Thromboembolism;;Advanced High Grade Ovarian Carcinoma
148861,Lenalidomide Versus Thalidomide Or Bortezomib As Maintenance Regimen For Non-Transplant Patients With Multiple Myeloma: Multi-Center Real World Experiences In China,Myeloma And Other Monoclonal Gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
181632,Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts),Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II,Relapsed/Refractory Non-Hodgkin Lymphoma,True,Relapsed/Refractory Non-Hodgkin Lymphoma,0.95,3,40,3,0.45,False,False,,,No comparison,Relapsed/Refractory Non-Hodgkin Lymphoma
198019,"Hippocampal volume, FKBP5 genetic risk alleles, and childhood trauma interact to increase vulnerability to chronic multisite musculoskeletal pain",Poster Session I (In-Person),Chronic Multisite Musculoskeletal Pain;;Childhood Trauma,True,Chronic Multisite Musculoskeletal Pain,0.95,4,38,1,0.3,False,False,,,No comparison,Chronic Multisite Musculoskeletal Pain
329094,"Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC(r)) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)",Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
148870,Real World Evidence Of Carfilzomib In Relapsed Refractory Multiple Myeloma (Rrmm),Myeloma And Other Monoclonal Gammopathies - Clinical,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
312715,Establishment And Characterization Of Two Er+/Her2- Xpdx Models Developed Sequentially Before And After Acquired Resistance To The Cdk4/6 Inhibitor Palbociclib From A Patient With Metastatic Breast Cancer,Tumor Cell And Molecular Biology: Drug Resistance,Metastatic Breast Cancer,True,ER-Positive HER2-Negative Metastatic Breast Cancer,0.95,5,50,3,0.55,True,False,,,No comparison,ER-Positive HER2-Negative Metastatic Breast Cancer
198028,Exposure to Prenatal Stress Induces Sex-Specific Vulnerability to Psychopathologic Domains in Adolescent Rats,Poster Session I (In-Person),,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
329101,Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
312718,Efficacy And Safety Of Pyrotinib-Based Therapy In The Treatment Of Her2-Positive Breast Cancer Patients With Brain Metastases:A Multi-Center Real-World Study,Treatment - Types And Sites Of Breast Cancer: Brain Metastases,Brain Metastasis;;Her2-Positive Breast Cancer,True,HER2-Positive Breast Cancer;;Brain Metastasis,0.95,4,45,2,0.4,False,False,,,No comparison,HER2-Positive Breast Cancer;;Brain Metastasis
148877,Analysis Of Delay In The Diagnosis Of Multiple Myeloma In A Sanitary Region Of Southern Spain.,Myeloma And Other Monoclonal Gammopathies - Clinical,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
312723,"A Randomized Phase Ii Trial Targeting Disseminated Dormant Tumor Cells With Hydroxychloroquine, Everolimus Or The Combination To Prevent Recurrent Breast Cancer (""Clever"")",Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted,Recurrent Breast Cancer,True,Recurrent Breast Cancer,0.95,3,23,1,0.25,False,False,,,No comparison,Recurrent Breast Cancer
181651,"Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo",Aggressive Lymphomas: Clinical and Epidemiological: Poster II,Diffuse Large B-Cell Lymphoma;;Human Immunodeficiency Virus Infection,True,Diffuse Large B-Cell Lymphoma;;HIV Infection,0.95,5,44,1,0.35,True,False,,,No comparison,Diffuse Large B-Cell Lymphoma;;HIV Infection
329119,Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed High-Risk Multiple Myeloma,0.95,5,42,2,0.45,False,False,,,No comparison,Newly Diagnosed High-Risk Multiple Myeloma
279967,How will we treat high-risk multiple myeloma in the future?,Janssen: Immunotherapy: evolution or revolution in the cure of multiple myeloma,High-Risk Multiple Myeloma,True,High-Risk Multiple Myeloma,0.95,3,26,1,0.25,False,False,,,No comparison,High-Risk Multiple Myeloma
263586,"International, Prospective Study Comparing Nilotinib Versus Imatinib With Early Switch To Nilotinib To Obtain Sustained Treatment-Free Remission In Patients With With Chronic Myeloid Leukemia",Treatment and monitoring in CML,Chronic Myeloid Leukemia,True,Chronic Myeloid Leukemia,0.95,3,24,2,0.35,False,False,,,No comparison,Chronic Myeloid Leukemia
148899,"A Phase 1 Study Of Tp-3654, An Oral Pim Kinase Inhibitor, In Patients With Intermediate-2 Or High-Risk Primary Or Secondary Myelofibrosis",Myeloproliferative Neoplasms - Clinical,Intermediate-Risk High-Risk Primary Myelofibrosis;;Intermediate-Risk High-Risk Secondary Myelofibrosis,True,High-Risk Primary Myelofibrosis;;High-Risk Secondary Myelofibrosis;;Intermediate-2 Primary Myelofibrosis;;Intermediate-2 Secondary Myelofibrosis,0.95,9,144,0,0.45,False,False,,,No comparison,High-Risk Primary Myelofibrosis;;High-Risk Secondary Myelofibrosis;;Intermediate-2 Primary Myelofibrosis;;Intermediate-2 Secondary Myelofibrosis
378277,Clinical trials in pediatric leukemia,Pediatric acute myeloid leukemia (AML),Pediatric Leukemia,True,Pediatric Acute Myeloid Leukemia,0.95,4,32,2,0.4,False,False,,,No comparison,Pediatric Acute Myeloid Leukemia
394663,Quality Of Life (Qol) Of Patients (Pts) With Advanced Malignant Pleural Mesothelioma (Ampm) Treated In A Real-World Setting,"Thoracic Malignancies, Other",Advanced Malignant Pleural Mesothelioma,True,Advanced Malignant Pleural Mesothelioma,0.95,4,39,1,0.3,False,False,,,No comparison,Advanced Malignant Pleural Mesothelioma
411051,Implications of the Acute and Chronic GFR Slopes for Time-to-Event End Points in Clinical Trials of CKD,"CKD Progression and Complications: Diagnosis, Prognosis, Risk Factors",Chronic Kidney Disease,True,Chronic Kidney Disease,0.95,3,22,2,0.35,False,False,,,No comparison,Chronic Kidney Disease
378288,Gene therapy in practise,What is hot in hemophilia?,Hemophilia,True,Hemophilia,0.95,1,10,0,0.05,False,False,,,No comparison,Hemophilia
198070,Systemic Inflammation Response Index (SIRI) May Predict Treatment Response in Treatment-Resistant Bipolar Depression (TRBDD),Poster Session I (In-Person),Treatment-Resistant Bipolar Depression,True,Treatment-Resistant Bipolar Depression,0.95,3,38,2,0.35,False,False,,,No comparison,Treatment-Resistant Bipolar Depression
329150,Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (>= 65; < 80 Years). IFM2020-05/Benefit,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I,Elderly Newly Diagnosed Non-Frail Multiple Myeloma,True,Elderly Newly Diagnosed Multiple Myeloma,0.95,5,40,2,0.45,False,False,,,No comparison,Elderly Newly Diagnosed Multiple Myeloma
329153,"Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults >=70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial",Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I,Elderly Newly Diagnosed Multiple Myeloma,True,Older Adult Newly Diagnosed Multiple Myeloma,0.95,6,44,2,0.5,False,False,,,No comparison,Older Adult Newly Diagnosed Multiple Myeloma
198082,Callous-Unemotional Traits Moderate the Relationship between Irritability and Threatening Responding,Virtual Poster Session I,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
181700,The High Mobility Group A1 Chromatin Regulator Drives Immune Evasion during MPN Progression By Repressing Genes Involved in Antigen Presentation and Immune Attack,Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II,Progressive Myeloproliferative Neoplasm,True,Progressive Myeloproliferative Neoplasm,0.95,3,39,0,0.15,False,False,,,No comparison,Progressive Myeloproliferative Neoplasm
263626,Alteration Of Iron Homeostasis Through Genetic And Pharmacologic Modulation Of Ferroportin Modifies Mds Pathophysiology In A Preclinical Mouse Model,Iron regulation in hematological disorders,Myelodysplastic Syndrome,True,Hematological Disorder;;Myelodysplastic Syndrome,0.95,3,48,2,0.35,False,False,,,No comparison,Hematological Disorder;;Myelodysplastic Syndrome
296396,"Associations between Psycho-Social-Spiritual Interventions, Reduced Aggressive End-of-Life Measures, and Increased Time after Final Oncologic Treatment",Palliative care,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
394706,Novel Genetic Markers Associated With Immune Checkpoint Inhibitor Induced Immune-Related Adverse Events,Translational Research (Agnostic),,True,Immune-Related Adverse Event,0.95,3,28,0,0.15,False,False,,,No comparison,Immune-Related Adverse Event
329172,Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma,Experimental Transplantation: Basic and Translational: Poster II,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
198103,Perceived Touch Deprivation is Associated with Increased Severity of the Body Focused Repetitive Behaviors [BFRB],Virtual Poster Session I,,True,Body Focused Repetitive Behavior,0.95,4,32,0,0.2,False,False,,,No comparison,Body Focused Repetitive Behavior
230872,Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Unresectable Esophageal Squamous Cell Carcinoma,True,Unresectable Esophageal Squamous Cell Carcinoma,0.95,5,47,1,0.35,False,False,,,No comparison,Unresectable Esophageal Squamous Cell Carcinoma
230874,Surgical intervention of hepatocellular carcinoma with wedge versus segmental resection: A SEER database analysis.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Hepatocellular Carcinoma,True,Hepatocellular Carcinoma,0.95,2,24,1,0.2,False,False,,,No comparison,Hepatocellular Carcinoma
263643,Functional Subsets Of Plasma Cells Associated With Amyloid Production Andvenetoclax Sensitivity In Al Amyloidosis,Myeloma and other monoclonal gammopathies: Translational and Biology,Al Amyloidosis,True,Al Amyloidosis,0.95,2,14,0,0.1,False,False,,,No comparison,Al Amyloidosis
280029,Treatment of MM patients based on their frailty status,Myeloma: Non transplant-eligible MM,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
312805,Performance Of Tumor Vascularity As A Biomarker Is Correlated With The Change Of Tumor Vascularity After Preoperative Systemic Treatment In Patients With Breast Cancer,Prognostic&Predictive Factors:Prognosis-Biomarkers Of Natural History-Prog Factors-Clin Testing&Val, Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
394726,Berberine Associated To Sglt-2I Exerts Synergistic Cardioprotective Effects In Cardiac Cells Exposed To The Her2-Blocking Agent Trastuzumab Through Pampk Activation And Reduction In Interleukin-6 Levels,Translational Research (Agnostic),,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
329193,Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation,Experimental Transplantation: Basic and Translational: Poster III,Acute Myelogenous Leukemia,True,Acute Myelogenous Leukemia,0.95,3,26,2,0.35,False,False,,,No comparison,Acute Myelogenous Leukemia
378351,Non-genetic mechanisms of resistance in B-ALL,Mechanisms of chemotherapy resistance in ALL,B-Cell Acute Lymphoblastic Leukemia,True,B-Cell Acute Lymphoblastic Leukemia,0.95,4,35,2,0.4,False,False,,,No comparison,B-Cell Acute Lymphoblastic Leukemia
230896,Racial and socioeconomic factors associated with palliative care utilization in pancreatic cancer: An analysis of National Inpatient Sample.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Pancreatic Cancer,True,Pancreatic Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Pancreatic Cancer
394737,Development Of An Oncolytic Virus For The Treatment Of High Grade Serous Ovarian Cancer And Other Stromal Rich Tumours,Translational Research (Agnostic),High Grade Serous Ovarian Cancer,True,High Grade Serous Ovarian Cancer;;Stromal Rich Tumor,0.95,7,52,3,0.65,False,False,,,No comparison,High Grade Serous Ovarian Cancer;;Stromal Rich Tumor
214515,"Global variation in quality of transurethral resection of bladder surgery, results from the RESECT study.",PD10: Bladder Cancer: Invasive II,Bladder Cancer,True,Invasive Bladder Cancer,0.95,3,23,1,0.25,False,False,,,No comparison,Invasive Bladder Cancer
329204,Absence of ILC2 Recovery Post-Transplant Is Mediated By Epigenetic Conversion of ILC2 to Pro-Inflammatory ILC1-like Cells,Experimental Transplantation: Basic and Translational: Poster I,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
214519,Acquired and Congenital Spinal Cord Injury is Associated with Lower Likelihood of PSA Screening,PD11: Prostate Cancer: Detection & Screening II,Prostate Cancer,True,Acquired Spinal Cord Injury;;Congenital Spinal Cord Injury,0.95,7,58,0,0.35,False,False,,,No comparison,Acquired Spinal Cord Injury;;Congenital Spinal Cord Injury
296440,Radiomics biomarkers are associated with survival in patients with Oesophageal Adenocarcinoma,Oesophagogastric cancer,Oesophageal Adenocarcinoma,True,Oesophageal Adenocarcinoma;;Oesophagogastric Cancer,0.95,3,51,2,0.35,False,False,,,No comparison,Oesophageal Adenocarcinoma;;Oesophagogastric Cancer
181759,Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster II,Intermediate-Risk Myelodysplastic Syndrome,True,Intermediate-Risk Myelodysplastic Syndrome,0.95,3,42,1,0.25,False,False,,,No comparison,Intermediate-Risk Myelodysplastic Syndrome
181766,Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster II,Newly Diagnosed High Grade Myelodysplastic Syndrome,True,Newly Diagnosed High Grade Myelodysplastic Syndrome,0.95,6,51,3,0.6,False,False,,,No comparison,Newly Diagnosed High Grade Myelodysplastic Syndrome
345609,Tepotinib treatment inhibits tumor growth and affects tumor permeability in an intracranial PDX model of MET-amplified NSCLC brain metastasis,Small Molecule Therapeutic Agents,MET-Amplified Non-Small Cell Lung Cancer;;Brain Metastasis,True,MET-Amplified Non-Small Cell Lung Cancer Brain Metastasis,0.95,7,57,1,0.45,True,False,,,No comparison,MET-Amplified Non-Small Cell Lung Cancer Brain Metastasis
149004,Role Of Telemedicine In Management Of Adult Egyptian Thalassaemia Patients During Covid-19 Pandemic; Patients Survey,Thalassemias,Adult Egyptian Thalassaemia,True,Adult Thalassemia,0.95,2,17,0,0.1,False,False,,,No comparison,Adult Thalassemia
280076,Chemotherapy plus TKIs in the treatment of Ph+ALL,Incyte: The Evolving landscape in the Treatment of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukaemia,0.95,5,52,2,0.45,False,False,,,No comparison,Ph Chromosome-Positive Acute Lymphoblastic Leukaemia
312846,Aesthetic Incisions And Early Complications  For Nipple-Sparing Mastectomy Followed By Immediate Breast Reconstruction,Treatment - Surgery And Radiotherapy: Reconstruction,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
280079,Q&A and panel discussion,Incyte: The Evolving landscape in the Treatment of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia,Ph-positive Acute Lymphoblastic Leukaemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukaemia,0.95,5,52,2,0.45,False,False,,,No comparison,Ph Chromosome-Positive Acute Lymphoblastic Leukaemia
312847,Impact Of Neoadjuvant Chemotherapy On The Short- And Long-Term Outcomes In Patients Who Underwent Immediate Breast Reconstruction After Mastectomy,Treatment - Surgery And Radiotherapy: Reconstruction,,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
411154,Association Between Sevelamer Use and Risk of Gastrointestinal Bleeding in Patients with Kidney Failure,Bone and Mineral Metabolism: CKD-MBD Updates,Gastrointestinal Bleeding,True,Gastrointestinal Bleeding;;Kidney Failure,0.95,3,41,0,0.15,False,False,,,No comparison,Gastrointestinal Bleeding;;Kidney Failure
165397,Risk Factors for Mortality in Severe COVID-19 Patients Admitted to the Intensive Care Unit: a Retrospective Single-Center Study in Saudi Arabia,"COVID-19 Complications, co-infections, and clinical outcomes",Severe COVID-19 Infection,True,Severe COVID-19,0.95,2,15,1,0.2,True,False,,,No comparison,Severe COVID-19
214551,Comparative outcomes of primary and recurrent high grade non-muscle invasive and primary and progressive muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study,PD14: Bladder Cancer: Epidemiology & Evaluation I,Primary Recurrent High Grade Non-Muscle Invasive Bladder Cancer;;Primary Progressive Muscle Invasive Bladder Cancer,True,Primary High Grade Non-Muscle Invasive Bladder Cancer;;Recurrent High Grade Non-Muscle Invasive Bladder Cancer;;Primary Muscle-Invasive Bladder Cancer;;Progressive Muscle-Invasive Bladder Cancer,0.95,19,194,2,1.0,False,False,,,No comparison,Primary High Grade Non-Muscle Invasive Bladder Cancer;;Recurrent High Grade Non-Muscle Invasive Bladder Cancer;;Primary Muscle-Invasive Bladder Cancer;;Progressive Muscle-Invasive Bladder Cancer
149018,Studies Of Geographic Variations In Risk Factors Associated With Thrombophilia And Its Possible Impact On Disease Management Planning,Thrombosis And Vascular Biology - Biology & Translational Research,Thrombophilia ,True,Thrombophilia,0.95,1,13,0,0.05,False,False,,,No comparison,Thrombophilia
230944,Outcomes of hepatocellular carcinoma in obese patients: Insights from a nationwide database.,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Hepatocellular Carcinoma,True,Hepatocellular Carcinoma,0.95,2,24,1,0.2,False,False,,,No comparison,Hepatocellular Carcinoma
329249,Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL,Cellular Immunotherapies: Basic and Translational: Poster II,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,True,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,0.95,4,47,3,0.5,False,False,,,No comparison,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
214562,Long term follow up in patients undergoing renal biopsy - seeding is not anecdotal,PD15: Kidney Cancer: Epidemiology & Evaluation/Staging/Surveillance I,Kidney Cancer,True,Kidney Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Kidney Cancer
263715,A Phase Ii Study Of Mini-Hyper-Cvd Plus Venetoclax In Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia,Acute lymphoblastic leukemia - Clinical,Ph-Negative Acute Lymphoblastic Leukemia,True,Ph Chromosome-Negative Acute Lymphoblastic Leukemia,0.95,5,51,3,0.55,False,False,,,No comparison,Ph Chromosome-Negative Acute Lymphoblastic Leukemia
263713,"Mini-Hyper-Cvd Plus Inotuzumab Ozogamicin, With Or Without Blinatumomab, In Older Adults With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updates From A Phase Ii Trial",Acute lymphoblastic leukemia - Clinical,Elderly Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia,True,Older Adult Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia,0.95,8,63,3,0.7,False,False,,,No comparison,Older Adult Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
165408,Lung cancer and hematologic malignancy ( HM) patients are associated with the highest risk of progressing to severe disease and mortality in cancer patients with COVID-19,"COVID-19 Complications, co-infections, and clinical outcomes",Lung Cancer;;Hematologic Malignancy,True,Lung Cancer;;Hematologic Malignancy;;COVID-19;;Severe COVID-19,0.95,4,62,2,0.4,True,False,,,No comparison,Lung Cancer;;Hematologic Malignancy;;COVID-19;;Severe COVID-19
230947,Single-nucleus RNA-sequencing analysis reveals transcriptome differences in TIGIT+ exhausted T-cell associated with poor prognosis in muscle-invasive bladder cancer (MIBC).,Genitourinary Cancer-Kidney and Bladder,Muscle-Invasive Bladder Cancer,True,Muscle Invasive Bladder Cancer,0.95,4,30,1,0.3,False,False,,,No comparison,Muscle Invasive Bladder Cancer
181796,Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II,Elderly Treatment-Naive Chronic Lymphocytic Leukemia,True,Older Adult Treatment-Naive Chronic Lymphocytic Leukemia,0.95,6,56,3,0.6,False,False,,,No comparison,Older Adult Treatment-Naive Chronic Lymphocytic Leukemia
411176,Canagliflozin Treatment Impact on Collagen Type III Turnover Is Associated with a Reduced Mortality Risk in CANVAS,Diabetic Kidney Disease: Clinical - I,,True,Diabetic Kidney Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Diabetic Kidney Disease
394789,Multi-Omic Spatial Phenotyping Of The Nsclc Tumour Microenvironment For The Development Of A Spatial Score Associated With Immunotherapy Resistance.,Tumour Biology And Pathology,Non-Small Cell Lung Cancer,True,Non-Small Cell Lung Cancer,0.95,4,26,1,0.3,False,False,,,No comparison,Non-Small Cell Lung Cancer
280115,ERCC6L2 as novel entity for inherited AML,Acute myeloid leukemia: Germline predisposition gene mutations in AML,Inherited Acute Myeloid Leukemia,True,Hereditary Acute Myeloid Leukemia,0.95,4,33,2,0.4,False,False,,,No comparison,Hereditary Acute Myeloid Leukemia
263732,A Retrospective Review Of Secondary Hemophagocytic Lymphohistiocytosis From A Teaching Hospital In Singapore.,Aggressive Non-Hodgkin lymphoma - Clinical,Secondary Hemophagocytic Lymphohistiocytosis,True,Secondary Hemophagocytic Lymphohistiocytosis,0.95,3,44,0,0.15,False,False,,,No comparison,Secondary Hemophagocytic Lymphohistiocytosis
230966,A novel approach to assessing the effects of smoking on treatment response rate in muscle-invasive bladder cancer.,Genitourinary Cancer-Kidney and Bladder,Muscle-Invasive Bladder Cancer,True,Muscle Invasive Bladder Cancer,0.95,4,30,1,0.3,False,False,,,No comparison,Muscle Invasive Bladder Cancer
198200,Prefrontal Cortical White Matter Integrity Mediates Associations between Racial Discrimination and Health Outcomes,Neurobiological Mechanisms of Individual and Structural Racism: Novel Pathways for Race-Related Health Disparities,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
149051,Novel treatments in hemophilia,Inherited And Acquired Hemostasis Defects,Hemophilia,True,Hemophilia,0.95,1,10,0,0.05,False,False,,,No comparison,Hemophilia
312891,Tumour Associated Macrophages In Breast Cancer - Are They Critical Players In Response To Neo Adjuvant Chemotherapy?,Tumor Cell And Molecular Biology:Microenvironment - Stromal-Epithelial Interactions,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
411198,Identification and Validation of Neutrophil Extracellular Traps-Associated Genes in Diabetic Kidney Disease: Integration Data from Bulk RNA and Single-Nucleus RNA Sequencing Analyses,Diabetic Kidney Disease: Clinical - I,Diabetic Kidney Disease,True,Diabetic Kidney Disease,0.95,3,23,1,0.25,False,False,,,No comparison,Diabetic Kidney Disease
394817,Whole Genome Sequencing Of Aya Patients,Tumour Biology And Pathology,Tumour ,True,Adolescent and Young Adult Tumor,0.95,5,32,1,0.35,False,False,,,No comparison,Adolescent and Young Adult Tumor
280134,Diagnosis and classification of T-Large Granular Lymphocyte Leukemia (T-LGL),EHA-ISLH Laboratory Diagnosis Workshop - Session 3: Diagnostics of rare T-cell/NK cell disorders,T-Large Granular Lymphocyte Leukemia,True,Rare T-Large Granular Lymphocyte Leukemia;;T-Large Granular Lymphocyte Leukemia,0.95,8,79,1,0.5,False,False,,,No comparison,Rare T-Large Granular Lymphocyte Leukemia;;T-Large Granular Lymphocyte Leukemia
198215,Epigenetic Intergenerational Transmission: Mothers' Adverse Childhood Experiences and Dna Methylation,Poster Session II (In-Person),,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
411209,Assessing Heart Rate Variability in Patients with CKD: Association with Vascular Dysfunction,Hypertension and CVD: Clinical - I,Chronic Kidney Disease;;Vascular Dysfunction,True,Chronic Kidney Disease;;Vascular Dysfunction,0.95,4,44,2,0.4,False,False,,,No comparison,Chronic Kidney Disease;;Vascular Dysfunction
296529,The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study,Oesophagogastric cancer,HER2-Positive Locally Advanced Unresectable or Metastatic Gastric Cancer;;HER2-Positive Locally Advanced Unresectable or Metastatic Gastroesophageal Junction Cancer,True,Untreated HER2-Positive Locally Advanced Unresectable/Metastatic Gastric Cancer;;Untreated HER2-Positive Locally Advanced Unresectable/Metastatic Gastroesophageal Junction Cancer,0.95,14,178,3,1.0,False,False,,,No comparison,Untreated HER2-Positive Locally Advanced Unresectable/Metastatic Gastric Cancer;;Untreated HER2-Positive Locally Advanced Unresectable/Metastatic Gastroesophageal Junction Cancer
149077,Treating low-risk MDS,Targeting Low-Risk Mds,Low-Risk Myelodysplastic Syndrome,True,Low-Risk MDS,0.95,2,12,0,0.1,True,False,,,No comparison,Low-Risk MDS
394839,Real-World Effectiveness Of Single Agent Enfortumab Vedotin (Ev) In Patients (Pts) With Locally Advanced Or Metastatic Urothelial Carcinoma (Muc) Based On Line Of Therapy And Impact Of Prior Platinum (Plat) Chemotherapy (Chemo) And Pd-1/Pd-L1 Inhibitors (Pd-1/Pd-L1I),Urothelial Cancer,Locally Advanced/Metastatic Urothelial Carcinoma,True,Locally Advanced/Metastatic Urothelial Carcinoma,0.95,4,48,2,0.4,False,False,,,No comparison,Locally Advanced/Metastatic Urothelial Carcinoma
394844,Long-Term Survival Upon Anti-Pd-(L)1 Monotherapy In Metastatic Urothelial Cancer (Muc): A Multicenter Retrospective Study,Urothelial Cancer,Metastatic Urothelial Cancer,True,Metastatic Urothelial Cancer,0.95,3,28,1,0.25,False,False,,,No comparison,Metastatic Urothelial Cancer
296548,"A phase 1 study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)","NSCLC, metastatic",Advanced or Metastatic Non-Small Cell Lung Cancer,True,Advanced/Metastatic Non-Small Cell Lung Cancer,0.95,5,46,2,0.45,False,False,,,No comparison,Advanced/Metastatic Non-Small Cell Lung Cancer
181862,Mutations in the Alternative Complement Pathway in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster II,Multiple Myeloma;;Thrombotic Microangiopathy,True,Multiple Myeloma;;Thrombotic Microangiopathy,0.95,3,44,1,0.25,False,False,,,No comparison,Multiple Myeloma;;Thrombotic Microangiopathy
296551,High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer,Gynaecological cancers,High Grade Epithelial Ovarian Cancer,True,High Grade Epithelial Ovarian Cancer,0.95,5,36,2,0.45,False,False,,,No comparison,High Grade Epithelial Ovarian Cancer
263786,Treatment Of Severe Steroid-Refractory Acute Gvhd With Mesenchymal Stromal Cells: Results Of The Phase Iii Randomized Double-Blind Multi-Center Hovon-113 Trial,Stem cell transplantation - Clinical,Acute Graft-Versus-Host Disease,True,Severe Refractory Acute Graft-versus-Host Disease,0.95,5,49,4,0.65,False,False,,,No comparison,Severe Refractory Acute Graft-versus-Host Disease
345706,"First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations",Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents,Advanced Solid Tumor;;Malignant Mesothelioma;;Neurofibromatosis Type 2 ,True,Advanced Solid Tumor;;Malignant Mesothelioma;;NF2-Mutated Tumor,0.95,5,63,2,0.45,False,False,,,No comparison,Advanced Solid Tumor;;Malignant Mesothelioma;;NF2-Mutated Tumor
394860,Detection Of Molecular Recurrence In Early-Stage Bladder Cancer Patients Using A Urinary Tumor Dna Assay After Transurethral Resection Of Bladder Tumor (Turbt),Urothelial Cancer,Early-Stage Bladder Cancer,True,Early Stage Bladder Cancer,0.95,4,26,3,0.5,False,False,,,No comparison,Early Stage Bladder Cancer
394862,Cdkn2A Deletions Are A Mechanism For P16 Inactivation In Urothelial Bladder Carcinomas And Are Associated With An Aggressive Tumor Phenotype,Urothelial Cancer,CDKN2A-Deleted Urothelial Bladder Carcinoma,True,Urothelial Bladder Carcinoma;;Aggressive Urothelial Bladder Carcinoma,0.95,6,69,1,0.4,False,False,,,No comparison,Urothelial Bladder Carcinoma;;Aggressive Urothelial Bladder Carcinoma
312943,Adiponectin Regulates Stem Cell Activity In Tamoxifen-Resistant Breast Cancer Cells,Tumor Cell And Molecular Biology: Other,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
198256,Hopelessness is Associated with Reduced Wide-Band Magnetoencephalographic Power in Anterior Medial Temporal Lobes in a Clinical Sample,Poster Session II (In-Person),,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
312945,Marvel D3 And Its Associated Junctional Proteins In Breast Cancer,Tumor Cell And Molecular Biology: Other,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
231026,The effect of PARP inhibition on androgen receptor localization and activity in castration resistant prostate cancer.,"Genitourinary Cancer-Prostate, Testicular, and Penile",Castration Resistant Prostate Cancer,True,Castration-Resistant Prostate Cancer,0.95,3,36,2,0.35,False,False,,,No comparison,Castration-Resistant Prostate Cancer
329328,"ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia",Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II,Relapsed/Refractory Chronic Lymphocytic Leukemia,True,Relapsed/Refractory Chronic Lymphocytic Leukemia,0.95,4,48,4,0.6,False,False,,,No comparison,Relapsed/Refractory Chronic Lymphocytic Leukemia
165490,Sensitivity and Specificity of the WHO Probable SARS-CoV-2 Case Definition Among Symptomatic Healthcare Personnel,COVID-19 Epidemiology and screening,SARS-CoV-2 Infection,True,Symptomatic SARS-CoV-2,0.95,2,22,0,0.1,True,False,,,No comparison,Symptomatic SARS-CoV-2
329332,Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial,Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
345720,Chairperson,How to Design a Successful Career Path in Cancer Research: The Dos and Don'ts for Early-Stage Investigators,Cancer,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
181883,Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study,Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma;;Severe Renal Impairment,0.95,5,61,4,0.65,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma;;Severe Renal Impairment
394876,The Mount Vernon Cancer Center Non Medical Prescriber Gi Oncology Clinic Experience,Cancer Nursing: Ehealth And Digital Innovations,,True,Gastrointestinal Cancer,0.95,2,23,1,0.2,False,False,,,No comparison,Gastrointestinal Cancer
280189,Overview of Guidelines,EHA-EuNet-INNOCHRON Guidelines on Chronic neutropenias,,True,Chronic Neutropenia,0.95,2,19,1,0.2,False,False,,,No comparison,Chronic Neutropenia
263809,Treatment Efficacy Of Progression Free Survival For Refractory/Relapsed Multiple Myeloma In Geriatric Patients: A Network Meta-Analysis,Myeloma and other monoclonal gammopathies - Clinical,Refractory/Relapsed Multiple Myeloma,True,Geriatric Refractory/Relapsed Multiple Myeloma,0.95,4,46,3,0.5,False,False,,,No comparison,Geriatric Refractory/Relapsed Multiple Myeloma
231041,"Effects of five prescriptions in Synopsis of Golden Chamber on the malignant phenotype and expression of CA125, CEA, HE4 proteins in human ovarian cancer cells.",Gynecologic Cancer,Ovarian Cancer ,True,Ovarian Cancer,0.95,2,14,1,0.2,False,False,,,No comparison,Ovarian Cancer
345732,Developmental pathways and spatial architecture of pediatric high-grade glioma,Cell-of-Origin and Tumor Heterogeneity in Childhood Cancers: A Pediatric Cancer Working Group Town Hall Meeting and Networking Reception,Pediatric High-Grade Glioma,True,Pediatric High Grade Glioma,0.95,4,27,1,0.3,False,False,,,No comparison,Pediatric High Grade Glioma
280200,Therapies intervening along the Sickle Cell Disease pathophysiological cascade,Global Blood Therapeutics: Optimising care in Sickle Cell Disease - focusing on the long term right from the beginning,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
394888,Evaluation Of Financial Toxicity And Associated Factors In Female Patients With Breast Cancer: A Systematic Review And Meta-Analysis,Cancer Nursing: Supportive Care,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
378511,Direct Endoscopic Versus Step-Up Transluminal Interventions In Necrotizing Pancreatitis (Destin): Results Of A Randomized Trial,DDW Clinical Late Breaking Abstract Session,Pancreatitis,True,Necrotizing Pancreatitis,0.95,2,24,0,0.1,False,False,,,No comparison,Necrotizing Pancreatitis
231055,The evolving landscape of practice pattern and survival outcomes in the management of localized low-risk prostate cancer.,"Genitourinary Cancer-Prostate, Testicular, and Penile",Localized Low-Risk Prostate Cancer,True,Localized Low-Risk Prostate Cancer,0.95,4,34,1,0.3,False,False,,,No comparison,Localized Low-Risk Prostate Cancer
378513,Clinical Validation Of A Cell-Free Dna Blood-Based Test For Colorectal Cancer Screening In An Average Risk Population,DDW Clinical Late Breaking Abstract Session,Colorectal Cancer ,True,Average-Risk Colorectal Cancer,0.95,3,30,1,0.25,False,False,,,No comparison,Average-Risk Colorectal Cancer
149141,Targeted therapy and immunotherapy in newly diagnosed Ph-negative ALL,European Working Group On Adult All (Ewall),Newly Diagnosed Ph-Negative Acute Lymphocytic Leukemia,True,Adult Newly Diagnosed Ph Chromosome-Negative Acute Lymphoblastic Leukemia,0.95,8,73,4,0.8,False,False,,,No comparison,Adult Newly Diagnosed Ph Chromosome-Negative Acute Lymphoblastic Leukemia
149142,Selecting the best targeted therapy. Role of drug profiling,European Working Group On Adult All (Ewall),Adult Acute Lymphoblastic Leukemia,True,Adult Acute Lymphoblastic Leukemia,0.95,4,34,2,0.4,False,False,,,No comparison,Adult Acute Lymphoblastic Leukemia
312981,Long-Term Heart Failure Risk Of Trastuzumab With Or Without Anthracyclines In Early Stage Breast Cancer: A Seer-Medicare Database Analysis,"Epidemiology, Risk, And Prevention: Epidemiology, Risk, And Prevention - Other",Early Stage Breast Cancer,True,Heart Failure;;Early Stage Breast Cancer,0.95,5,40,3,0.55,False,False,,,No comparison,Heart Failure;;Early Stage Breast Cancer
214681,Low-grade urothelial carcinoma recurs at a tempo that naturally accelerates from Adagio to Allegro,PD26: Bladder Cancer: Non-invasive I,Low-Grade Urothelial Carcinoma,True,Non-Invasive Recurrent Low-Grade Urothelial Carcinoma,0.95,5,53,2,0.45,False,False,,,No comparison,Non-Invasive Recurrent Low-Grade Urothelial Carcinoma
378521,Investigating the use of focused ultrasound to induce blood-brain barrier opening and increase drug delivery into a murine model of primary high grade glioma tumors,General Neurology,Primary High Grade Glioma Tumor,True,Primary High Grade Glioma,0.95,4,25,1,0.3,False,False,,,No comparison,Primary High Grade Glioma
214683,Comparison of Intravesical Therapy and Surgery as Treatment Options for Recurrent Bladder Cancer (CISTO): Update on an Ongoing Multicenter Pragmatic Study,PD26: Bladder Cancer: Non-invasive I,Recurrent Bladder Cancer,True,Non-Invasive Recurrent Bladder Cancer,0.95,4,37,1,0.3,False,False,,,No comparison,Non-Invasive Recurrent Bladder Cancer
231067,Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01.,Gynecologic Cancer,BRCA Non-Mutated Platinum-Sensitive Recurrent Ovarian Cancer,True,Platinum-Sensitive Recurrent BRCA Wild Type Ovarian Cancer,0.95,7,58,1,0.45,True,False,,,No comparison,Platinum-Sensitive Recurrent BRCA Wild Type Ovarian Cancer
149153,DDX41 and leukemia predisposition: Where is the link?,Mechanisms Of Transformation: Insights From Genetic Predisposition Disorders,Leukemia,True,Genetic Predisposition Disorder;;Leukemia,0.95,3,41,2,0.35,False,False,,,No comparison,Genetic Predisposition Disorder;;Leukemia
345762,Chairperson,Early Detection and Interception of Cancer,Cancer,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
378532,Racial Disparities in Alzheimer's Disease: the association between early life adversity and AD,General Neurology,Alzheimer's Disease,True,Alzheimer's Disease,0.95,2,19,1,0.2,False,False,,,No comparison,Alzheimer's Disease
214692,"Prostate Volume, Baseline Urinary Symptoms, and Their Association with Post-Treatment Urinary Function in Men Treated for Localized Prostate Cancer",PD27: Prostate Cancer: Localized: Surgical Therapy II,Localized Prostate Cancer,True,Localized Prostate Cancer,0.95,3,25,1,0.25,False,False,,,No comparison,Localized Prostate Cancer
329382,Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT,Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I,Pediatric B-Cell Acute Lymphoblastic Leukemia;;Adult B-Cell Acute Lymphoblastic Leukemia,True,Adult Relapsed B-Cell Acute Lymphoblastic Leukemia;;Pediatric Relapsed B-Cell Acute Lymphoblastic Leukemia,0.95,11,106,3,0.85,False,False,,,No comparison,Adult Relapsed B-Cell Acute Lymphoblastic Leukemia;;Pediatric Relapsed B-Cell Acute Lymphoblastic Leukemia
296615,Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay,Oesophagogastric cancer,First-Line Oesophagogastric Adenocarcinoma,True,First-Line Oesophagogastric Adenocarcinoma,0.95,3,42,1,0.25,False,False,,,No comparison,First-Line Oesophagogastric Adenocarcinoma
263850,Utility Of Kit P.D816 In Myeloid Neoplasm Without Documented Systemic Mastocytosis To Detect Hidden Mast Cells In Bone Marrow,Myeloproliferative neoplasms - Biology & Translational Research,Myeloid Neoplasm;;Systemic Mastocytosis,True,Myeloid Neoplasm,0.95,2,16,0,0.1,False,False,,,No comparison,Myeloid Neoplasm
296620,Time to Development of Central Nervous System (CNS) Metastases (mets) With Atezolizumab (A) or Placebo (P) Combined With Vemurafenib (V) + Cobimetinib (C): Updated Results From the Phase 3 IMspire150 Study,Melanoma and other skin tumours,Central Nervous System Metastasis,True,Melanoma;;Other Skin Tumour,0.95,3,27,0,0.15,False,False,,,No comparison,Melanoma;;Other Skin Tumour
345772,Racial and ethnic disparities associated with the intratumor microbiome in female cancers,"Late-Breaking Research: Prevention, Early Detection, and Interception",Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
345775,Bio-printed 3D cell models and high-content imaging for testing anti-cancer compounds,"Late-Breaking Research: Prevention, Early Detection, and Interception",,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
394925,Pragmatic Trials,More Intelligent Trial Design,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
345777,Simultaneous whole-body ultrasound contrast imaging: a novel high throughput preclinical platform for targeted molecular imaging studies,"Late-Breaking Research: Prevention, Early Detection, and Interception",,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
313009,Trends In Clinical Treatment Of Early Stage Er+Pr- Breast Cancer In The National Cancer Database,Prognostic And Predictive Factors - Prognostic Factors: Other,Early Stage Er+Pr- Breast Cancer,True,Early Stage ER-Positive PR-Negative Breast Cancer,0.95,6,49,5,0.8,True,False,,,No comparison,Early Stage ER-Positive PR-Negative Breast Cancer
313012,"Racial Disparities Among Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy Therapy And Impact On Pathologic Response: An Urban, Single-Institution Experience",Prognostic And Predictive Factors - Prognostic Factors: Other,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
345782,What can we learn from phosphoproteomics compared to transcriptomics in DNA damage and other processes?,Proteomics and Biomarker Discovery,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
313018,Breast Cancer Characteristics In Premenopausal Women By Contraception Method,Prognostic And Predictive Factors - Prognostic Factors: Other,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
280253,Patient case presentation,EHA Guidelines on Antifungal prophylaxis and therapy in patients with AML treated with new agents,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
149183,Molecular definition,What Is High-Risk Disease In The Era Of Modern Agents?,,True,High-Risk Disease,0.95,2,17,1,0.2,False,False,,,No comparison,High-Risk Disease
198339,Acute Stress Induces Memory Bias and Stronger Preference for Smoking-Associated Places in Smokers,Poster Session II (In-Person),Acute Stress,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
411332,Random Forest Can Accurately Predict the Technique Failure of Peritoneal Dialysis-Associated Peritonitis Patients,Home Dialysis - I,Peritoneal Dialysis-Associated Peritonitis,True,Peritoneal Dialysis-Associated Peritonitis,0.95,3,42,0,0.15,False,False,,,No comparison,Peritoneal Dialysis-Associated Peritonitis
345801,Understanding how IL-2 cytokine synergizes with PD-1 therapy during chronic viral infection,Late-Breaking Research: Immunology 1,Chronic Viral Infection,True,Chronic Viral Infection,0.95,3,23,1,0.25,False,False,,,No comparison,Chronic Viral Infection
165580,Delayed Mortality among Solid Organ Transplant Recipients Hospitalized for Covid-19: An International Multicenter Study,"COVID-19 Special populations (e. g. pregnant women, children, immunocompromised, etc)",COVID-19,True,COVID-19,0.95,1,8,0,0.05,True,False,,,No comparison,COVID-19
329422,"Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up",Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II,Multiple Myeloma,True,Early Relapsed Multiple Myeloma,0.95,4,31,3,0.5,False,False,,,No comparison,Early Relapsed Multiple Myeloma
263889,Erythrocytes' Oxidative Stress And Antioxidant Response In Patients With Hereditary Spherocytosis And B-Thalassemia Minor - A Small Number Case Study,"Enzymopathies, membranopathies and other anemias",Hereditary Spherocytosis;;B-Thalassemia Minor,True,Hereditary Spherocytosis;;B-Thalassemia Minor,0.95,3,45,0,0.15,False,False,,,No comparison,Hereditary Spherocytosis;;B-Thalassemia Minor
345810,Identifying novel targets for CAR-T therapies from single cell RNA-sequencing data,"Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1",,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
329431,Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience,Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma;;Renal Insufficiency,0.95,4,57,3,0.5,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma;;Renal Insufficiency
329434,Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups,Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
394977,Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial,"Mini Oral Session - Breast Cancer, Early Stage",Invasive Cancer,True,Early Stage Invasive Breast Cancer,0.95,5,34,3,0.55,False,False,,,No comparison,Early Stage Invasive Breast Cancer
165602,Uptake and Perceptions of COVID-19 Vaccines among US Pregnant Women,"COVID-19 Special populations (e. g. pregnant women, children, immunocompromised, etc)",COVID-19 Infection,True,COVID-19,0.95,1,8,0,0.05,True,False,,,No comparison,COVID-19
329442,CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany,Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III,Pediatric Young Adult B-Lineage Acute Lymphoblastic Leukemia,True,Pediatric Relapsed B-Lineage Acute Lymphoblastic Leukemia;;Young Adult Relapsed B-Lineage Acute Lymphoblastic Leukemia,0.95,12,118,3,0.9,False,False,,,No comparison,Pediatric Relapsed B-Lineage Acute Lymphoblastic Leukemia;;Young Adult Relapsed B-Lineage Acute Lymphoblastic Leukemia
296678,Phase 1 Study of SAR444245 (SAR'245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors,Investigational immunotherapy,Advanced Solid Tumor,True,Advanced Solid Tumor,0.95,3,20,2,0.35,False,False,,,No comparison,Advanced Solid Tumor
329443,Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel,Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III,Cytokine Release Syndrome,True,Cytokine Release Syndrome,0.95,3,25,1,0.25,False,False,,,No comparison,Cytokine Release Syndrome
263910,Vkorc1 -1639 G/A Gene Polymorphism Can Modulate The Risk Of Venous Thromboembolism In Elderly Patients With Fv Leiden Mutation,Thrombosis and vascular biology - Biology & Translational Research,Elderly Venous Thromboembolism,True,Elderly Fv Leiden-Mutated Venous Thromboembolism,0.95,5,48,0,0.25,False,False,,,No comparison,Elderly Fv Leiden-Mutated Venous Thromboembolism
214761,Incidence and significance of 20% decrease from new baseline estimated glomerular filtration rate after radical and partial nephrectomy,PD33: Kidney Cancer: Localized: Surgical Therapy II,Kidney Cancer,True,Localized Kidney Cancer,0.95,3,23,1,0.25,False,False,,,No comparison,Localized Kidney Cancer
165611,Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-a antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure,COVID-19 Treatment,Severe COVID-19 Infection,True,Severe COVID-19 Respiratory Failure;;Critical COVID-19 Respiratory Failure,0.95,7,74,1,0.45,True,False,,,No comparison,Severe COVID-19 Respiratory Failure;;Critical COVID-19 Respiratory Failure
296691,Current use of breast cancer multigene signatures in clinical practice among European experts: results from the PROCURE Project,"Breast cancer, early stage",Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
182010,Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II",High-Risk Hematologic Malignancy,True,High-Risk Hematologic Malignancy,0.95,3,32,0,0.15,False,False,,,No comparison,High-Risk Hematologic Malignancy
182014,Sequential Therapy with Fitcy Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II",Primary Refractory Acute Myeloid Leukemia,True,Refractory Acute Myeloid Leukemia,0.95,4,33,3,0.5,False,False,,,No comparison,Refractory Acute Myeloid Leukemia
165631,Risk Factor Analysis for Hospital Admission Following Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Monoclonal Antibody Treatment,COVID-19 Treatment,Severe Acute Respiratory Syndrome Coronavirus-2 Infection,True,Severe Acute Respiratory Syndrome Coronavirus-2,0.95,5,47,3,0.55,False,False,,,No comparison,Severe Acute Respiratory Syndrome Coronavirus-2
198398,"Brain Function during Risky Decision-Making is Associated with Profiles of Hiv Knowledge, Perceived Severity, and Worry",Virtual Poster Session II,Human Immunodeficiency Virus Infection,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
198402,Longitudinal Changes in Neural Activation that Discriminates between Aspects of Reward Processing in Early Adolescence,Virtual Poster Session II,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
263941,Overall Survival With Intensive Chemotherapy (Ic) Vs Non-Ic In Patients (Pts) With Newly Diagnosed (Nd) Aml From The Connect(r) Myeloid Disease Registry Ineligible For Randomized Clinical Trials (Rct),Acute myeloid leukemia - Clinical,Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed Acute Myeloid Leukemia,0.95,5,38,3,0.55,False,False,,,No comparison,Newly Diagnosed Acute Myeloid Leukemia
214789,The impact of older age on the oncological outcomes for high-risk metastatic hormone-sensitive prostate cancer treated with upfront intensive therapy,PD35: Prostate Cancer: Advanced (including Drug Therapy) II,High-Risk Metastatic Hormone-Sensitive Prostate Cancer,True,Elderly High-Risk Metastatic Hormone-Sensitive Prostate Cancer,0.95,6,62,1,0.4,False,False,,,No comparison,Elderly High-Risk Metastatic Hormone-Sensitive Prostate Cancer
165642,Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population,COVID-19 Treatment,SARS-CoV-2 Infection,True,High-Risk SARS-CoV-2 Infection,0.95,3,30,0,0.15,True,False,,,No comparison,High-Risk SARS-CoV-2 Infection
329488,High-Density Cryopreservation of Off-the-Shelf CAR-NK Cells Facilitates On-demand Treatment Access,Cell Collection and Processing: Poster I,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
395025,Long-term residential and workplace exposure to air pollution and breast cancer risk: A case-control study nested in the French E3N cohort from 1990 to 2011,"Mini Oral Session - Breast Cancer, Early Stage",Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
411410,Correction of PKD by Gene Transfer into Pkd1-Null Mouse Model,Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis,Polycystic Kidney Disease,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
313106,Self-Renewal Signatures Of Peripheral Blood T Cells Are Associated With Successful Engraftment To Establish A Humanized Mouse Model Of Breast Cancer,Tumor Cell And Molecular Biology: Animal Models,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
149271,Panel discussion and concluding remarks,Fresh Perspectives On Enduring Conversations In Relapsed/Refractory Multiple Myeloma (Rrmm),Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
182040,Sex Differences in EBV Viremia after Haplo-HSCT Imply Sex Bias during Immune Reconstitution,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II",,True,EBV Viremia,0.95,2,11,0,0.1,True,False,,,No comparison,EBV Viremia
329497,Frequent Early Geriatric Complications after Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Adults Impairs Disability-Free Survival (DiFS),"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II",,True,Early Onset Geriatric Complication,0.95,4,34,1,0.3,False,False,,,No comparison,Early Onset Geriatric Complication
198426,Increased Frontal and Parietal Resting-State Lower Alpha Power as a Potential Marker of a Compensatory Mechanism Against Negative Symptoms in Clinical High-Risk Individuals for Psychosis,Virtual Poster Session II,,True,Clinical High-Risk for Psychosis,0.95,4,32,0,0.2,False,False,,,No comparison,Clinical High-Risk for Psychosis
165659,Risk Factors Associated with 30-Day Mortality in a Large Cohort of Patients who Received Remdesivir and Corticosteroids for Severe COVID-19,COVID-19 Treatment,Severe COVID-19,True,Severe COVID-19,0.95,2,15,1,0.2,True,False,,,No comparison,Severe COVID-19
329500,Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II",Graft-Versus Host Disease,True,Cytokine Release Syndrome,0.95,3,25,1,0.25,False,False,,,No comparison,Cytokine Release Syndrome
329498,Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34+-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II",Bone Marrow Failure Syndrome,True,Bone Marrow Failure Syndrome,0.95,4,28,1,0.3,False,False,,,No comparison,Bone Marrow Failure Syndrome
345879,The application of a PLGA scaffold for the dual delivery of Y15 and metformin for the treatment of platinum resistant ovarian cancer,Drug Delivery,Platinum Resistant Ovarian Cancer,True,Platinum-Resistant Ovarian Cancer,0.95,3,33,2,0.35,False,False,,,No comparison,Platinum-Resistant Ovarian Cancer
182048,The Incidence and Impact of Clostridioides Difficile Infection (CDI) on Outcomes after Allogeneic Hematopoietic Cell Transplant (alloHCT) - a CIBMTR Study,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II",Clostridioides Difficile Infection,True,Clostridioides Difficile Infection,0.95,3,34,0,0.15,False,False,,,No comparison,Clostridioides Difficile Infection
182051,CD45RO+ T-Cell Add Back and Prophylactic Blinatumomab Administration Post Tcrab/CD19-Depleted Haploidentical Transplantation in Pediatric Patients with High Risk Acute Leukemia,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II",Pediatric High Risk Acute Leukemia,True,Pediatric High-Risk Acute Leukemia,0.95,4,34,2,0.4,False,False,,,No comparison,Pediatric High-Risk Acute Leukemia
182053,Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia,Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II,Acute Lymphoblastic Leukemia,True,Acute Lymphoblastic Leukemia,0.95,3,28,2,0.35,False,False,,,No comparison,Acute Lymphoblastic Leukemia
182056,Clinical Risk Factors and Prognostic Model for Idiopathic Inflammatory Demyelinating Diseases after Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies,Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II,Idiopathic Inflammatory Demyelinating Disease;;Hematological Malignancy,True,Idiopathic Inflammatory Demyelinating Disease;;Hematological Malignancy,0.95,5,71,1,0.35,False,False,,,No comparison,Idiopathic Inflammatory Demyelinating Disease;;Hematological Malignancy
263983,Ciltacabtagene Autoleucel In Lenalidomide-Refractory Patients With Progressive Multiple Myeloma After 1-3 Prior Lines Of Therapy: Cartitude-2 Biological Correlative Analyses And Updated Clinical Data,Myeloma and other monoclonal gammopathies - Clinical,Progressive Multiple Myeloma,True,Progressive Refractory Multiple Myeloma;;Refractory Progressive Multiple Myeloma,0.95,7,80,2,0.55,False,False,,,No comparison,Progressive Refractory Multiple Myeloma;;Refractory Progressive Multiple Myeloma
411442,Prognosis of Polycystic Kidney Disease: FinnGen Study,Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis,Polycystic Kidney Disease,True,Polycystic Kidney Disease,0.95,3,25,1,0.25,False,False,,,No comparison,Polycystic Kidney Disease
182069,The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell Lymphoma,Autologous Transplantation: Clinical and Epidemiological: Poster II,Newly Diagnosed Mantle Cell Lymphoma,True,Newly Diagnosed Mantle Cell Lymphoma,0.95,5,36,2,0.45,False,False,,,No comparison,Newly Diagnosed Mantle Cell Lymphoma
214837,Evaluating Factors That Influence Healthcare Resource Utilization in Transurethral Resection of Prostate,"PD39: Benign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-surgical Therapy",Benign Prostatic Hyperplasia,True,Benign Prostatic Hyperplasia,0.95,3,28,0,0.15,False,False,,,No comparison,Benign Prostatic Hyperplasia
263993,"Camma 3: A Multicenter Phase Ib Trial Evaluating The Safety, Pharmacokinetics, And Activity Of Subcutaneous Cevostamab Monotherapy In Patients With Relapsed Or Refractory Multiple Myeloma",Myeloma and other monoclonal gammopathies - Clinical,Relapsed Or Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
378681,Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.,Biomarkers of the Future: New Strategies to Predict Sarcoma Outcomes,High-Risk Soft Tissue Sarcoma,True,High-Risk Soft Tissue Sarcoma,0.95,4,29,0,0.2,False,False,,,No comparison,High-Risk Soft Tissue Sarcoma
182078,A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Interim Results,Gene Therapies: Poster II,Severe Leukocyte Adhesion Deficiency-I,True,Pediatric Severe Leukocyte Adhesion Deficiency-I,0.95,5,48,1,0.35,False,False,,,No comparison,Pediatric Severe Leukocyte Adhesion Deficiency-I
313151,Prognosis And Treatment Landscape Of Her2-Positive Metastatic Breast Cancer (Mbc) Before The Availability Of Tucatinib And Trastuzumab-Deruxtecan: Results From The Austrian Agmt_Mbc-Registry,Treatment - Advanced Disease Treatment: Advanced Therapy - Targeted,Her2-Positive Metastatic Breast Cancer,True,HER2-Positive Metastatic Breast Cancer,0.95,4,38,2,0.4,False,False,,,No comparison,HER2-Positive Metastatic Breast Cancer
182082,Administration of Granulocyte Colony-Stimulating Factor Post-Transplant Impedes Engraftment of CRISPR-Cas9 Edited Long-Term Repopulating Hematopoietic Stem and Progenitor Cells,Gene Therapies: Poster II,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
296771,Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): results from CheckMate 9LA,"NSCLC, metastatic",Metastatic Non-Small Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
313155,High Incidence Of Palbociclib Related Neutropenia In Asian Patients Associated With Genetic Polymorphisms,Treatment - Advanced Disease Treatment: Advanced Therapy - Targeted,Neutropenia,True,Palbociclib-Related Neutropenia,0.95,2,31,0,0.1,False,False,,,No comparison,Palbociclib-Related Neutropenia
345926,Rare neoplastic subpopulation predicts relapse in nasopharyngeal carcinoma,Diagnostic and Prognostic Biomarkers 2,Relapsed Nasopharyngeal Carcinoma,True,Nasopharyngeal Carcinoma,0.95,2,24,1,0.2,False,False,,,No comparison,Nasopharyngeal Carcinoma
198471,Gene Dosage Influences Sensitive Periods of Brain Development and Divergent Phenotypes in Reciprocal 22q11.2 Copy Number Variants,The Case for Deep Phenotyping in Psychiatric Genetics: Insights from Rare Variants in Neurodevelopment,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
214859,Moving Beyond PSA: Identifying the Optimal Diagnostic Strategy to Assess Prostate Cancer Risk,PD41: Prostate Cancer: Detection & Screening IV,Prostate Cancer,True,Prostate Cancer,0.95,2,15,1,0.2,False,False,,,No comparison,Prostate Cancer
345931,Longitudinal tracking of circulating rare events in the liquid biopsy of stage III-IV NSCLC patients during treatment,Diagnostic and Prognostic Biomarkers 2,Stage III-IV Non-Small Cell Lung Cancer,True,Stage III Non-Small Cell Lung Cancer;;Stage IV Non-Small Cell Lung Cancer,0.95,11,73,2,0.75,True,False,,,No comparison,Stage III Non-Small Cell Lung Cancer;;Stage IV Non-Small Cell Lung Cancer
296782,Efficacy and safety of almonertinib in the adjuvant treatment of resectable stage I non-small cell lung cancer(NSCLC) with epidermal growth factor receptor (EGFR)-sensitizing mutations in solid and/or micropapillary components,"NSCLC, early stage",Resectable Stage I EGFR-Mutated Non-Small Cell Lung Cancer,True,Resectable Stage I EGFR-Mutated Non-Small Cell Lung Cancer,0.95,8,58,2,0.6,True,False,,,No comparison,Resectable Stage I EGFR-Mutated Non-Small Cell Lung Cancer
198479,Identifying Genetic Components of Anorexia Nervosa through Pathway Polygenic Risk Scores,"Oral Session 2: Addiction, Alzheimers, Eating Disorders, OCD & Sex Differences",Anorexia Nervosa,True,Anorexia Nervosa,0.95,2,16,0,0.1,False,False,,,No comparison,Anorexia Nervosa
296783,"Adjuvant nivolumab with chemotherapy in pleural mesothelioma aEUR"" the NICITA trial","Thoracic malignancies, other",Pleural Mesothelioma,True,Pleural Mesothelioma,0.95,2,20,0,0.1,False,False,,,No comparison,Pleural Mesothelioma
395089,Igsf8 Is An Innate Immune Checkpoint And Cancer Immunotherapy Target,Proffered Paper session 2 - Basic Science and Translational research,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
345939,TERT C228T and KDM6A alterations are potential predictive biomarkers in non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin instillation,Biomarkers of Therapeutic Benefit 2,Non-Muscle-Invasive Bladder Cancer,True,TERT C228T-Altered Non-Muscle-Invasive Bladder Cancer;;KDM6A-Altered Non-Muscle-Invasive Bladder Cancer,0.95,8,103,1,0.5,True,False,,,No comparison,TERT C228T-Altered Non-Muscle-Invasive Bladder Cancer;;KDM6A-Altered Non-Muscle-Invasive Bladder Cancer
313170,Predictors Of Long-Term Durable Response In De Novo Her2 Positive Metastatic Breast Cancer And The Real World Treatment Experience At Two Institutions,Prognostic And Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers-Other,De Novo Her2-Positive Metastatic Breast Cancer,True,De Novo HER2-Positive Metastatic Breast Cancer,0.95,6,46,2,0.5,False,False,,,No comparison,De Novo HER2-Positive Metastatic Breast Cancer
214869,Radical vs Partial Cystectomy for Urachal Carcinoma: A Population-Based Analysis,PD42: Bladder Cancer: Invasive IV,Urachal Carcinoma,True,Urachal Carcinoma,0.95,2,17,1,0.2,False,False,,,No comparison,Urachal Carcinoma
329558,Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",,True,Cytomegalovirus,0.95,1,15,0,0.05,False,False,,,No comparison,Cytomegalovirus
214871,Do Prophylactic Antibiotics Reduce Urinary Tract Infections Following Robot-Assisted Radical Cystectomy? A Randomized Control Trial,PD42: Bladder Cancer: Invasive IV,Urinary Tract Infection,True,Invasive Bladder Cancer;;Urinary Tract Infection,0.95,5,48,1,0.35,False,False,,,No comparison,Invasive Bladder Cancer;;Urinary Tract Infection
313169,Serial Monitoring Of Circulating Tumor Cells And Circulating Tumor Dna In Metastatic Lobular Breast Cancer Identifies Intra-Tumor Heterogeneity And Precision And Immuno-Oncology Biomarkers Of Therapeutic Importance,Prognostic And Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers-Other,Metastatic Lobular Breast Cancer,True,Metastatic Lobular Breast Cancer,0.95,4,32,1,0.3,False,False,,,No comparison,Metastatic Lobular Breast Cancer
345942,Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha,Biomarkers of Therapeutic Benefit 2,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
182100,Mapbatch: Conservative Batch Normalization for Single Cell RNA-Sequencing Data Enables Discovery of Rare Cell Populations in a Multiple Myeloma Cohort,Emerging Diagnostic Tools and Techniques: Poster II,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
395100,Non-Oncogene-Addicted Metastatic Nsclc Discussion,Esmo Clinical Practice Guidelines 2,Metastatic Non-Small Cell Lung Cancer,True,Non-Oncogene-Addicted Metastatic Non-Small Cell Lung Cancer,0.95,6,59,1,0.4,False,False,,,No comparison,Non-Oncogene-Addicted Metastatic Non-Small Cell Lung Cancer
231260,Clinical application of precision medicine among oncologists: A case study in RET-targeted therapy.,Health Services Research and Quality Improvement,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
313185,Utility Of The 70-Gene Signature And 10 Year Follow Up In Patients With Early-Stage Breast Cancer In A Single Institution Study,Prognostic And Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers-Other,Early-Stage Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
231266,Outcomes of malignant pericardial effusion associated with solid cancers based on treatment modality.,Health Services Research and Quality Improvement,Malignant Pericardial Effusion;;Solid Cancer,True,Malignant Pericardial Effusion;;Solid Cancer,0.95,4,44,1,0.3,False,False,,,No comparison,Malignant Pericardial Effusion;;Solid Cancer
329574,Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II",Chronic Graft-Versus-Host Disease,True,Chronic Graft-versus-Host Disease,0.95,3,33,2,0.35,False,False,,,No comparison,Chronic Graft-versus-Host Disease
378731,Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.,Knives Out: Surgical Management of Gynecologic Cancers,Ovarian Cancer ,True,Ovarian Cancer,0.95,2,14,1,0.2,False,False,,,No comparison,Ovarian Cancer
378732,Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.,Knives Out: Surgical Management of Gynecologic Cancers,Platinum-Sensitive Relapsed Epithelial Ovarian Cancer,True,Platinum-Sensitive Relapsed Epithelial Ovarian Cancer,0.95,5,53,2,0.45,False,False,,,No comparison,Platinum-Sensitive Relapsed Epithelial Ovarian Cancer
378734,An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).,Knives Out: Surgical Management of Gynecologic Cancers,Low-Risk Early-Stage Cervical Cancer,True,Low-Risk Early Stage Cervical Cancer,0.95,5,36,3,0.55,False,False,,,No comparison,Low-Risk Early Stage Cervical Cancer
165745,"Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence",Clinical trials,Clostridioides Difficile Infection,True,Recurrent Clostridioides Difficile Infection,0.95,4,44,0,0.2,False,False,,,No comparison,Recurrent Clostridioides Difficile Infection
313205,Cumulative Environmental Quality Is Associated With Differential Breast Cancer Incidence  By Summary Stage And Urbanicity,"Epidemiology, Risk, And Prevention: Epidemiology - Population Studies",Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
165758,"Rapid, Non-invasive Detection Of Cryptic Tularemia Using A Plasma-Based Microbial Cell-Free DNA Next-Generation Sequencing Test",Diagnostics: Bacteriology/mycobacteriology,Tularemia,True,Cryptic Tularemia,0.95,2,17,0,0.1,False,False,,,No comparison,Cryptic Tularemia
198526,The Neurobiology of Childhood Trauma - Aldosterone and Blood Pressure Changes in a Community Sample,Oral Session 4: Anxiety/Psychosis/PTSD/Suicide,Childhood Trauma,True,Anxiety;;Psychosis;;PTSD;;Suicide;;Childhood Trauma,0.95,2,51,0,0.1,True,False,,,No comparison,Anxiety;;Psychosis;;PTSD;;Suicide;;Childhood Trauma
296833,"Stable, controllable, and scalable manufacturing of B7-H3 UCAR-T, an allogeneic CAR-T product for advanced glioma, from healthy donors",CNS tumours,Advanced Glioma,True,Advanced Glioma,0.95,2,15,1,0.2,False,False,,,No comparison,Advanced Glioma
329603,Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III",Chronic Graft-Versus-Host Disease,True,Chronic Refractory Graft vs Host Disease;;Refractory Chronic Graft vs Host Disease,0.95,11,82,3,0.85,False,False,,,No comparison,Chronic Refractory Graft vs Host Disease;;Refractory Chronic Graft vs Host Disease
313220,The Impact Of Sociodemographic Disparities On Overall Survival Of Adolescent And Young Adults (Aya) With Invasive Breast Cancer,"Epidemiology, Risk, And Prevention: Epidemiology - Population Studies",Adolescent Young Adult Invasive Breast Cancer,True,Adolescent and Young Adult Invasive Breast Cancer,0.95,7,49,1,0.45,False,False,,,No comparison,Adolescent and Young Adult Invasive Breast Cancer
296839,Tertiary lymphoid structure predicts major pathological response in resectable non-small cell lung cancer patients with neoadjuvant chemotherapy,Basic Science,Resectable Non-Small Cell Lung Cancer,True,Resectable Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Resectable Non-Small Cell Lung Cancer
345992,"Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel",Biomarkers of Therapeutic Benefit 3,Pancreatic Ductal Adenocarcinoma,True,Pancreatic Ductal Adenocarcinoma,0.95,3,32,1,0.25,False,False,,,No comparison,Pancreatic Ductal Adenocarcinoma
345995,A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE),Biomarkers of Therapeutic Benefit 3,Unresectable Stage III Non-Small Cell Lung Cancer,True,Unresectable Stage III Non-Small Cell Lung Cancer,0.95,7,49,2,0.55,True,False,,,No comparison,Unresectable Stage III Non-Small Cell Lung Cancer
198543,Making the MOSTest of genetics: The Multivariate Omnibus Statistical Test Boosts Discovery of the Genetic Determinants of the Brain and Its Disorders,Poster Session III (In-Person),Brain Disorder,True,Brain Disorder,0.95,2,14,1,0.2,False,False,,,No comparison,Brain Disorder
198548,Identification of Structural Brain Alterations in Adolescents at Suicide Risk: A Machine Learning Approach,Poster Session III (In-Person),,True,Adolescent Suicide Risk,0.95,3,23,0,0.15,False,False,,,No comparison,Adolescent Suicide Risk
395159,Chairman'S Introduction,Merck Healthcare Kgaa - Putting Patients First: Cultivating Care In Bladder Cancer,Bladder Cancer,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
313244,Surgical Outcomes For Reconstruction After Delayed Contralateral Prophylactic Mastectomy,"Psychosocial, Qol, And Educational Aspects - Qol Issues: Psychosocial Aspects",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
329629,Complex Restrictive Lung Disease Patterns Affecting Survival and Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant: A Single-Institution Retrospective Analysis,Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II,Lung Disease,True,Complex Restrictive Lung Disease,0.95,4,32,1,0.3,False,False,,,No comparison,Complex Restrictive Lung Disease
378783,Neoadjuvant Therapy in Triple-Negative Breast Cancer: Where We Are and What's Next?,"The Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between",Triple-Negative Breast Cancer,True,Early Stage Triple-Negative Breast Cancer,0.95,5,41,4,0.65,False,False,,,No comparison,Early Stage Triple-Negative Breast Cancer
296867,Staging strategies of newly diagnosed triple-negative breast cancer (TNBC): comparison between CT scan and 18F-FDG-PET/CT,"Breast cancer, early stage",Newly Diagnosed Triple-Negative Breast Cancer,True,Newly Diagnosed Triple-Negative Breast Cancer,0.95,5,45,3,0.55,False,False,,,No comparison,Newly Diagnosed Triple-Negative Breast Cancer
378794,Medical Oncology Perspective,Gliomas in Adolescents and Young Adults: Which Paradigm Works Best?,Adolescent Young Adult Glioma,True,Adolescent and Young Adult Glioma,0.95,5,33,0,0.25,False,False,,,No comparison,Adolescent and Young Adult Glioma
296875,Serum metabolomics based risk assessment of disease recurrence in elderly patients with early breast cancer (eBC),"Breast cancer, early stage",Elderly Early Breast Cancer,True,Elderly Early Stage Breast Cancer,0.95,5,33,3,0.55,False,False,,,No comparison,Elderly Early Stage Breast Cancer
329644,Efficacy of Azacitidine Post-Transplant Maintenance for FLT3-Negative Acute Myeloid Leukemia and Myelodysplastic Syndrome,Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III,FLT3-Negative Acute Myeloid Leukemia;;Myelodysplastic Syndrome,True,FLT3-Negative Acute Myeloid Leukemia;;Myelodysplastic Syndrome,0.95,5,62,4,0.65,False,False,,,No comparison,FLT3-Negative Acute Myeloid Leukemia;;Myelodysplastic Syndrome
313262,Implementation Of A Bone Modifying Agent Pathway At Uchicago Medicine For Metastatic Breast Cancer Patients,Treatment - Treatment: Other,Metastatic Breast Cancer,True,Metastatic Breast Cancer,0.95,3,24,1,0.25,False,False,,,No comparison,Metastatic Breast Cancer
346030,Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial,Phase III and Pediatric Clinical Trials,Advanced Cervical Cancer,True,Advanced Cervical Cancer,0.95,3,24,2,0.35,False,False,,,No comparison,Advanced Cervical Cancer
313261,Real World Data Of Adjuvant Endocrine Therapy For Breast Cancer In Very Young Women. A Chilean 20-Year Experience,Treatment - Treatment: Other,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
165813,Peritoneal Coccidioidomycosis in a Pediatric Patient: An Extremely Rare Presentation and Literature Review,Enteric infection,Pediatric Peritoneal Coccidioidomycosis ,True,Pediatric Peritoneal Coccidioidomycosis,0.95,3,39,0,0.15,False,False,,,No comparison,Pediatric Peritoneal Coccidioidomycosis
214972,Medium to Long Term Health-Related Quality of Life and Treatment-Related Side-Effects in Patients treated with a single dose of adjuvant Carboplatin for High-risk Seminoma - results from a pilot study,PD51: Penile & Testicular Cancer II,High-Risk Seminoma,True,High-Risk Seminoma,0.95,2,18,0,0.1,False,False,,,No comparison,High-Risk Seminoma
378817,Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma.,Genitourinary Cancer-Kidney and Bladder,Newly Diagnosed Oligometastatic Renal Cell Carcinoma,True,Newly Diagnosed Oligometastatic Renal Cell Carcinoma,0.95,6,52,2,0.5,False,False,,,No comparison,Newly Diagnosed Oligometastatic Renal Cell Carcinoma
329670,Distinct Patterns in the Reconstitutions of Treg and T-Helper Subsets after Autologous Hematopoietic Stem Cell Transplantation in Juvenile-Onset Systemic Sclerosis Patients,Autologous Transplantation: Clinical and Epidemiological: Poster II,Juvenile-Onset Systemic Sclerosis ,True,Juvenile Systemic Sclerosis,0.95,3,27,0,0.15,False,False,,,No comparison,Juvenile Systemic Sclerosis
296903,Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study),Oesophagogastric cancer,Advanced Gastric Cancer,True,Advanced Gastric Cancer,0.95,3,23,2,0.35,False,False,,,No comparison,Advanced Gastric Cancer
329673,Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) Is Safe and Well Tolerated and Improves Clinical and Patient-Reported Outcomes,Autologous Transplantation: Clinical and Epidemiological: Poster II,Refractory Juvenile-Onset Systemic Sclerosis,True,Juvenile Refractory Systemic Sclerosis;;Refractory Juvenile Systemic Sclerosis,0.95,7,78,1,0.45,False,False,,,No comparison,Juvenile Refractory Systemic Sclerosis;;Refractory Juvenile Systemic Sclerosis
411593,Mood Changes Associated with High-Dose Corticosteroids in Adults with Glomerular Disease,Glomerular Diseases: Clinical and Epidemiologic Studies,Adult Glomerular Disease,True,Adult Glomerular Disease,0.95,3,24,1,0.25,False,False,,,No comparison,Adult Glomerular Disease
231376,National claims data analysis of outcomes of hospitalized cancer patients without COVID-19 infection during versus prior to the COVID-19 pandemic.,Health Services Research and Quality Improvement,COVID-19 Infection,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
149467,Case 3: It's simple Watson - persistence pays off!,The Sherlock Holmes Approach To Differential Diagnosis: Rare And Not-So Rare Diseases Involving Thrombocytopenia,Thrombocytopenia,True,Thrombocytopenia,0.95,1,16,0,0.05,False,False,,,No comparison,Thrombocytopenia
313307,Impact Of The Theralink Clia Protein/Phosphoprotein Assay On Treatment Selection In Routine Clinical Practice: A Prospective Observational Study In Advanced Breast Cancer,Treatment - Treatment: Other,Advanced Breast Cancer,True,Advanced Breast Cancer,0.95,3,22,2,0.35,False,False,,,No comparison,Advanced Breast Cancer
198621,Evidences for 10 Hz Rtms-Mediated Ltp,Poster Session III (In-Person),,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
215006,Revisiting current National Comprehensive Cancer Network (NCCN) high risk prostate cancer stratification: A National Cancer Database analysis,PD54: Prostate Cancer: Localized: Surgical Therapy III,High Risk Prostate Cancer,True,High-Risk Prostate Cancer,0.95,3,25,1,0.25,False,False,,,No comparison,High-Risk Prostate Cancer
346081,Misclassification of clonal hematopoietic mutations as tumor-derived confound accurate ctDNA-response assessment in patients with metastatic non-small-cell lung cancer: analyses from the phase 3 MYSTIC trial,Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2,Metastatic Non-Small-Cell Lung Cancer,True,Metastatic Non-Small-Cell Lung Cancer,0.95,4,37,1,0.3,False,False,,,No comparison,Metastatic Non-Small-Cell Lung Cancer
296935,Efficacy and safety of palliative procedures for malignant gastric outlet obstruction: a systematic review and network meta analysis,Palliative care,,True,Malignant Gastric Outlet Obstruction,0.95,4,36,0,0.2,False,False,,,No comparison,Malignant Gastric Outlet Obstruction
329708,HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY),Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
182253,Association between Hospitalised Vaso-Occlusive Crises and Acute/Chronic Complications in Sickle Cell Disease Patients Aged 16 Years and Older Using the French National Health Insurance Database (SNDS),"Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III",Vaso-Occlusive Crises;;Adolescent Acute/Chronic Sickle Cell Disease;;Adult Acute/Chronic Sickle Cell Disease,True,Vaso-Occlusive Crisis;;Sickle Cell Disease,0.95,4,42,1,0.3,False,False,,,No comparison,Vaso-Occlusive Crisis;;Sickle Cell Disease
411632,The Impact of Late Renal Biopsy on Renal Survival in Patients with Lupus Nephritis,Glomerular Diseases: Clinical and Epidemiologic Studies,Lupus Nephritis,True,Glomerular Disease;;Lupus Nephritis,0.95,3,35,1,0.25,False,False,,,No comparison,Glomerular Disease;;Lupus Nephritis
395248,Summary And Close,Bristol Myers Squibb - The Changing Paradigm Of Melanoma Treatment: A Clinical Update For 2023,Melanoma,True,Melanoma,0.95,1,8,0,0.05,False,False,,,No comparison,Melanoma
231411,"Implementation of a ""genetic testing station"" in a safety net hospital to optimize access and increase equity.",Health Services Research and Quality Improvement,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
165876,Readmissions of Hospitalized Patients with Clostridioides difficile Infection (CDI) for Recurrent CDI is Common,Health Care-Associated Infections: C. difficile,Recurrent Clostridioides Difficile Infection,True,Clostridioides Difficile Infection;;Recurrent Clostridioides Difficile Infection,0.95,6,80,0,0.3,False,False,,,No comparison,Clostridioides Difficile Infection;;Recurrent Clostridioides Difficile Infection
378873,Phase I/II randomized clinical trial of in-clinic acupuncture prior to BCG in patients with high-risk non-muscle invasive bladder cancer.,Genitourinary Cancer-Kidney and Bladder,High-Risk Non-Muscle Invasive Bladder Cancer,True,High-Risk Non-Muscle Invasive Bladder Cancer,0.95,5,44,1,0.35,False,False,,,No comparison,High-Risk Non-Muscle Invasive Bladder Cancer
198655,Prefrontal Connections to the Extended Amygdala and Their Role in Early-Life Inhibited Temperament in Adolescent Rhesus Monkeys,Poster Session III (In-Person),,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
296961,Lutetium-177-Prostate-Specific Membrane Antigen therapy (177Lu-PSMA) in Patients (Pts) with Prior Radium-223 (223Ra): Safety and Effectiveness Outcomes,Prostate cancer,Prostate Cancer,True,Prostate Cancer,0.95,2,15,1,0.2,False,False,,,No comparison,Prostate Cancer
182278,A Multicompartment Mathematical Model Based on Host Immunity for Dissecting COVID-19 Heterogeneity,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder,True,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder;;COVID-19,0.95,5,82,1,0.35,True,False,,,No comparison,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder;;COVID-19
231430,Cancer incidence in U.S. adolescent and young adult (AYA) women stratified by race/ethnicity and region.,Health Services Research and Quality Improvement,Adolescent and Young Adult Cancer,True,Adolescent and Young Adult Cancer,0.95,5,33,1,0.35,False,False,,,No comparison,Adolescent and Young Adult Cancer
182281,Clinical and Immunological Assessment of Patients with Sars-Cov-2 Infections,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III,Sars-Cov-2 Infection,True,Sars-Cov-2 Infection,0.95,2,20,0,0.1,False,False,,,No comparison,Sars-Cov-2 Infection
149515,Introduction,Off-Label And On-Label Clinical Updates From Pivotal To Practice,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
231436,Developing and refining a theory of change to improve time to antibiotic administration for febrile pediatric oncology patients in real-world settings.,Health Services Research and Quality Improvement,Pediatric Cancer,True,Pediatric Cancer,0.95,2,16,1,0.2,False,False,,,No comparison,Pediatric Cancer
165901,Outbreak of Multidrug-resistant Pseudomonas aeruginosa in a Tertiary Healthcare System in Detroit,Health Care-Associated Infections: Gram-negatives (MDR-GNR),Pseudomonas Aeruginosa Infection,True,Multidrug-Resistant Pseudomonas Aeruginosa Infection,0.95,4,52,1,0.3,False,False,,,No comparison,Multidrug-Resistant Pseudomonas Aeruginosa Infection
329741,Alternative Bone Marrow Transplantation with Post-Transplant Cyclophosphamide (PTCy) As Initial Therapy for Acquired Severe Aplastic Anemia (SAA),Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I,Severe Aplastic Anemia,True,Acquired Severe Aplastic Anemia,0.95,4,31,1,0.3,False,False,,,No comparison,Acquired Severe Aplastic Anemia
231435,Factors influencing the initiation of adjuvant endocrine therapy in patients with Estrogen receptor-positive ductal carcinoma in situ: A single institution experience.,Health Services Research and Quality Improvement,ER-Positive Ductal Carcinoma ,True,ER-Positive Ductal Carcinoma In Situ,0.95,5,36,2,0.45,True,False,,,No comparison,ER-Positive Ductal Carcinoma In Situ
231442,Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO).,Health Services Research and Quality Improvement,Newly Diagnosed Advanced High Grade Ovarian Cancer ,True,Newly Diagnosed Advanced High Grade Ovarian Cancer,0.95,7,50,4,0.75,False,False,,,No comparison,Newly Diagnosed Advanced High Grade Ovarian Cancer
329752,Combination Azacitidine and Lenalidomide: A Novel Relapse Prophylaxis Option in Patients after Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia,Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
395289,"First-In-Human/Phase I Trial Of Hs-20089, A B7-H4 Adc, In Patients With Advanced Solid Tumors","Proffered Paper session - Breast cancer, metastatic",Advanced Solid Tumor,True,Advanced Solid Tumor,0.95,3,20,2,0.35,False,False,,,No comparison,Advanced Solid Tumor
346139,"TRIDENT phase 3 study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma",Phase II and Phase III Clinical Trials in Progress,Newly Diagnosed Glioblastoma,True,First-Line Newly Diagnosed Glioblastoma,0.95,4,39,1,0.3,False,False,,,No comparison,First-Line Newly Diagnosed Glioblastoma
329758,Hematopoietic and Immunological Assessment in Fanconi Anemia after Ex Vivo Lentiviral FANCA Gene Therapy with RP-L102,Gene Therapies: Poster II,Fanconi Anemia,True,Fanconi Anemia,0.95,2,14,0,0.1,False,False,,,No comparison,Fanconi Anemia
231453,"Not just biology: Comparing social determinants of health in patients diagnosed with late-stage lung, breast, and colon cancer.",Health Services Research and Quality Improvement,Late Stage Lung Cancer;;Late Stage Breast Cancer;;Late Stage Colon Cancer,True,Late Stage Lung Cancer;;Late Stage Breast Cancer;;Late Stage Colon Cancer,0.95,10,73,2,0.7,False,False,,,No comparison,Late Stage Lung Cancer;;Late Stage Breast Cancer;;Late Stage Colon Cancer
329764,Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease,Gene Therapies: Poster II,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
215076,Microwave Ablation Combined with Anti-PD-1/CTLA-4 Therapy Induces Anti-Tumor Immune Response to Renal Cell Carcinoma in a Murine Model,PD59: Kidney Cancer: Advanced (including Drug Therapy) II,Renal Cell Carcinoma,True,Renal Cell Carcinoma,0.95,3,20,1,0.25,False,False,,,No comparison,Renal Cell Carcinoma
182313,"A Retrospective Multicenter Case Study Evaluating the Characteristics, Management and Outcome of Acquired Amegakaryocytic Thrombocytopenia",Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III,Acquired Amegakaryocytic Thrombocytopenia,True,Acquired Amegakaryocytic Thrombocytopenia,0.95,3,41,0,0.15,False,False,,,No comparison,Acquired Amegakaryocytic Thrombocytopenia
395312,"My Preferred Choice Is Pd-1 Monotherapy, And These Are The Reasons Why",First-Line Therapy In Advanced Melanoma: What Is My Preferred Choice?,First-Line Advanced Melanoma,True,First-Line Advanced Melanoma,0.95,3,28,1,0.25,False,False,,,No comparison,First-Line Advanced Melanoma
378935,Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.,"Genitourinary Cancer-Prostate, Testicular, and Penile",Metastatic Castration-Resistant Prostate Cancer,True,Metastatic Castration-Resistant Prostate Cancer,0.95,4,47,2,0.4,False,False,,,No comparison,Metastatic Castration-Resistant Prostate Cancer
231482,Impact of weekend effect on neutropenic fever admissions associated with malignancy.,Health Services Research and Quality Improvement,Neutropenic Fever,True,Neutropenic Fever;;Cancer,0.95,2,25,1,0.2,False,False,,,No comparison,Neutropenic Fever;;Cancer
198714,Responses to Positive Affect and Unique Connectivity in Individuals at Clinical High-Risk for Psychosis,Virtual Poster Session III,High-Risk Psychosis,True,High-Risk Psychosis,0.95,2,19,0,0.1,False,False,,,No comparison,High-Risk Psychosis
182330,"Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial",Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III,Severe Hemophilia A,True,Previously Untreated Severe Hemophilia A,0.95,5,40,2,0.45,False,False,,,No comparison,Previously Untreated Severe Hemophilia A
329790,"Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)",Gene Therapies: Poster I,Severe or Moderately Severe Hemophilia B,True,Severe Hemophilia B;;Moderately Severe Hemophilia B,0.95,6,51,2,0.5,False,False,,,No comparison,Severe Hemophilia B;;Moderately Severe Hemophilia B
297023,"Breast cancer overdiagnosis in England, 1995-2019","Breast cancer, early stage",Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
378944,Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.,"Genitourinary Cancer-Prostate, Testicular, and Penile",Metastatic Castration-Resistant Prostate Cancer,True,Metastatic Castration-Resistant Prostate Cancer,0.95,4,47,2,0.4,False,False,,,No comparison,Metastatic Castration-Resistant Prostate Cancer
329793,Vector Analysis of Multicentric Lymphoma in a Severe Hemophilia A Dog after AAV Gene Therapy,Gene Therapies: Poster I,Severe Hemophilia A;;Lymphoma ,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
313411,How To Reconcile Novel Reconstructive Techniques With The Need To Radiate,Local Therapy- Best Breast Practice,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
182340,Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration,Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III,Hemophilia B,True,Hemophilia B,0.95,2,12,0,0.1,False,False,,,No comparison,Hemophilia B
182343,Sustained Improvement in Health-Related Quality of Life in Patients with Hemophilia A with or without Inhibitors Treated with Fitusiran Prophylaxis,Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III,Hemophilia A,True,Hemophilia A with Inhibitors;;Hemophilia A without Inhibitors,0.95,7,61,0,0.35,False,False,,,No comparison,Hemophilia A with Inhibitors;;Hemophilia A without Inhibitors
395357,Discussion Led By Chair,How Do We Manage Patients With Complicated Toxicity To Immunotherapy?,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
215136,A single stage Urethroplasty for Primary penoscrotal adult Hypospadias,V04: Lower Tract Reconstruction,Adult Hypospadias,True,Adult Primary Penoscrotal Hypospadias,0.95,4,37,0,0.2,False,False,,,No comparison,Adult Primary Penoscrotal Hypospadias
215141,Repair of Entero-Conduit Fistula Using Robot-Assisted Laparoscopy,V05: Misc. Benign/Transplant/Renovascular,,True,Entero-Conduit Fistula,0.95,2,22,0,0.1,False,False,,,No comparison,Entero-Conduit Fistula
215143,Robotic-Assisted Laparoscopic Left Renal Vein Transposition for Treatment of Nutcracker Syndrome,V05: Misc. Benign/Transplant/Renovascular,Nutcracker Syndrome,True,Nutcracker Syndrome,0.95,2,19,1,0.2,False,False,,,No comparison,Nutcracker Syndrome
149608,Live Q&A Panel Discussion: Inherited and acquired hemostasis defects,Live Q&A Panel Discussion: Inherited And Acquired Hemostasis Defects,,True,Inherited Hemostasis Defect;;Acquired Hemostasis Defect,0.95,5,55,0,0.25,False,False,,,No comparison,Inherited Hemostasis Defect;;Acquired Hemostasis Defect
215147,Laparoscopic management of xanthogranulomatous pyelonephritis - comparison of two different yet similar cases,V05: Misc. Benign/Transplant/Renovascular,Xanthogranulomatous Pyelonephritis,True,Xanthogranulomatous Pyelonephritis,0.95,2,34,0,0.1,False,False,,,No comparison,Xanthogranulomatous Pyelonephritis
215148,Robotic-assisted Laparoscopic Excision of Retroperitoneal Ganglioneuroma,V05: Misc. Benign/Transplant/Renovascular,Retroperitoneal Ganglioneuroma,True,Retroperitoneal Ganglioneuroma,0.95,2,30,0,0.1,False,False,,,No comparison,Retroperitoneal Ganglioneuroma
395383,Presentation By Expert,East Meets West In The Management Of Head And Neck Cancer: Learning From Each Other,Head And Neck Cancer,True,Head And Neck Cancer,0.95,4,20,1,0.3,False,False,,,No comparison,Head And Neck Cancer
329853,Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype,"Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II",TP53-Mutated Complex Karyotype Myelodysplastic Syndrome,True,TP53-Mutated Myelodysplastic Syndrome with Complex Karyotype,0.95,6,60,1,0.4,False,False,,,No comparison,TP53-Mutated Myelodysplastic Syndrome with Complex Karyotype
329855,High-Efficiency Multi-Drug Functional Profiling in a Microfluidic Device Towards Personalized Predictions in Pediatric Leukemia,"Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II",Pediatric Leukemia,True,Pediatric Leukemia,0.95,2,18,1,0.2,False,False,,,No comparison,Pediatric Leukemia
215171,Varying approaches to the prostate apex to optimize urethral stability and early continence recovery after robotic radical prostatectomy,"V07: Prostate, Penile, Testis & Misc. Oncology I",,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
166023,Hepatitis A Burden of Disease and Associated Complications in Children and Adults in Mexico: A Retrospective Database Study from 2000-2019,Hepatitis A,Childhood Hepatitis A;;Adult Hepatitis A,True,Childhood Hepatitis A;;Adult Hepatitis A,0.95,5,40,0,0.25,False,False,,,No comparison,Childhood Hepatitis A;;Adult Hepatitis A
297097,Novel potential predictive biomarker to immunotherapy (Io) treatment in metastatic colorectal cancer (mCRC) patients: the role of the VHIO immune gene-expression signature (VIGex),Colorectal cancer,Metastatic Colorectal Cancer,True,Metastatic Colorectal Cancer,0.95,3,28,1,0.25,False,False,,,No comparison,Metastatic Colorectal Cancer
231565,"Impact of TKI combination therapy and MRD negativity on outcomes in Philadelphia chromosome-positive ALL: A retrospective, single-center experience.","Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant",Ph-Positive Acute Lymphoblastic Leukemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,5,51,3,0.55,False,False,,,No comparison,Ph Chromosome-Positive Acute Lymphoblastic Leukemia
329868,High Throughput Epigenomic Mapping of Hematopoietic Stem and Progenitor Cells Using Low Cell Input Acoustic Enhanced Immunoprecipitation,"Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III",,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
182420,Investigating Germline Predisposition to Clonal Hematopoiesis through Perturbation of a Variant-Harboring Enhancer of TET2,"Clonal Hematopoiesis, Aging and Inflammation: Poster III",,True,Clonal Hematopoiesis,0.95,2,20,0,0.1,False,False,,,No comparison,Clonal Hematopoiesis
329878,"Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment","Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I",Acute Leukemia,True,Acute Leukemia,0.95,2,14,2,0.3,False,False,,,No comparison,Acute Leukemia
395416,Her2 And Beyond: What'S Next?,Her2 Positive Gastroesophageal Cancer,HER2 Positive Gastroesophageal Cancer,True,HER2-Positive Gastroesophageal Cancer,0.95,3,37,2,0.35,False,False,,,No comparison,HER2-Positive Gastroesophageal Cancer
198813,Case Report of Myotonia Permanens with SNEL (Severe Neonatal Episodic Laryngospasm) Onset,Clinical Management,Severe Neonatal Episodic Laryngospasm,True,Myotonia Permanens;;Severe Neonatal Episodic Laryngospasm,0.95,5,57,1,0.35,False,False,,,No comparison,Myotonia Permanens;;Severe Neonatal Episodic Laryngospasm
215198,Robotic partial nephrectomy with reversible selective artery endoluminal balloon occlusion on a kidney graft,V10: Adrenal & Renal Oncology I,Adrenal Cancer;;Renal Cancer,True,Renal Cancer,0.95,2,12,1,0.2,False,False,,,No comparison,Renal Cancer
215200,Minimally-invasive partial nephrectomy employing 4K visualization system with OPAL 1 near-Infrared and indocyanine green technology,V10: Adrenal & Renal Oncology I,,True,Adrenal Oncology;;Renal Oncology,0.95,3,32,0,0.15,False,False,,,No comparison,Adrenal Oncology;;Renal Oncology
297129,Outcomes and Tolerability of Neoadjuvant Chemoradiation in elderly patients with Oesophageal Cancer: An Irish Cancer Centre Retrospective Analysis:,Oesophagogastric cancer,Esophageal Cancer,True,Elderly Oesophageal Cancer,0.95,3,26,1,0.25,False,False,,,No comparison,Elderly Oesophageal Cancer
182442,Metabolic Profiling Reveals Cellular Reprogramming of Acute Myeloid Leukemia By Omipalisib through Serine Synthesis Pathway,Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster III,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
297133,FDG-positive/PSMA-negative PET lesion prevalence in metastatic castration resistant prostate cancer and its correlation with lines of systemic therapy: results from the prospective 3TMPO imaging study,Prostate cancer,Metastatic Castration Resistant Prostate Cancer,True,Metastatic Castration-Resistant Prostate Cancer,0.95,4,47,2,0.4,False,False,,,No comparison,Metastatic Castration-Resistant Prostate Cancer
231599,Efficacy and safety of high-intensity versus reduced-intensity induction in Philadelphia chromosome-positive all ineligible for HSCT.,"Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant",Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,5,51,3,0.55,False,False,,,No comparison,Ph Chromosome-Positive Acute Lymphoblastic Leukemia
329914,Perceptions and Barriers Related to Outpatient Management of Low-Risk PE Patients: A Community Center Experience,Health Services and Quality-Non-Malignant Conditions: Poster II,Low-Risk Pulmonary Embolism,True,Low-Risk Pulmonary Embolism,0.95,3,27,0,0.15,False,False,,,No comparison,Low-Risk Pulmonary Embolism
215227,Surgical Technique for Concurrent Penile Plication and Excision with Grafting for Severe Peyronie's Disease,V12: Sexual Dysfunction/Infertility/Andrology,Severe Peyronie's Disease,True,Severe Peyronie's Disease,0.95,3,25,2,0.35,False,False,,,No comparison,Severe Peyronie's Disease
379074,Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer.,Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology,Platinum Resistant Epithelial Ovarian Cancer,True,Platinum-Resistant Epithelial Ovarian Cancer,0.95,4,44,2,0.4,False,False,,,No comparison,Platinum-Resistant Epithelial Ovarian Cancer
231623,"Analysis of real-world outcomes of IKZFmut in Philadelphia chromosome-positive ALL: A retrospective, single-institution experience.","Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant",Ph-Positive Acute Lymphoblastic Leukemia,True,IKZF-Mutated Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,6,64,3,0.6,True,False,,,No comparison,IKZF-Mutated Ph Chromosome-Positive Acute Lymphoblastic Leukemia
215238,Open Right Partial Nephrectomy with Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma,V13: Adrenal & Renal Oncology II,Renal Cell Carcinoma,True,Renal Cell Carcinoma,0.95,3,20,1,0.25,False,False,,,No comparison,Renal Cell Carcinoma
182476,Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models,Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III,Acute Myeloid Leukemia,True,Acute Myeloid Leukemia,0.95,3,22,2,0.35,False,False,,,No comparison,Acute Myeloid Leukemia
166093,Incidence of Invasive Fungal Infections in Previously Untreated Patients with Acute Myeloid Leukemia Receiving Venetoclax and Azacitadine,Clinical studies of fungal infections,Previously Untreated Acute Myeloid Leukemia,True,Invasive Fungal Infection;;Previously Untreated Acute Myeloid Leukemia,0.95,7,70,3,0.65,False,False,,,No comparison,Invasive Fungal Infection;;Previously Untreated Acute Myeloid Leukemia
297167,Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to Immune-checkpoint blockers (ICBs) in Non-small cell lung cancer (NSCLC),"NSCLC, metastatic",Non-Small Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
411858,Hypercalcemia of Humoral Malignancy After Kidney Transplant,Transplantation: Clinical - I,Hypercalcemia,True,Hypercalcemia of Humoral Malignancy,0.95,4,35,0,0.2,False,False,,,No comparison,Hypercalcemia of Humoral Malignancy
329945,Retrospective Assessment of Total Cost of Care in Non-Dialysis Dependent Chronic Kidney Disease Patients Receiving Parenteral Iron Therapy for Iron Deficiency Anemia,Health Services and Quality-Non-Malignant Conditions: Poster I,Chronic Kidney Disease;;Anemia,True,Non-Dialysis Dependent Chronic Kidney Disease;;Iron Deficiency Anemia,0.95,7,69,2,0.55,False,False,,,No comparison,Non-Dialysis Dependent Chronic Kidney Disease;;Iron Deficiency Anemia
198874,"Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: a Phase III, randomized study (PROPEL)",Clinical Trials,Late-Onset Pompe Disease,True,Late Onset Pompe Disease,0.95,4,24,1,0.3,False,False,,,No comparison,Late Onset Pompe Disease
297179,PET derived parameters for response assessment in neoadjuvant atezolizumab - a secondary analysis of PRINCEPS phase 2 trial.,"NSCLC, early stage",Early Stage Non-Small Cell Lung Cancer,True,Early Stage Non-Small Cell Lung Cancer,0.95,6,38,3,0.6,False,False,,,No comparison,Early Stage Non-Small Cell Lung Cancer
297181,Phase 2 Trial of Retifanlimab (anti-PD-1) in Combination With INCAGN02385 (anti-LAG-3) and INCAGN02390 (anti-TIM-3) as First-Line Treatment in Patients With PD-L1-Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,"Head and neck cancer, excluding thyroid",First-Line PD-L1-Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,True,First-Line PD-L1-Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,0.95,11,91,2,0.75,True,False,,,No comparison,First-Line PD-L1-Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
346330,Fibroblast growth factor receptor-1 is a novel therapeutic target in mantle cell Lymphoma,"Cell Cycle Progression, Checkpoint, and Telomeres",Mantle Cell Lymphoma,True,Mantle Cell Lymphoma,0.95,3,20,1,0.25,False,False,,,No comparison,Mantle Cell Lymphoma
313569,"The Forces that Shape us: Interactions of Early experience, sex, and Puberty on the Development of Circuitry and Behavior","The Forces That Shape Us: Interactions of Early Experience, Sex, and Puberty on The Development of Circuitry and Behavior",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
182504,Recurrent Germline Variant in the Cohesin Complex Gene RAD21 Predisposes Children to Lymphoblastic Leukemia and Lymphoma,Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III,Childhood Lymphoblastic Leukemia;;Childhood Lymphoma,True,RAD21-Mutated Germline Childhood Acute Lymphoblastic Leukemia;;RAD21-Mutated Germline Childhood Lymphoma,0.95,9,104,3,0.75,False,False,,,No comparison,RAD21-Mutated Germline Childhood Acute Lymphoblastic Leukemia;;RAD21-Mutated Germline Childhood Lymphoma
166120,Predicting RSV Efficacy for MK-1654 in Temperate and Tropical Climates using MBMA and Clinical Trial Simulation to Account for Seasonal Differences in RSV Force-of-Infection,Studies of correlates of protection (or biomarkers) against microbial infection and disease in patients or experimental models,Respiratory Syncytial Virus Infection,True,Respiratory Syncytial Virus Infection,0.95,4,37,0,0.2,False,False,,,No comparison,Respiratory Syncytial Virus Infection
182509,Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III,Relapsed-Refractory Ph-Negative B-Cell Acute Lymphoblastic Leukemia,True,Relapsed/Refractory Ph Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,0.95,7,78,5,0.85,False,False,,,No comparison,Relapsed/Refractory Ph Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
379120,Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.,Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
182517,Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS),Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III,TP53-Mutated Acute Myeloid Leukemia;;High-Risk Myelodysplastic Syndrome,True,TP53-Mutated Acute Myeloid Leukemia;;High-Risk Myelodysplastic Syndrome,0.95,6,71,3,0.6,False,False,,,No comparison,TP53-Mutated Acute Myeloid Leukemia;;High-Risk Myelodysplastic Syndrome
198904,"Onset of LAMA2-congenital muscular dystrophy in the mouse involves cell cycle deregulation, oxidative stress and DNA damage",Pre-Clinical Research,LAMA2-congenital muscular dystrophy,True,LAMA2-Congenital Muscular Dystrophy,0.95,3,35,0,0.15,False,False,,,No comparison,LAMA2-Congenital Muscular Dystrophy
297208,Adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab (T) alone in patients achieving pathologic complete response after chemotherapy with TP,"Breast cancer, early stage",Early Stage Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
411902,Higher Dialysis Facility Patient-to-Nurse Staffing Ratio Is Associated with Lower Hazard of Kidney Transplantation Among Adolescents and Young Adults,Transplantation: Donation and Access,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
182529,"A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States",Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III,Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed Acute Myeloid Leukemia,0.95,5,38,3,0.55,False,False,,,No comparison,Newly Diagnosed Acute Myeloid Leukemia
149762,Patient Case Study: R/R High-risk Patient,Abbvie: Product Theater On Venclyxto/Venetoclax,,True,Relapsed/Refractory High-Risk,0.95,2,29,2,0.3,False,False,,,No comparison,Relapsed/Refractory High-Risk
231684,Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated lymphoma administered highly active antiretroviral therapy: Central and Western China AIDS Lymphoma League 001 study (cw-CALL 001).,Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia,HIV-Associated Lymphoma,True,Newly Diagnosed Human Immunodeficiency Virus-Associated Lymphoma,0.95,6,64,2,0.5,False,False,,,No comparison,Newly Diagnosed Human Immunodeficiency Virus-Associated Lymphoma
297223,Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC),Prostate cancer,Metastatic Hormone Sensitive Prostate Cancer,True,Metastatic Hormone-Sensitive Prostate Cancer,0.95,4,44,1,0.3,False,False,,,No comparison,Metastatic Hormone-Sensitive Prostate Cancer
297224,Prospective study to evaluate pathological complete response after neoadjuvant therapy in breast cancer: are we ready to avoid surgery?,"Breast cancer, early stage",Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
215306,Multiomic analyses reveal the central role of the pentose phosphate pathway in resident thymic macrophages to cope with efferocytosis-associated stress,Metabolic Instruction of Immunity,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
215307,BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus,Metabolic Instruction of Immunity,Systemic Lupus Erythematosus,True,Systemic Lupus Erythematosus,0.95,3,28,0,0.15,False,False,,,No comparison,Systemic Lupus Erythematosus
313613,Adolescents' Sexual Orientation and Behavioral and Neural Reactivity to Peer Acceptance and Rejection: The Moderating Role of Family Support,Minority Stress and Its Mechanisms: From Systemic and Proximal Social Context to Mental Health Disparities in Sexual and Gender Minority Youth,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
411924,High-Salt and Low-Salt Diets Can Modulate Kidney Immune Cells and Endothelial Cells,"Health Maintenance, Nutrition, Metabolism - I",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
411927,Diet and the Discrepancy Between Cystatin C- and Creatinine-Based eGFR in Middle-Aged and Older Community-Dwelling Japanese Adults,"Health Maintenance, Nutrition, Metabolism - I",,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
182557,A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III",Relapsed/Refractory Acute Myeloid Leukemia;;High-Risk Myelodysplastic Syndrome,True,Relapsed/Refractory Acute Myeloid Leukemia;;High-Risk Myelodysplastic Syndrome,0.95,6,78,5,0.8,False,False,,,No comparison,Relapsed/Refractory Acute Myeloid Leukemia;;High-Risk Myelodysplastic Syndrome
379167,Selective recognition of over-expressed self-antigens in solid tumors using calibrated CAR-T therapy.,Developmental Therapeutics-Immunotherapy,Solid Tumor,True,Solid Tumor,0.95,2,11,1,0.2,False,False,,,No comparison,Solid Tumor
346411,A novel reversible inhibitor of XPO1 with potent efficacy in multiple preclinical mouse models,Novel Antitumor Agents 4,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
182577,Age-Related Clonal Hematopoiesis Is a Precursor for Adult Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Adult Acute Lymphoblastic Leukemia,True,Adult Acute Lymphoblastic Leukemia,0.95,4,34,2,0.4,False,False,,,No comparison,Adult Acute Lymphoblastic Leukemia
297267,Density lowering effect of ovarian function suppression in premenopausal breast cancer patients who had no density change with one year of tamoxifen treatment (DELFINO study),"Breast cancer, early stage",Breast Cancer,True,Early Stage Breast Cancer,0.95,4,25,3,0.5,False,False,,,No comparison,Early Stage Breast Cancer
330033,A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation,Health Services and Quality-Myeloid Malignancies: Poster III,Myeloid Malignancy,True,Hereditary Myeloid Malignancy Syndrome,0.95,4,38,1,0.3,False,False,,,No comparison,Hereditary Myeloid Malignancy Syndrome
182581,Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Relapsed Infant T(4;11) Acute Lymphoblastic Leukemia,True,Infant Relapsed T(4;11) Acute Lymphoblastic Leukemia,0.95,6,52,3,0.6,False,True,,,No comparison,Infant Relapsed T(4;11) Acute Lymphoblastic Leukemia
395574,Discussion,Yo Masterclass: Tackling New Challenges Facing Young Investigators,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
166196,Validation of an allometrically scaled body weight equation to predict vancomycin clearance and guide 24-hour vancomycin AUC dosing in obese patients,PK/PD studies,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
182578,Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,5,51,3,0.55,False,False,,,No comparison,Ph Chromosome-Positive Acute Lymphoblastic Leukemia
182595,A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa,Lymphomas: Translational-Molecular and Genetic: Poster III,Diffuse Large B-Cell Lymphoma,True,Diffuse Large B-Cell Lymphoma;;Lymphoma,0.95,4,39,1,0.3,False,False,,,No comparison,Diffuse Large B-Cell Lymphoma;;Lymphoma
231749,Intratumor heterogeneity analysis in lung adenocarcinoma by single-cell RNA sequencing and construction of a prognostic gene signature.,Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Lung Adenocarcinoma,True,Lung Adenocarcinoma,0.95,2,19,1,0.2,False,False,,,No comparison,Lung Adenocarcinoma
182599,Whole-Exome Sequencing in Multiplex Families to Identify Novel AYA Classical Hodgkin Lymphoma Predisposition Genes,Lymphomas: Translational-Molecular and Genetic: Poster III,Adolescent and Young Adult Classical Hodgkin Lymphoma,True,Adolescent and Young Adult Classical Hodgkin Lymphoma,0.95,7,53,1,0.45,False,False,,,No comparison,Adolescent and Young Adult Classical Hodgkin Lymphoma
330056,Pediatric Age at Hematopoietic Stem Cell Transplant: Associations with Non-Malignant Genetic Disease and Race,Outcomes Research-Non-Malignant Conditions: Poster II,Non-Malignant Genetic Disease,True,Pediatric Non-Malignant Disease,0.95,3,31,1,0.25,False,False,,,No comparison,Pediatric Non-Malignant Disease
231753,Long-term survival in small-cell lung cancer patients: Extension of the SMALLBRAIN study.,Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Small-Cell Lung Cancer,True,Small Cell Lung Cancer,0.95,4,22,1,0.3,False,False,,,No comparison,Small Cell Lung Cancer
182608,Establishment of Patient-Derived Organoid Culture Platform of Mantle Cell Lymphoma,Lymphomas: Translational-Molecular and Genetic: Poster III,Mantle Cell Lymphoma,True,Mantle Cell Lymphoma,0.95,3,20,1,0.25,False,False,,,No comparison,Mantle Cell Lymphoma
346449,Multiregional sampling of high grade glioma identifies regional biologic signatures,Tumor Heterogeneity and Clonal Evolution,High Grade Glioma,True,High Grade Glioma,0.95,3,17,1,0.25,False,False,,,No comparison,High Grade Glioma
297296,Trustworthy Artificial Intelligence Models using Real World and circulating genomics data for the prediction of Immunotherapy efficacy in Non-Small Cell Lung Cancer patients,"NSCLC, metastatic",Non-Small Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
395602,Invited Discussant 1262Mo And 1263Mo,Mini Oral Session 1 - Non-Metastatic Nsclc And Other Thoracic Malignancies,Non-Metastatic Non-Small Cell Lung Cancer;;Thoracic Malignancy,True,Non-Metastatic Non-Small Cell Lung Cancer;;Thoracic Malignancy,0.95,6,62,1,0.4,False,False,,,No comparison,Non-Metastatic Non-Small Cell Lung Cancer;;Thoracic Malignancy
182617,Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients >=65 Years Receiving Bendamustine-Rituximab,Lymphomas: Translational-Non-Genetic: Poster III,Elderly Mantle Cell Lymphoma,True,Elderly Mantle Cell Lymphoma,0.95,4,28,1,0.3,False,False,,,No comparison,Elderly Mantle Cell Lymphoma
330074,Patient and Health Care Professional Perspectives on Quality of Life and Unmet Needs of People with Chronic Neutropenia: A Survey-Based Assessment,Outcomes Research-Non-Malignant Conditions: Poster II,Chronic Neutropenia,True,Chronic Neutropenia,0.95,2,19,1,0.2,False,False,,,No comparison,Chronic Neutropenia
379227,Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).,Developmental Therapeutics-Immunotherapy,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
166238,The Effect of Penicillin Allergy Labels on Antibiotic Prescribing for Children Diagnosed with Upper Respiratory Tract Infections in two Primary Care Networks,Pediatric Antimicrobial stewardship (inpatient/outpatient pediatric focused),Childhood Upper Respiratory Tract Infection,True,Childhood Upper Respiratory Tract Infection,0.95,5,43,0,0.25,False,False,,,No comparison,Childhood Upper Respiratory Tract Infection
330082,Causes of Death in Patients with Sickle Cell Disease from a Large Population-Based Cohort,Outcomes Research-Non-Malignant Conditions: Poster III,Sickle Cell Disease,True,Sickle Cell Disease,0.95,3,19,1,0.25,False,False,,,No comparison,Sickle Cell Disease
231779,Driver mutations and air pollution in advanced non-small cell lung cancer (NSCLC) at two reference hospitals in Mexico City.,Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Advanced Non-Small Cell Lung Cancer,True,Advanced Non-Small Cell Lung Cancer,0.95,5,35,2,0.45,False,False,,,No comparison,Advanced Non-Small Cell Lung Cancer
395621,Patients At The Centre Of The New Digital Solutions: Healthday And Personalised Care,How Does Digitalisation Help Personalised Care Throughout The Patient Journey?,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
313701,Genetic Regulation of Caudate Nucleus Transcriptome in Schizophrenia,Functionalizing Common Variants in Schizophrenia,Schizophrenia,True,Schizophrenia,0.95,1,13,0,0.05,False,False,,,No comparison,Schizophrenia
166251,Duration of antibiotic therapy in the treatment of bacterial meningitis in young infants: a systematic review and narrative synthesis,Pediatric Bacterial studies (natural history and therapuetic),Infant Bacterial Meningitis,True,Infant Bacterial Meningitis,0.95,3,27,0,0.15,False,False,,,No comparison,Infant Bacterial Meningitis
231790,Co-occurring mutations in the DDR pathway and tumor-associated genes for predicting immunotherapeutic efficacy in non-small cell lung cancer patients.,Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Non-Small Cell Lung Cancer,True,Non-Small Cell Lung Cancer,0.95,4,26,1,0.3,False,False,,,No comparison,Non-Small Cell Lung Cancer
231795,Treatment patterns and outcomes associated with small cell lung cancer by platinum sensitivity status in a U.S. Medicare population.,Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Small Cell Lung Cancer,True,Platinum-Sensitive Small Cell Lung Cancer;;Platinum-Resistant Small Cell Lung Cancer,0.95,9,84,2,0.65,False,False,,,No comparison,Platinum-Sensitive Small Cell Lung Cancer;;Platinum-Resistant Small Cell Lung Cancer
412025,Interpretable Machine Learning-Based Individual Analysis of AKI in Immune Checkpoint Inhibitor Therapy,"AI, Digital Health, Data Science - II",Acute Kidney Injury,True,Acute Kidney Injury,0.95,3,19,1,0.25,False,False,,,No comparison,Acute Kidney Injury
166280,Vaccinate Lurie (VaLu) a QI project to improve pediatric pre-transplant immunization rates,Pediatric Vaccines,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
379279,A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.,Developmental Therapeutics-Immunotherapy,Cancer,True,PD-L1-Expressing Cancer,0.95,2,23,1,0.2,True,False,,,No comparison,PD-L1-Expressing Cancer
182680,Nilotinib and Dasatinib Evoked Distinct Immune Effects during Tfr Phase of Each Discontinuation Trial,Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III,Myeloproliferative Syndrome;;Chronic Myeloid Leukemia,True,Myeloproliferative Syndrome;;Chronic Myeloid Leukemia,0.95,4,53,3,0.5,False,False,,,No comparison,Myeloproliferative Syndrome;;Chronic Myeloid Leukemia
231833,First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).,Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Relapsed/Refractory Small-Cell Lung Cancer,True,Relapsed/Refractory Small-Cell Lung Cancer,0.95,4,42,3,0.5,False,False,,,No comparison,Relapsed/Refractory Small-Cell Lung Cancer
215450,Distinct super-enhancer elements differentially control Il2ra gene expression in a cell-type specific fashion,Molecular Mechanisms of Cytokine Function,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
330143,Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy,Outcomes Research-Lymphoid Malignancies: Poster II,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.95,5,49,3,0.55,False,False,,,No comparison,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
199072,A framework for extrapolating evidence for molecularly targeted therapies from common to rare cancers - bridging the gap,Regulatory Science and Policy / Science and Health Policy,Cancer,True,Cancer;;Rare Cancer,0.95,2,19,1,0.2,False,False,,,No comparison,Cancer;;Rare Cancer
182689,The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients,Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III,Myeloproliferative Neoplasm,True,Myeloproliferative Neoplasm;;Chronic Myeloid Leukemia,0.95,4,53,2,0.4,False,False,,,No comparison,Myeloproliferative Neoplasm;;Chronic Myeloid Leukemia
412065,Success of Virtual Patient Simulation at Improving Management of CKD-Associated Pruritus,Educational Research,Chronic Kidney Disease-Associated Pruritus,True,Chronic Kidney Disease;;Pruritus,0.95,3,32,2,0.35,False,False,,,No comparison,Chronic Kidney Disease;;Pruritus
379296,A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).,Developmental Therapeutics-Immunotherapy,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
231854,Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.,Lung Cancer-Non-Small Cell Metastatic,Non-Small Cell Lung Cancer,True,EGFR Exon20 Insertion Non-Small Cell Lung Cancer,0.95,7,48,1,0.45,True,False,,,No comparison,EGFR Exon20 Insertion Non-Small Cell Lung Cancer
313775,Randomized Controlled Trial of Prazosin for Prophylaxis of Posttraumatic Headaches,"Prazosin for Neuropsychiatric Disorders Beyond PTSD: Efficacy Signals for Alcohol Use Disorder, for Chronic Posttraumatic Headache, and for Disruptive Agitation in Alheimer's Disease",,True,Posttraumatic Headache,0.95,2,22,0,0.1,False,False,,,No comparison,Posttraumatic Headache
379314,Updates on Abstract 398868: First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).,ASCO Plenary Series: Rapid Abstract Updates,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia,0.95,7,67,4,0.75,False,False,,,No comparison,Newly Diagnosed Ph Chromosome-Positive Acute Lymphoblastic Leukemia
182713,Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171),Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Chronic Myeloid Leukemia,True,MRD-Positive Chronic Myeloid Leukemia,0.95,4,37,3,0.5,True,False,,,No comparison,MRD-Positive Chronic Myeloid Leukemia
379322,Moderator,Rare Gynecologic Cancers: A Case of Gestational Trophoblastic Neoplasia,Gestational Trophoblastic Neoplasia,True,Rare Gynecologic Cancer;;Gynecologic Cancer;;Gestational Trophoblastic Neoplasia,0.95,6,80,1,0.4,False,False,,,No comparison,Rare Gynecologic Cancer;;Gynecologic Cancer;;Gestational Trophoblastic Neoplasia
330175,Examination of Disparities in Access to Chimeric Antigen Receptor (CAR) T Cell Therapies in Medicare Patients (Pts) with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Had Failed at Least 2 Prior Lines of Therapy (LOT),Outcomes Research-Lymphoid Malignancies: Poster III,Relapsed or Refractory Diffuse Large B-Cell Lymphoma,True,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,0.95,5,49,3,0.55,False,False,,,No comparison,Relapsed/Refractory Diffuse Large B-Cell Lymphoma
231873,"Relationship between IFN-a, IL-1B, IL-5, IL-6 and effectiveness of the first-line with camrelizumab combined with chemotherapy in non small cell lung cancer.",Lung Cancer-Non-Small Cell Metastatic,First-Line Non-Small Cell Lung Cancer,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
215493,The plasma cell proteome initiates early in B cell activation in advance of Blimp-1,Molecular and Cellular Control of Humoral Immunity,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
297416,Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment,Translational research (agnostic),Microsatellite Stable Metastatic Colorectal Cancer,True,Microsatellite Stable Metastatic Colorectal Cancer,0.95,5,50,1,0.35,False,False,,,No comparison,Microsatellite Stable Metastatic Colorectal Cancer
215499,SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation,Pathogenesis of SARS-CoV-2 Infection,SARS-CoV-2 Infection,True,SARS-CoV-2 Infection,0.95,2,20,0,0.1,True,False,,,No comparison,SARS-CoV-2 Infection
199117,A multilevel outreach framework to increase representation of African Americans and Latinx populations in genomic research,A Multilevel Outreach Framework to Increase Representation of African Americans and Latinx Populations in Genomic Research,,True,,0.99,0,0,0,0.0,False,False,,,No comparison,
297422,Atezolizumab (ATZ) plus Carboplatin (Cb) and Etoposide (eto) in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC): results from the Interim Analysis of MAURIS trial,SCLC,Untreated Extensive-Stage Small-Cell Lung Cancer,True,Untreated Extensive Stage Small Cell Lung Cancer,0.95,7,48,2,0.55,False,False,,,No comparison,Untreated Extensive Stage Small Cell Lung Cancer
215507,Bystander CD8 T cell memory responses partially protect mice against lethal vaginal HSV-2 challenge,Tissue Immunity at Barrier Sites,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
346582,An expression study of circadian clock-associated transcription factors and nuclear receptors in mouse prostate gland and tumor,Gene Regulation in Hormonal and Pediatric Cancers,Tumor,True,Hormonal Cancer;;Pediatric Cancer,0.95,3,33,1,0.25,False,False,,,No comparison,Hormonal Cancer;;Pediatric Cancer
346583,PDEF restricts prostate cancer cellular plasticity in part by modulating YAP1/TAZ-TEAD transcriptional network,Gene Regulation in Hormonal and Pediatric Cancers,Prostate Cancer,True,Prostate Cancer,0.95,2,15,1,0.2,False,False,,,No comparison,Prostate Cancer
182742,"A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)",Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III,Adult Nonadvanced Systemic Mastocytosis,True,Adult Systemic Mastocytosis,0.95,3,27,0,0.15,False,False,,,No comparison,Adult Systemic Mastocytosis
379360,"A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.",Hematologic Malignancies-Plasma Cell Dyscrasia,Relapsed/Refractory Multiple Myeloma,True,Relapsed/Refractory Multiple Myeloma,0.95,3,36,3,0.45,False,False,,,No comparison,Relapsed/Refractory Multiple Myeloma
231919,Anti-neoplastic drugs for malignant pleural effusion in non-small cell lung cancer: A meta-analysis.,Lung Cancer-Non-Small Cell Metastatic,Non-Small Cell Lung Cancer,True,Malignant Pleural Effusion;;Metastatic Non-Small Cell Lung Cancer,0.95,7,65,1,0.45,False,False,,,No comparison,Malignant Pleural Effusion;;Metastatic Non-Small Cell Lung Cancer
215538,Immune determinants of cardiometabolic risk in pre-existing type-2 diabetes (T2D) severe COVID-19 patients,Immunoregulation-Infection and Immunity,Type-2 Diabetes;;Severe COVID-19,True,Type-2 Diabetes;;Severe COVID-19,0.95,3,32,1,0.25,True,False,,,No comparison,Type-2 Diabetes;;Severe COVID-19
379384,"Talk, test, and take one click to curb prostate cancer mortality.",Health Services Research and Quality Improvement,Prostate Cancer,True,Prostate Cancer,0.95,2,15,1,0.2,False,False,,,No comparison,Prostate Cancer
346617,Persistent mutation burden drives sustained anti-tumor immune responses in human cancers,Biomarker Discovery,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
330237,Architecture and Early Construction of a Multi-Modal Oncology Registry for Follicular Lymphoma,Outcomes Research-Lymphoid Malignancies: Poster I,Follicular Lymphoma,True,Follicular Lymphoma,0.95,2,19,1,0.2,False,False,,,No comparison,Follicular Lymphoma
297480,Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis,"NSCLC, metastatic",First Line Advanced or Metastatic Non-Small Cell Lung Cancer,True,First-Line Advanced/Metastatic Non-Small Cell Lung Cancer,0.95,6,57,2,0.5,False,False,,,No comparison,First-Line Advanced/Metastatic Non-Small Cell Lung Cancer
231947,Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.,Lung Cancer-Non-Small Cell Metastatic,TKI-Refractory EGFR-Mutated Lung Adenocarcinoma,True,Metastatic Refractory EGFR-Mutated Lung Adenocarcinoma,0.95,5,54,2,0.45,True,False,,,No comparison,Metastatic Refractory EGFR-Mutated Lung Adenocarcinoma
313869,Questions & Answers,Oral Session 4 - Research,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
412174,Alveolar Type II Cell-Specific Mitofusins Modulate Kidney Fibrosis and Associated Lung Injury,"CKD Mechanisms: Progression, Fibrosis, and Beyond",Kidney Fibrosis;;Lung Injury,True,Kidney Fibrosis;;Lung Injury,0.95,3,28,0,0.15,False,False,,,No comparison,Kidney Fibrosis;;Lung Injury
231951,"Neoadjuvant Toripalimab plus chemotherapy in patients with stage IIB-IIIB NSCLC: A single-center, prospective, single-arm, phase 2 trial (Renaissance Study).",Lung Cancer-Non-Small Cell Metastatic,Stage IIB-IIIB Non-Small Cell Lung Cancer,True,Stage IIB-IIIB Non-Small Cell Lung Cancer,0.95,6,41,2,0.5,True,False,,,No comparison,Stage IIB-IIIB Non-Small Cell Lung Cancer
166420,In Vitro Activity of Lefamulin against Staphylococcus aureus isolated from the Lower Respiratory Tract of Children with Cystic Fibrosis,Respiratory infections - bacterial,Cystic Fibrosis,True,Childhood Staphylococcus aureus Lower Respiratory Tract Infection;;Childhood Cystic Fibrosis,0.95,9,92,0,0.45,False,False,,,No comparison,Childhood Staphylococcus aureus Lower Respiratory Tract Infection;;Childhood Cystic Fibrosis
313875,Effect of Fractional CO2 Laser Vs Sham Treatment on Symptom Severity of Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial,Oral Session 5 - New Instrumentation,,True,Vaginal Symptom,0.95,2,15,0,0.1,False,False,,,No comparison,Vaginal Symptom
231957,Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers.,Lung Cancer-Non-Small Cell Metastatic,HER2-Amplified Non-Small Cell Lung Cancer,True,Metastatic HER2-Amplified Non-Small Cell Lung Cancer,0.95,6,52,1,0.4,False,False,,,No comparison,Metastatic HER2-Amplified Non-Small Cell Lung Cancer
395795,Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study,Mini oral session - Gynaecological cancers,Previously Treated Ovarian Cancer,True,Previously Treated Ovarian Cancer,0.95,4,33,2,0.4,False,False,,,No comparison,Previously Treated Ovarian Cancer
166429,Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF),Respiratory infections - viral,Elderly Respiratory Syncytial Virus Infection,True,Older Adult Respiratory Syncytial Virus Infection;;Older Adult Chronic Obstructive Pulmonary Disease;;Older Adult Congestive Heart Failure,0.95,15,138,2,0.95,False,False,,,No comparison,Older Adult Respiratory Syncytial Virus Infection;;Older Adult Chronic Obstructive Pulmonary Disease;;Older Adult Congestive Heart Failure
231968,The feasibility of weekly paclitaxel in improving performance status(PS) of advanced non-small cell lung cancer (NSCLC) patients with poor performance status: A single-arm phase two trial.,Lung Cancer-Non-Small Cell Metastatic,Advanced Non-Small Cell Lung Cancer ,True,Metastatic Non-Small Cell Lung Cancer,0.95,5,37,1,0.35,False,False,,,No comparison,Metastatic Non-Small Cell Lung Cancer
182823,Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III,High-Risk Chronic Lymphocytic Leukemia,True,High-Risk Chronic Lymphocytic Leukemia,0.95,4,38,2,0.4,False,False,,,No comparison,High-Risk Chronic Lymphocytic Leukemia
379442,Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.,Health Services Research and Quality Improvement,Stage I-III Cutaneous Melanoma,True,Stage 1-3 Cutaneous Melanoma,0.95,4,28,1,0.3,False,False,,,No comparison,Stage 1-3 Cutaneous Melanoma
297537,Taxanes plus immunotherapy might be a potential option for HER2-altered NSCLC beyond first-line progression: a retrospective real-world study,"NSCLC, metastatic",HER2-Altered Non-Small Cell Lung Cancer,True,Metastatic Progressive HER2-Altered Non-Small Cell Lung Cancer,0.95,7,62,1,0.45,False,False,,,No comparison,Metastatic Progressive HER2-Altered Non-Small Cell Lung Cancer
166466,"Deep neck infections: Bacteriology and antimicrobial susceptibilities, Akron children's experience",Skin and soft tissue,Childhood Deep Neck Infection,True,Childhood Deep Neck Infection,0.95,4,29,0,0.2,False,False,,,No comparison,Childhood Deep Neck Infection
412232,Ferroptosis of Kidney After SARS-CoV-2 Infection,COVID-19 - II,SARS-CoV-2 Infection,True,SARS-CoV-2 Infection,0.95,2,20,0,0.1,True,False,,,No comparison,SARS-CoV-2 Infection
166480,Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-),Studies of treatment and prevention of viral infections,High Risk Cytomegalovirus Infection,True,High-Risk Cytomegalovirus Infection,0.95,3,35,0,0.15,False,False,,,No comparison,High-Risk Cytomegalovirus Infection
199248,A population-based assessment of cancer risk in children with recurrent multiple congenital anomalies,Pediatric Oncology: Clinical Investigation,Childhood Recurrent Multiple Congenital Anomalies,True,Childhood Recurrent Multiple Congenital Anomaly,0.95,5,47,0,0.25,False,False,,,No comparison,Childhood Recurrent Multiple Congenital Anomaly
232024,"Toxicity and outcomes of BRAF and MEK inhibitor ""ramp-up"" dosing strategies for patients with melanoma: A real-world institutional experience.",Melanoma/Skin Cancers,Melanoma,True,Melanoma,0.95,1,8,0,0.05,False,False,,,No comparison,Melanoma
166489,Nontuberculous Mycobacterial Infections of the Upper Extremity,Tuberculosis and other Mycobacterial Infections,Mycobacterial Infection,True,Upper Extremity Nontuberculous Mycobacterial Infection,0.95,5,54,0,0.25,False,False,,,No comparison,Upper Extremity Nontuberculous Mycobacterial Infection
182876,Lenalidomide Compared to Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster III,Newly Diagnosed Multiple Myeloma,True,Newly Diagnosed Multiple Myeloma,0.95,4,32,2,0.4,False,False,,,No comparison,Newly Diagnosed Multiple Myeloma
412259,Impact of Using Blood Warmer During Continuous Kidney Replacement Therapy on Hemodynamic Instability,"AKI: Outcomes, RRT",,True,Acute Kidney Injury,0.95,3,19,1,0.25,False,False,,,No comparison,Acute Kidney Injury
346727,Hypoxic extracellular vesicles induce a pro-metastatic phenotype in neuroblastoma: from the delivery of miR-210-3p to the preconditioning of a metastatic niche,Metastatic and Premetastatic Microenvironments,Neuroblastoma,True,Metastatic Neuroblastoma,0.95,2,24,0,0.1,False,False,,,No comparison,Metastatic Neuroblastoma
412268,Calcium Balance in Slow Extended Dialysis: Effect of Regional Citrate vs. Other Anticoagulation Strategies in a Randomized Trial,"AKI: Outcomes, RRT",Acute Kidney Injury,True,Acute Kidney Injury,0.95,3,19,1,0.25,False,False,,,No comparison,Acute Kidney Injury
379504,Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation.,Care Delivery and Regulatory Policy,Symptomatic Cancer ,True,Symptomatic Cancer,0.95,2,18,1,0.2,False,False,,,No comparison,Symptomatic Cancer
182897,Loss of Spleen Visualization on Whole-Body Diffusion-Weighted Imaging in Patients with Multiple Myeloma Is Associated with Poor Prognosis and High Tumor Burden,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster III,Multiple Myeloma,True,Multiple Myeloma,0.95,2,16,1,0.2,False,False,,,No comparison,Multiple Myeloma
182896,Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster III,Multiple Myeloma,True,Multiple Myeloma;;Plasma Cell Dyscrasia,0.95,4,39,1,0.3,False,False,,,No comparison,Multiple Myeloma;;Plasma Cell Dyscrasia
346736,Aging increases malignant peritoneal mesothelioma metastasis,Metastatic and Premetastatic Microenvironments,Elderly Metastatic Malignant Peritoneal Mesothelioma,True,Metastatic Malignant Peritoneal Mesothelioma,0.95,4,44,0,0.2,False,False,,,No comparison,Metastatic Malignant Peritoneal Mesothelioma
232058,Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naive BRAF-mutant advanced melanoma: A single institution retrospective analysis.,Melanoma/Skin Cancers,Treatment-Naive BRAF-Mutant Advanced Melanoma,True,Treatment-Naive Advanced BRAF-Mutated Melanoma,0.95,4,46,2,0.4,True,False,,,No comparison,Treatment-Naive Advanced BRAF-Mutated Melanoma
346754,Outcomes of patients treated with neoadjuvant chemotherapy for breast cancer at a safety net hospital,Cancer Disparities 2,Breast Cancer ,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
166534,"Treatment Patterns, Healthcare Resource Use, and Associated Costs in Females with Uncomplicated Urinary Tract Infection in the United States",UTIs,Urinary Tract Infection,True,Uncomplicated Urinary Tract Infection,0.95,4,37,0,0.2,False,False,,,No comparison,Uncomplicated Urinary Tract Infection
395918,Optimal Neo-Adjuvant Therapy In Tnbc: Does One Size Fit All?,Controversies In Early Stage Triple Negative Breast Cancer,Triple-Negative Breast Cancer,True,Early Stage Triple Negative Breast Cancer,0.95,6,41,4,0.7,False,False,,,No comparison,Early Stage Triple Negative Breast Cancer
232079,The RNA signature of immune-related genes and distinct spatial distribution of immune cells are closely associated with the treatment outcomes in the malignant melanoma patients receiving immune checkpoint inhibitors.,Melanoma/Skin Cancers,Malignant Melanoma,True,Malignant Melanoma,0.95,2,18,0,0.1,False,False,,,No comparison,Malignant Melanoma
330385,Role of Genetic Evaluation in the Diagnosis of Bone Marrow Failure Syndrome,Bone Marrow Failure Syndromes: Diagnostic Principles in 2022,Bone Marrow Failure Syndrome,True,Bone Marrow Failure Syndrome,0.95,4,28,1,0.3,False,False,,,No comparison,Bone Marrow Failure Syndrome
379539,Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.,Central Nervous System Tumors,Unresectable High Grade Glioma,True,Unresectable High Grade Glioma,0.95,4,30,1,0.3,False,False,,,No comparison,Unresectable High Grade Glioma
395927,Discussion,Controversies In Early Stage Triple Negative Breast Cancer,Early Stage Triple Negative Breast Cancer,True,Early Stage Triple-Negative Breast Cancer,0.95,5,41,4,0.65,False,False,,,No comparison,Early Stage Triple-Negative Breast Cancer
395936,Radiotherapy In Bladder Preservation,Bladder Preservation Strategies,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
232099,Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.,Pediatric Oncology,High-Risk Neuroblastoma,True,Pediatric High-Risk Neuroblastoma,0.95,3,33,0,0.15,False,False,,,No comparison,Pediatric High-Risk Neuroblastoma
330405,Dissecting Heterogeneity in Diamond-Blackfan Anemia: Insight from Single Cell Studies and Clinical Findings,Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias,Diamond-Blackfan Anemia,True,Diamond-Blackfan Anemia;;Childhood Red Cell Disorder;;Anemia,0.95,5,60,1,0.35,False,False,,,No comparison,Diamond-Blackfan Anemia;;Childhood Red Cell Disorder;;Anemia
215718,Inhibition of DNMTs and RNA editing increases immunogenic transposable element RNA to reduce tumor burden and prolong survival in a murine ovarian cancer model,Tumor Microenvironment (TME) I,Ovarian Cancer,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
412332,Lats2 Ablation Exacerbates Severe Ischemia/Reperfusion-Induced Renal Maladaptive Repair Through the Upregulation of p53,AKI: Mechanisms - II,,True,Severe Ischemia/Reperfusion-Induced Acute Kidney Injury,0.95,5,55,2,0.45,False,False,,,No comparison,Severe Ischemia/Reperfusion-Induced Acute Kidney Injury
330414,"Exome Sequencing of 628,388 Individuals Identifies Common and Rare Variant Associations with Clonal Hematopoiesis Phenotypes",Clonal Hematopoiesis and Inflammation in Patients with Germline Predisposition Syndromes,,True,Clonal Hematopoiesis,0.95,2,20,0,0.1,False,False,,,No comparison,Clonal Hematopoiesis
346802,Chairperson,Informing Future Precision Medicine Trials for Pancreatic Cancer, Pancreatic Cancer,True,Pancreatic Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Pancreatic Cancer
346806,The cellular heterogeneity of pancreatic cancer drives local and systemic immune responses and leads to opportunities for patient stratification and trial design,Informing Future Precision Medicine Trials for Pancreatic Cancer,Pancreatic Cancer,True,Pancreatic Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Pancreatic Cancer
232118,"Mammography screening is associated with more favorable breast cancer tumor characteristics and better overall survival: Case-only analysis of 3,739 Asian breast cancer patients.","Prevention, Risk Reduction, and Hereditary Cancer",Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
182969,Decreased Chimeric Antigen Receptor T-Cell Efficacy with Severe or Prolonged Post-Infusion Cytopenias,Cellular Immunotherapies: Clinical: Poster III,Severe Cytopenia,True,Severe Cytopenia;;Prolonged Cytopenia,0.95,3,37,1,0.25,False,False,,,No comparison,Severe Cytopenia;;Prolonged Cytopenia
182970,Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy,Cellular Immunotherapies: Clinical: Poster III,Large B-Cell Lymphoma,True,Large B-Cell Lymphoma,0.95,3,21,1,0.25,False,False,,,No comparison,Large B-Cell Lymphoma
232126,Trends in incidence and mortality in kidney cancer patients over the last 25 years in Reggio Emilia Province of the North Italy.,"Prevention, Risk Reduction, and Hereditary Cancer",Kidney Cancer,True,Kidney Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Kidney Cancer
232129,"Step up to health, Nigeria! utilizing information from abuja's world cancer day walks for equity-based cancer prevention interventions.","Prevention, Risk Reduction, and Hereditary Cancer",Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
232139,Is a 'cancer check-up' near for high-risk adults? clinician attitudes and perspectives on multicancer early detection tests.,Professional Development and Education Advances,High-Risk Adult Cancer ,True,Adult High-Risk Cancer,0.95,3,22,1,0.25,False,False,,,No comparison,Adult High-Risk Cancer
183002,Association of Donor and Recipient Interleukin-1 Gene Single Nucleotide Polymorphisms with Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III",Acute Graft-Versus-Host Disease;;Chronic Graft-Versus-Host Disease,True,Childhood Acute GVHD;;Childhood Chronic GVHD,0.95,5,44,2,0.45,True,False,,,No comparison,Childhood Acute GVHD;;Childhood Chronic GVHD
183004,Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease,"Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III",Chronic Graft-Versus-Host Disease,True,Chronic Graft-Versus-Host Disease,0.95,3,33,2,0.35,False,False,,,No comparison,Chronic Graft-Versus-Host Disease
183006,"Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation","Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III",Graft-Versus-Host Disease,True,Graft-Versus-Host Disease,0.95,2,25,1,0.2,False,False,,,No comparison,Graft-Versus-Host Disease
346847,The effect of circulating CXCL10 on osteosarcoma metastasis using orthotopic xenograft mouse models,Metastasis Promoting and Suppressing Genes,Osteosarcoma Metastasis,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
314080,The Pelvic Sidewall and the Endometriosis-Surgeon,Advanced Anatomy - Accessing The Pelvic Sidewall,,True,Endometriosis,0.95,1,13,0,0.05,False,False,,,No comparison,Endometriosis
166627,Polling 1 (led by chair),"What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?",Second-Line Metastatic Somatostatin-Receptor Positive Liver-Dominant Midgut Neuroendocrine Tumor,True,Second-Line Metastatic Somatostatin Receptor-Positive Liver-Dominant Midgut Neuroendocrine Tumor,0.95,8,96,2,0.6,False,False,,,No comparison,Second-Line Metastatic Somatostatin Receptor-Positive Liver-Dominant Midgut Neuroendocrine Tumor
330471,Moderator Introduction,Gene Editing in Immunotherapy,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
199413,Aggregation of HER2 receptors on the tumor cell surface induced by a novel anti-HER2 bispecific antibody led to enhanced tumor cell growth inhibition,Biological Therapeutic Agents,Tumor,True,Tumor,0.95,1,5,1,0.15,False,False,,,No comparison,Tumor
346871,PAUF stimulates monocytes and induces their differentiation into tumor-associated macrophages,"Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells",Tumor,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
215808,Maternally derived epidermal growth factor mediates protection in neonates from opportunistic intestinal pathogens,Neonatal Mucosal Immunity,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
232196,Complete pathological response after neoadjuvant treatment in soft tissue sarcoma: A single-institution experience.,Sarcoma,Soft Tissue Sarcoma,True,Soft Tissue Sarcoma,0.95,3,19,0,0.15,False,False,,,No comparison,Soft Tissue Sarcoma
199435,Allogenic HER2-CAR T cells overcome intrinsic trastuzumab resistance in vitro and in vivo in a preclinical model of breast cancer,Adoptive Cell Therapy 2,Breast Cancer,True,Breast Cancer,0.95,2,13,1,0.2,False,False,,,No comparison,Breast Cancer
232210,In vitro evidence that combination treatment with anti-PD-1 and anti-CD47 immunotherapy may not be efficient in human soft tissue sarcoma.,Sarcoma,Soft Tissue Sarcoma,True,Soft Tissue Sarcoma,0.95,3,19,0,0.15,False,False,,,No comparison,Soft Tissue Sarcoma
379667,KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.,Melanoma/Skin Cancers,High-Risk Stage II-IV Melanoma,True,High-Risk Stage II-IV Melanoma,0.95,4,30,1,0.3,True,False,,,No comparison,High-Risk Stage II-IV Melanoma
199452,Amplifying STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy,Antibodies and Immune Therapies,Systemic Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
330526,Pregnancy in Women with a History of Thrombotic Microangiopathy,Long Term Outcomes of Thrombotic Microangiopathy,Thrombotic Microangiopathy,True,Thrombotic Microangiopathy,0.95,2,26,0,0.1,False,False,,,No comparison,Thrombotic Microangiopathy
183072,Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient and Specific Genome Engineering for Cell Therapy Development,Gene Therapies: Poster III,,True,,1.0,0,0,0,0.0,False,False,,,No comparison,
215852,"Collaboration of therapeutic, systemic IL12p40 with locally released IL12p35 focuses immunity to the tumor microenvironment",Cytokine and Chemokine Control of Cellular Immunity,,True,Tumor,0.95,1,5,1,0.15,False,False,,,No comparison,Tumor
215870,Leveraging genetic correlation across immune-mediated disease to gain insights into underpowered studies of rare conditions,Adaptive Immunity in Inflammation,,True,Immune-Mediated Disease;;Rare Condition,0.95,3,39,1,0.25,False,False,,,No comparison,Immune-Mediated Disease;;Rare Condition
199489,Analysis of KRAS wildtype pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma,Late-Breaking Research: Molecular/Cellular Biology and Genetics 2,Cholangiocarcinoma;;KRAS Wildtype Pancreatic Ductal Adenocarcinoma,True,KRAS Wild Type Pancreatic Ductal Adenocarcinoma;;Cholangiocarcinoma,0.95,6,67,1,0.4,True,False,,,No comparison,KRAS Wild Type Pancreatic Ductal Adenocarcinoma;;Cholangiocarcinoma
379717,Cardiorespiratory fitness and BMI in youth and site-specific cancer mortality in men: A population-based cohort study with register linkage.,"Prevention, Risk Reduction, and Hereditary Cancer",Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
199499,Analytical performance of a novel next generation sequencing assay for myeloid MRD,Cancer Genomics 3,Cancer ,True,Myeloid Malignancy,0.95,2,18,0,0.1,False,False,,,No comparison,Myeloid Malignancy
379731,"Racial disparities in germline testing among men with pancreas, breast and metastatic prostate cancers in two health systems.","Prevention, Risk Reduction, and Hereditary Cancer",Pancreatic Cancer;;Breast Cancer;;Metastatic Prostate Cancer,True,Pancreas Cancer;;Breast Cancer;;Metastatic Prostate Cancer,0.95,5,58,1,0.35,False,False,,,No comparison,Pancreas Cancer;;Breast Cancer;;Metastatic Prostate Cancer
166744,"IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)","Mini oral session - Gastrointestinal tumours, non-colorectal",Intermediate Stage Hepatocellular Carcinoma,True,Intermediate Stage Hepatocellular Carcinoma,0.95,4,43,2,0.4,False,False,,,No comparison,Intermediate Stage Hepatocellular Carcinoma
183137,Healthcare Resource Utilization and Costs of Medicare Fee for Service Beneficiaries Newly Diagnosed with Moderate to Severe Non-Advanced Systemic Mastocytosis,Health Services Research-Myeloid Malignancies: Poster III,Newly Diagnosed Moderate-Severe Non-Advanced Systemic Mastocytosis,True,Newly Diagnosed Moderate-Severe Systemic Mastocytosis,0.95,5,53,3,0.55,False,False,,,No comparison,Newly Diagnosed Moderate-Severe Systemic Mastocytosis
379748,The impact of extending CRC screening to the older population: Results from CRC-AIM microsimulation model.,"Prevention, Risk Reduction, and Hereditary Cancer",Elderly Colorectal Cancer,True,Elderly Colorectal Cancer,0.95,3,25,1,0.25,False,False,,,No comparison,Elderly Colorectal Cancer
199526,Anti-myeloid poly-pharmacy allows FGFR4-targeted chimeric antigen receptors to effectively treat an orthotopic model of rhabdomyosarcoma,Adoptive Cell Therapy 2,Rhabdomyosarcoma,True,Rhabdomyosarcoma,0.95,1,16,0,0.05,False,False,,,No comparison,Rhabdomyosarcoma
183143,"Pediatric Hydroxyurea Treatment Patterns, Sickle Cell Disease-Related Complication Rates, and Costs in a Large US Administrative Claims Database: A Retrospective Analysis",Outcomes Research-Non-Malignant Conditions: Poster III,Pediatric Sickle Cell Disease,True,Pediatric Sickle Cell Disease,0.95,4,29,1,0.3,False,False,,,No comparison,Pediatric Sickle Cell Disease
183147,Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study,Outcomes Research-Non-Malignant Conditions: Poster III,Recurrent Venous Thromboembolism,True,Recurrent Venous Thromboembolism;;Major Bleeding,0.95,4,48,0,0.2,False,False,,,No comparison,Recurrent Venous Thromboembolism;;Major Bleeding
183148,Disability Associated with Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation,Outcomes Research-Non-Malignant Conditions: Poster III,Chronic Graft-Versus-Host Disease,True,Chronic Graft-Versus-Host Disease,0.95,3,33,2,0.35,False,False,,,No comparison,Chronic Graft-Versus-Host Disease
183150,"Understanding the Association between Red Blood Cell Transfusion Dependency and Humanistic, Psychosocial, and Psychological Burden in Patients with b-Thalassemia from the Patients' Perspective",Outcomes Research-Non-Malignant Conditions: Poster III,B-Thalassemia,True,Transfusion-Dependent-B-Thalassemia,0.95,1,35,0,0.05,False,False,,,No comparison,Transfusion-Dependent-B-Thalassemia
330609,Feasibility and Clinical Utility of an Rnaseq-Workflow for Subtype Classification and Genomic Characterization of Pediatric B-Lymphoblastic Leukemia (B-ALL),Novel Genomic Blood Cancer Entities - Part 1,Pediatric B-Lymphoblastic Leukemia ,True,Pediatric B-Lymphoblastic Leukemia,0.95,3,34,1,0.25,False,False,,,No comparison,Pediatric B-Lymphoblastic Leukemia
215923,"IL-18R signaling impairs hematopoietic recovery after severe, shock-like infection",HSCs and Myelopoiesis,Severe Shock-Like Infection,True,Severe Shock-Like Infection,0.95,3,27,1,0.25,False,False,,,No comparison,Severe Shock-Like Infection
379764,Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?,"Prevention, Risk Reduction, and Hereditary Cancer",Breast Cancer,True,Hereditary Breast Cancer,0.95,3,24,1,0.25,False,False,,,No comparison,Hereditary Breast Cancer
379768,Comprehensive analysis of patients with cancer with a positive CHEK2 test: Are we getting closer to a genotype/phenotype correlation?,"Prevention, Risk Reduction, and Hereditary Cancer",Cancer ,True,CHEK2-Positive Cancer,0.95,2,21,2,0.3,False,False,,,No comparison,CHEK2-Positive Cancer
330620,PICKUP Study: Pneumonia in the ImmunoCompromised - Use of the Karius Test(r) for the Detection of Undiagnosed Pathogens,PICKUP Study: Pneumonia in the ImmunoCompromised - Use of the Karius Test(r) for the Detection of Undiagnosed Pathogens,Pneumonia,True,Pneumonia in the ImmunoCompromised,0.95,4,34,0,0.2,False,False,,,No comparison,Pneumonia in the ImmunoCompromised
199551,Antitumor activity of liposomal formulation of eribulin combined with anti-PD-1,Preclinical Immunotherapy,,True,,0.95,0,0,0,0.0,False,False,,,No comparison,
199553,Antitumor and mechanism of selective serotonin reuptake inhibitor fluoxetine on muscle invasive bladder cancer,Biological Therapeutic Agents,Muscle Invasive Bladder Cancer,True,Muscle Invasive Bladder Cancer,0.95,4,30,1,0.3,False,False,,,No comparison,Muscle Invasive Bladder Cancer
166786,Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) +- ribociclib (RIB),"Proffered Paper session - Breast cancer, metastatic",HR-Positive HER2-Negative Advanced Breast Cancer,True,Advanced HR-Positive/HER2-Negative Breast Cancer,0.95,4,48,4,0.6,True,False,,,No comparison,Advanced HR-Positive/HER2-Negative Breast Cancer
379779,Evaluating interventions to increase the uptake of NCCN genetic counseling recommendations.,"Prevention, Risk Reduction, and Hereditary Cancer",Hereditary Cancer,True,Hereditary Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Hereditary Cancer
183174,Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US),Outcomes Research-Lymphoid Malignancies: Poster III,First-Line Chronic Lymphocytic Leukemia,True,First-Line Chronic Lymphocytic Leukemia,0.95,4,39,2,0.4,False,False,,,No comparison,First-Line Chronic Lymphocytic Leukemia
379783,Healthcare utilization among individuals diagnosed with Lynch syndrome through a universal germline genetic testing program.,"Prevention, Risk Reduction, and Hereditary Cancer",Lynch Syndrome,True,Lynch Syndrome,0.95,2,14,1,0.2,False,False,,,No comparison,Lynch Syndrome
379782,Clinical utility of reporting research genetic predisposition testing results to Total Cancer Care participants.,"Prevention, Risk Reduction, and Hereditary Cancer",Cancer ,True,Hereditary Cancer,0.95,2,17,1,0.2,False,False,,,No comparison,Hereditary Cancer
379786,A comprehensive analysis of clinical characterization in 149 Chinese patients with Lynch syndrome.,"Prevention, Risk Reduction, and Hereditary Cancer",Lynch Syndrome,True,Lynch Syndrome,0.95,2,14,1,0.2,False,False,,,No comparison,Lynch Syndrome
412560,The Utilization of Gabapentin and Pregabalin for the Treatment of CKD-Associated Pruritus and Other Indications in Manitoba,"Hemodialysis: Quality of Life, Symptoms, Palliative Care",Chronic Kidney Disease;;Pruritus,True,Chronic Kidney Disease;;Pruritus,0.95,3,32,2,0.35,False,False,,,No comparison,Chronic Kidney Disease;;Pruritus
330643,The RNA Binding Protein Syncrip Is Required for Leukemia Stem Cell Self-Renewal,Promoting Minorities in Hematology Oral Presentations St. Charles Ballroom - Malignant Hematology,Leukemia,True,Leukemia,0.95,1,8,1,0.15,False,False,,,No comparison,Leukemia
379795,Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.,"Prevention, Risk Reduction, and Hereditary Cancer",Advanced Solid Tumor,True,Advanced Solid Tumor;;Hereditary Cancer,0.95,4,39,3,0.5,False,False,,,No comparison,Advanced Solid Tumor;;Hereditary Cancer
379803,Impact of risk-reducing mastectomy on quality of life of women with Li-Fraumeni syndrome.,"Prevention, Risk Reduction, and Hereditary Cancer",Li-Fraumeni Syndrome,True,Li-Fraumeni Syndrome,0.95,2,20,1,0.2,False,False,,,No comparison,Li-Fraumeni Syndrome
396217,Meeting the Unmet Needs in Cancer Screening,Exact Sciences - Shifting the Paradigm in Cancer Screening: Multi-cancer Early Detection (MCED) Testing,Cancer,True,Cancer,0.95,1,6,1,0.15,False,False,,,No comparison,Cancer
183228,Impact of Post-Remission Maintenance Therapy (MT) on Outcomes in Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) in Real-World Practice,Outcomes Research-Myeloid Malignancies: Poster III,Newly Diagnosed Acute Myeloid Leukemia,True,Newly Diagnosed Acute Myeloid Leukemia,0.95,5,38,3,0.55,False,False,,,No comparison,Newly Diagnosed Acute Myeloid Leukemia
232396,"A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.",Breast Cancer-Metastatic,Unresectable HR-Positive HER2-Negative Metastatic Breast Cancer,True,Unresectable/Metastatic HER2-Negative Breast Cancer;;Metastatic HR-Positive HER2-Negative Breast Cancer,0.95,8,103,3,0.7,True,False,,,No comparison,Unresectable/Metastatic HER2-Negative Breast Cancer;;Metastatic HR-Positive HER2-Negative Breast Cancer
